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The successful launch, sustainable operations and broad applicability of 
population-based biobank research relies primarily on public trust, engagement and 
widespread voluntary participation. In Abu Dhabi, UAE, there were no existing 
emirate-wide data on the Emirati general public's views regarding establishing a 
population-based biobank for future genomic research. There were also, no data on 
their understanding of the benefits, risks and implications of donating biosamples and 
health information for a biobank for future genomic and other biomedical research.  
Study Aims: This study aims to establish the first emirate-wide data regarding 
the Emirati general public's knowledge and attitudes towards biobanking for genomic 
research, assess their willingness to participate in a proposed population-based 
biobank for future genomic research, and explore factors associated with their 
willingness to participate.   
Methods: This study was a cross-sectional, Emirate-wide study in which data 
were collected through telephone interviews, using a structured survey questionnaire. 
Eligible participants were adult Emirati volunteers drawn at random from a list of 
individuals who underwent Weqaya screening, as prospective participants of the 
future biobank project. The sample was equally balanced by gender. The study was 
conducted over 11 months, from April, 2015 to March, 2016. Quantitative statistical 
analysis was conducted using Stata Statistical Data Analysis software version 11.2. 
Basic descriptive summary statistics was performed to address research objectives. 
Univariate and multivariate analysis were conducted to explore the association 
between the independent variables and willingness to participate in a population based 




Results: A total of 603 telephone interviews were conducted, 313 males and 
290 females. The vast majority of the survey respondents had a positive attitudes 
about biomedical research, donation of biosamples for research and the potential 
value of the biobank, as well as had trust in the Health Authority-Abu Dhabi, the 
custodian of the biobank. However, only a few had good knowledge on biomedical 
research, genomics or were familiar with biobanking. In addition, there was limited 
understanding of the potential risks of biobanking for future research and some 
reported important misconceptions about its potential benefits. The overall probability 
of those definitely willing to participate in the proposed biobank was 76.6%, 80.8% 
for males and 71.0% for females, (P=0.005). After adjusting for other covariates, the 
independent factors associated with willingness to participate in the biobank were: 
being a male (OR=1.52; 95%CI: 0.96 to 2.39, P=0.07), having good knowledge on 
biomedical research (OR=10.4; 95%CI: 1.11 to 97.8, P=0.04), perceived altruistic 
benefits such as 'improve health of future generation' (OR=2.17; 95%CI: 1.44 to 3.63, 
P<0.001) or 'support medical research' (OR=2.11; 95%CI: 1.36 to 3.46, P=0.001),  
positive attitudes towards the potential value of the biobank (OR= 2.62; 95%CI: 1.27 
to 5.39, P=0.009), definitely accept recontact (OR=3.25; 95%CI: 2.03 to 5.19, 
P<0.001), definitely desire to receive feedback on individual genomic research results 
(OR=3.16; 95%CI: 1.84 to 5.54, P<0.001) and family influence on participation 
(OR=3.19; 95%CI: 1.84 to 5.53, P<0.001).  
Conclusions and recommendations: Comparable with findings from other 
countries, including other Arabs, the Emirati general public were positive about 
biomedical research and optimistic about the potential value of the biobank, however 
they had limited knowledge on biomedical research and the concept of biobanking for 




enthusiastic about participation in the biobank, had high trust in the government, 
tolerated future recontact and had high expectation for returning individual genomic 
research results. Overall, factors associated with public's willingness to participate in 
a population-based biobank were context specific and varied across populations. To 
ensure informed participation and active engagement in the biobank, this study's 
conclusions support the following recommendation: (i) ensuring ongoing public 
consultation and empowerment; (ii) developing tailored information and educational 
resources and (iii) strengthening medical research regulations and establishing a 
governance framework and structure for biobanks. Future follow-up studies are 
recommended, to explore the Emirati general public's views on other important areas 
not addressed in this study, evaluate actual participation after implementation of the 
biobank project and assess and enhance health and research literacy, to improve trust 
and overall experience with healthcare system.    
 Keywords: Population-based biobank; public engagement; participation; 
willingness to participate; biomedical research; biobanking; knowledge; attitudes;  
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1 Chapter 1: Introduction 
1.1 Context   
The United Arab Emirates (UAE), is a Middle Eastern country in Western 
Asia, located in the southeastern corner of the Arabian Peninsula on the Arabian Gulf, 
between Oman and Saudi Arabia. It is a federation of seven independent emirates, 
established in 1971.  The UAE Government works at three levels- federal, emirate 
and municipal. The UAE political system is mix of the traditional and modern 
political systems that has brought political stability, security and supported the 
socioeconomic development of the country. The UAE economy is the most 
diversified in the Arabian Gulf Region, however relied heavily on oil (UAEinteract, 
n.d.). Since the discovery of oil more than 50 years ago,  the UAE underwent major 
transformation and development and it has become a modern state with a high 
standard of living (Central Intelligence Agency [CIA], 2016). It is classified as a high 
income country by the World Bank based on its economic development. The GDP in 
price market in 2014 was $ 339.5 billion (US 2014 Dollars)  (The World Bank, 2016; 
UN Data, 2016).  The per capita GDP in 2014 was $ 66,300, ranking, the UAE as 13 
out of the 230 countries in terms of per capita income. The UAE is a high influx 
country with labor migration from more than 202 nationalities, with a total population 
of over 9.4 million, according to mid-year 2014. Islam is the official state religion and 
Arabic is the national language (CIA, 2016; UAEinteract, n.d.; UN Data, 2016) 
The emirate of Abu Dhabi is the largest in terms of area (67,340 km²), 
accounting for 87% of total land area of the UAE, and has the largest population. 
According to mid-year 2014 estimates, the population of Abu Dhabi was 2.65 million. 
Emiratis constitute less than one-fifth (19.1%) of the total population of Abu Dhabi. 
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The Emirati population is relatively young: 39.1% of the population are below 15 
years, 58.5% between 15-64 years and only 2.1% are above 65 years.  The gender 
distribution is fairly balanced, male to female ratio is 1:1.06 (51.5% of total 
population were males and 48.5% were females). The emirate is divided into three 
Municipal Regions: Abu Dhabi Central Capital District Region; Al Ain (Eastern) 
Region and Al Gharbia (Western) Region, Figure ‎1-1. Almost half of Abu Dhabi 
Emirati population, 51.6%, lives in Abu Dhabi Central Capital District Region, 42.5% 
in the Eastern region and a small percentage (5.8%) in the Western region. Urban to 
rural distribution of the population is 1.5. According to the report, the overall literacy 
rate among Emiratis was 94.7%, 96.6% in males and 92.6% in females. The life 
expectancy at birth for males was 75.2 years and for females was 78.7 years (Statistic 
Centre Abu Dhabi [SCAD], 2016).  
 
 
Figure ‎1-1: Abu Dhabi Emirate Regions 
 
(Source: UAEinteract, n.d.)  
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In the emirate of Abu Dhabi, non-communicable diseases (NCDs), also 
commonly referred to as chronic diseases, are the leading causes of mortality and 
morbidity. The major NCDs, comprised of cardiovascular diseases, diabetes, cancer 
and chronic respiratory diseases, accounted for more than 56.6% of all deaths in 2015. 
Cardiovascular disease was responsible for 35% of all deaths, followed by cancer at 
13.5%, respiratory disease at 5.1%, and endocrine, nutrient and metabolic diseases at 
3%. Deaths due to major NCDs have been steadily increasing, and  NCDs remain the 
leading cause of mortality in the emirate (Health Authority-Abu Dhabi [HAAD], 
2016a). Globally, it has been forecasted that with an ageing population, and  with the 
epidemiological shift away from communicable diseases, deaths from NCDs will 
continue to rise. As such, NCDs are a major public health threat, and may hinder the 
social and economic development of many countries. Innovative and comprehensive 
solutions for control and prevention of NCDs are needed (Bloom et al., 2011; World 
Health Organization [WHO], 2013).  
The emirate also has high prevalence of risk factors for cardiovascular 
diseases, including obesity, hypercholesterolemia and diabetes. Data from the Weqaya 
screening program revealed high rates of cardiovascular diseases risk factors in the 
Emirati population (Hajat, Harrison, & Shather, 2012). The Weqaya screening 
program in its first cycle between 2008 and 2010, screened 94% of the adult Emirati 
population. The results showed that more than two-thirds of Emirati adult population 
(71%)  had at least one cardiovascular disease risk factor, 67% were either overweight 
or obese, 19.3% had hypercholesterolemia, 18% were diabetic, and a further 27% had 
evidence of pre-diabetes (Hajat, Harrison, & Shather, 2012). 
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Weqaya in Arabic means prevention. Weqaya in this context, is a unique 
screening program that was launched in 2008 in the emirate of Abu Dhabi. It is a 
population-based screening program for cardiovascular diseases and its risk factors, 
targeting adult Emiratis of 18 years and above. It includes completing a health and 
lifestyle questionnaire, anthropometric measurements, clinical examination and 
collecting blood samples. The screening program is currently provided in more than 
60 public and private healthcare facilities distributed across the emirate, in addition to 
three mobile clinics. 
HAAD is the regulatory body of the healthcare sector in the emirate of Abu 
Dhabi, and reports at the federal level to the UAE Ministry of Health and the National 
Health Council. It was established in 2007, with the mission to regulate and develop 
the healthcare sector and to protect the health of individuals. HAAD's main roles are 
to define the strategy for the health sector, shape the regulatory framework, inspect 
against regulations, set premiums and reimbursement rates, and monitor the 
performance of the health care system. In addition, HAAD monitors and analyzes the 
health status of the population, and drives public health programs (HAAD, 2016b).  
Healthcare services in the emirate are provided by both public and private 
providers. SEHA,‎Arabic‎word‎for‎‘health’,‎ is‎ the‎main‎‎public‎provider.‎ It‎manages‎
most of public healthcare facilities in partnerships with prominent international 
operators. UAE nationals are covered by Thiqa health insurance plan, which provides 
'free at the point of care' access to care in both public and privates providers. Thiqa is 
the Arabic word for 'trust' and it is the single-payor health insurance plan for UAE 
nationals. Expatriates were granted access to healthcare, through mandatory health 
insurance, introduced in 2006 (HAAD, 2016a).  
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In 2015, HAAD published a five-year strategy to improve the healthcare 
sector in the emirate of Abu Dhabi. The new strategy has identified seven strategic 
priorities and 52 new initiatives. One of key priorities was 'Wellness and Prevention', 
and to address this priority, activations such as public health community initiatives to 
enhance community wellness and awareness, and establishing a population-based 
biobank for genomic research on major chronic diseases were undertaken (HAAD, 
2016b). The biobank initiative is based on best practices, and is scheduled to be  
established 2016-2017. The purpose of the biobank is to provide a resource that 
supports a diverse range of genomic and biomedical research intended to improve the 
health and wellness of the Emirati population, as well as to demonstrate its potential 
to pilot personalized medicine.  
The proposed plan for the Abu Dhabi population-based biobank project is to 
link it to the existing Weqaya screening program. Abu Dhabi biobank will be 
managed by a healthcare provider. Blood samples collected during the screening visit 
which would otherwise have been discarded, will instead be retained and matched 
with the detailed behavioral, lifestyle and health information collected via a 
questionnaire, and deposited in the biobank.  All Emirati adults 18 years and above in 
the emirate of Abu Dhabi will be invited to participate in the population-based 
biobank research. The target is to recruit 100,000 Emirati adult individuals. 
Participation in the biobank will be completely voluntary, and samples and health 
information to be included in the biobank will be deposited only with the participants' 
permission. Participants also have the option to withdraw the same from the biobank 
at any time in the future without giving any reason. The biobank will prospectively 
collect and store biosamples, and update related data every three years, according to 
the regular Weqaya screening cycle.  
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1.2 Population-based Biobanks  
Since‎ the‎ late‎ 1990’s,‎ several‎ countries‎ have‎ established‎ population-based 
biobanks to study the health of population, with particular focus on complex chronic 
diseases (Rudan, Marusic, & Campbell, 2011). Biobanks are biorepositories that store 
human biological samples such as, cells, tissues, blood or DNA, as well as related 
health information for use in genomic and other types of biomedical research 
(Holzinger & Jurisica, 2014). Population-based biobanks are key resources for a wide 
range of epidemiological research.  The knowledge gained from the contributed 
biosamples and health information will help understand the gene-behavior 
contributions to disease risk and health, and develop improved strategies for the 
prevention, diagnosis and treatment of  major chronic diseases and health traits 
(Knoppers, Zawati, & Kirby, 2012). Such improvements may eventually lead to more 
precise, individually stratified health care, the so called 'personalized medicine' 
(Harris et al., 2012; Hewitt & Watson, 2013) . 
Population-based biobanks are unique resources, and as such, highly complex 
in their operations. Since their implementation, a significant number of ethical, legal, 
and social concerns have been raised among professionals and the public regarding 
the same (Budin-Ljøsne et al., 2012; Master, Campo-Engelstein, & Caulfield, 2015). 
Major ethical concerns were related to informed consent, i.e., ensuring that research 
participants are adequately informed  about the risks and benefits of biobank research, 
especially in the context of long-term storage of biosamples and data, and the 
uncertainty of future possible multiple uses of biosamples and data in various research 
(Rahm, Wrenn, Carroll, & Feigelson, 2013). In addition were concerns related to 
privacy and confidentiality protection. Biobanks collect and store huge quantities of 
phenotype and genotype data of many individuals, and this may pose information 
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risks, including loss of privacy, breach of confidentiality and misuse of data – 
discrimination by a third party such as insurer, employer or others (Fisher & 
Harrington McCarthy, 2013). Other commonly reported concerns were related to 
managing and returning individual genomic research findings: when, who and how to 
return the results (Appelbaum et al., 2014; Bledsoe et al., 2012).  There are also 
concerns about the commercialization of the biobank resources, ownership of data and 
biosamples, as well as about benefits sharing  (Budimir et al., 2011).  
Furthermore, the success of biobanks is dependent on public engagement and 
participation (Critchley, Nicol, Otlowski, & Stranger, 2012; Husedzinovic, Ose, 
Schickhardt, Frohling, & Winkler, 2015; Nobile, Vermeulen, Thys, Bergmann, & 
Borry, 2013; Porteri et al., 2014; Watson et al., 2014). Significant social challenges 
related to population-based biobanks include public engagement and participation, 
particularly in terms of ensuring informed decision about participation and active 
engagement in biobank governance structure development (Silverman et al., 2015; 
Silverman et al., 2013).  Several studies show that community consultation and 
empowerment are believed to be critical in order to increase public trust and wider 
participation in biobank research, thereby ensuring success, sustainability (McWhirter 
et al., 2014; Critchley et al., 2012) and broad applicability of population-based 
biobank research (Marko-Varga et al., 2014; Olson et al., 2014). Moreover, active 
engagement of participants and the general public in biobank governance framework 
and structure could help in reaching consensus on endless debates about major ethical, 
legal and social implications of biobank research (O'Doherty et al., 2011; O'Doherty, 
Hawkins, & Burgess, 2012), It would also ensure biobank research is conducted in an 
ethical, locally appropriate manner that respects specific population interests and 
preferences (Lemke et al., 2010; O'Doherty et al., 2011; O'Doherty et al., 2012). 
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Population-based biobank is a relatively new concept (Hewitt & Watson, 
2013). Most of the experience in the field of national or population-based biobanks 
comes from Europe (European Commission [EC], 2012). Experience in biomedical 
research from Arab countries in the Middle-East region is scarce, but growing 
(Alahmad, Al-Jumah, & Dierickx, 2012; Silverman et al., 2015; Silverman, Edwards, 
Shamoo, & Matar, 2013). Population-based biobanks were recently introduced in the 
region by Qatar and Kingdom of Saudi Arabia (Al Kuwari et al., 2015; Alahmad & 
Dierickx, 2014).  
International literature on population-based biobanks is generally limited 
(Wells et al., 2014). Published studies from Europe and North America found that the 
general public was not familiar with the biobank, nor the science and technology 
behind it (Department of Health Western Australia [DHWA], 2010; EC, 2012; 
Gaskell et al., 2013; Simon et al., 2011). Little was known about their support or 
concerns on the establishment of population-based biobanks for research (Gaskell et 
al., 2013).  
In general, literature on medical research from the Middle East in general is 
very scarce. There is a significant gap in knowledge on the general publics' 
knowledge and attitudes towards participation in a biobank for genomic and other 
biomedical research. Studies published in Jordan, Egypt, and Saudi Arabia have 
explored patients' knowledge and opinions regarding biomedical research or disease-
specific biobanks (Abou-Zeid et al., 2010; Ahram et al., 2014; Al-Hussaini & Abu-
Hmaidan, 2014; Al-Jumah et al., 2011). One national survey in Jordan and another 
study on biobank participants in Qatar have evaluated the perception of the general 
public about biobanking and explored factors influencing participation in a 
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population-based biobank research (Ahram, Othman, & Shahrouri, 2012; 2013; 
Ahram, Othman, Shahrouri, & Mustafa, 2013; Nasrella & Clark, 2012).  
Overall, published studies- international as well as regional- show great 
variation in the intention to participate in a population-based biobanks across 
populations and subgroups within the same population. There is also variation in the 
factors influencing their intention to participate (Ahram et al., 2013; Banks, Herbert, 
Mather, Rogers, & Jorm, 2012; Critchley et al., 2012; Ridgeway et al., 2013; 
Sanderson et al., 2013; Tauali et al., 2014; Tupasela et al., 2010 ). These factors 
needed to be explored in Abu Dhabi, UAE, in order to ensure higher, wider 
participation and longer-term engagement of the Emirati general public in  the 
proposed project.  
1.3 Problem Statement 
There is a growing interest world-wide, as well as in the UAE, to establish a 
population-based biobank to study and improve the population's health and wellness. 
The successful launch, sustainable operations and broad applicability of population-
based biobank research relies primarily on public trust, active engagement and 
widespread voluntary participation. In Abu Dhabi, UAE, there were no existing 
emirate-wide data on the Emirati general public's views, support or concerns 
regarding establishing a population-based biobank for future genomic research. There 
were also, no data on their understanding of the benefits, risks and implications of 
donating biosamples and health information for a biobank for future genomic and 
other biomedical research. 
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1.4 Research Significance 
This study is the first of its kind in the UAE, and it intends to fill the gaps in 
knowledge regarding the Emirati general public's views on establishing a population-
based biobank for future genomic and other biomedical research, as well as their 
understanding of the risks, benefits and implications of donating biosamples and 
health information data to a biobank for future research. It will add to the existing 
regional and international literature on factors associated with the general public's 
decision regarding participation in a population-based biobank for future research. 
As a novel initiative to be introduced in the UAE and the greater Arab world, 
it is imperative that we fully understand how best to launch this new initiative, while 
protecting the interests of the Emirati population of Abu Dhabi. This study can be 
considered as a first step towards a deliberative community consultation and 
engagement. It will be used to shape the development of regulations and policies for 
which a thorough understanding of local context and expectations is essential. It will 
also support the development of tailored, meaningful and culturally appropriate 
information resources and communication strategies to improve health and research 
literacy, while ensuring higher, wider and longer-term public engagement and 
participation.   
1.5 Study Aims and Objectives 
1.5.1 Study aims 
This study aims to establish the first emirate-wide data regarding the Emirati 
general public's knowledge and attitudes towards biobanking for genomic research, 
assess their willingness to participate in a proposed population-based biobank for 
future genomic research, and explore factors associated with their willingness to 
participate.   




1.5.2 Study objectives 
To elaborate on the study aims, the following study objectives were included:   
1. Assess the Emirati general public's knowledge and attitudes towards biobanking 
for future genomic and other biomedical research.  
2. Explore the Emirati general public's perception of the benefits and risks of 
biobanking for future research. 
3.  Assess the Emirati general public's views regarding future recontact and return 
of biobank research findings, both general aggregate and individual genomic. 
4. Estimate the overall probability, at population level, of the Emirati general 
public's willingness to participate in a proposed population-based biobank and 
explore gender differences. 
5. Identify factors associated with the Emirati general public's willingness to 
participate in the proposed biobank.  
6. Explore the Emirati general public's preferences for various health information 
and communication channels.  
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2 Chapter 2: Literature Review 
The databases of PubMed, Web of Science, Scopus and Google were 
searched using a combination of key words or concepts described in Appendix I.  
The search was conducted between 15 December 2015 and 31 January 2016.  
Studies included were those from January 2010 onward, written in English 
language, have the key words of search in the title or abstract and were full 
articles. Articles related to disease-oriented biobanks, or on patients' prospective, 
including minors, were excluded. The review also included important reports, 
guidelines, book sections and a couple of key biobank studies, older than 2010.    
Most of the literature was from North America and Europe, and a few 
were from Australia, Asia, Africa and the Middle East. The literature from the 
Middle East was expanded to capture medical research in general as well as 
biobanking. Most of the international literature on biobanks focus on governance 
challenges, the ethical, legal and social implications (ELSI) of biobanks.  
The literature review summarizes the main aspects related to population-
based biobanks. It describes definitions and types of biobanks, purposes of 
population-based biobanks, biobank set up requirements as well as governance 
framework and structure. It also covers the ELSI challenges, and strategies for 
effective and innovative governance. In addition, it provides some examples of 
existing national and large-scale population-based biobanks in selected countries, 
including experiences from Arab countries in the Middle East. 
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2.1 History of Biobanking  
The collection of samples and data for research and cohorts studies have 
been part of educational and medical practice for several years (EC, 2012; Harris 
et al., 2012; Lee et al., 2012; Li, Guo, Chen, Chen, & Peto, 2012). What is 
exceptional and novel about biobanks is the large-scale collections of various 
human biological samples for a wide range of research on various diseases. The 
creation of large-scale infrastructures or 'industrial size' biobanks have been encouraged 
by the advancement and innovation that have taken place in two sciences. Firstly, 
the invention and rapid developments in the field of information and robotic 
technologies as well as bioinformatics have supported the establishment of 
biobanks. Bioinformatics facilitated the systemic approach and automization in 
the collection, linkage and tracking of biosamples and data for diverse research 
purposes (EC, 2012; Prainsack & Buyx, 2013). Secondly, the advancements in 
genomics since the beginning of the Human Genome Project in 199, has increased 
the demand for a large number of high quality biosamples for research and has led 
to a significant increase in the number of biobanks in recent years (GBI Research, 
2011; Zielhuis, 2012). 
The term biobank is relatively new. This terminology was first used in the 
title or abstract in PubMed was in 1996, in relation to a population-based biobank 
research (Hewitt & Watson, 2013).  Over time, other new terminology such as 
biorepository (International Society for Biological and Environmental 
Repositories [ISBER], 2001) and biological resource center (BRC) emerged 
(Organization of Economic Co-operation and Development [OECD], 2007). 
These terms refer to structured facilities that collect biosamples and relevant data 
for future research. It collects a wide range of human and non-human biosamples 
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(De Souza & Greenspan, 2013; Hewitt & Watson, 2013; Parodi, 2015). However, 
both biorepositories and BRCs collect biosamples from humans and non-humans 
such as animals, plants, microbes and even the environments, while biobanks 
typically collect human biosamples (Parodi, 2015).  It is noticed that the term 
biobank is used more commonly in Europe, while the term biorepository, and is 
used more frequently in the United States (US). This could be because most 
population-based biobanks, from where the term originated, were established 
early and abundantly in Europe, while the US lagged behind.  Disease-oriented 
and clinical trials biorepositories or tissue banks were most common in the US.    
A directory of global biobanks can be found on specimencentral.com. 
Most of the existing biobanks are based in North America, mainly the US, 
followed by Europe; there are a very few in Asia, Australia, Africa and the Middle 
East. Currently, biobanks are established either within academic, medical or 
research institutions, pharmaceutical or biotechnology companies, or as stand-
alone facilities (Parodi, 2015). They receive funding from not-for-profit 
organizations such as government, academia, and research bodies, profit-making 
entities such as pharmaceuticals and private healthcare industry, or could a 
combination of both (Edwards, Cadigan, Evans, & Henderson, 2014; Hewitt & 
Watson, 2013).  
Biobanks acquire specimens in a variety of ways. The two most common 
ways are direct donation by individuals or patients, and residual samples from 
clinical settings (Henderson et al., 2013). Human biosamples collected include 
whole blood, peripheral blood cells, cord blood, saliva, urine, stool, bone marrow, 
solid tissues and pathological body fluids. The number of specimens stored could 
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range from less than 500 to over 50 million (Edwards et al., 2014; Henderson et 
al., 2013; Hewitt & Watson, 2013).  A majority (60%) of the existing biobanks are 
small in scale, and collect and store samples from less than 100,000 donors. Only 
a few (10%) collect and store samples from more than one million donors (Kang 
et al., 2013).  Biobanks receive requests from researchers affiliated with academic 
or research institutions, federal government, hospitals or other clinical setting, 
pharmaceutical and insurance companies, and health or disease advocacy 
organizations (Edwards et al., 2014).  
2.2 Types and Definitions of Biobanks 
There are various types of biobanks; the most common are population-
based, disease-oriented, case-control, tissue banks, clinical trials, twin registries 
and virtual biobanks. Other less common ones are the cord blood, Guthrie card, 
stem cells, and forensic biobanks, among others (Branković, Malogajski, & 
MorrÃ, 2014; De Souza & Greenspan, 2013; EC, 2012; Hewitt & Watson, 2013; 
Parodi, 2015). As per the pan-European Biobanking and Bimolecular Resources 
Research Infrastructure (BBMRI), biobanks can be classified into population-
based biobanks and disease-oriented biobanks (Parodi, 2015). 
 Population based biobanks aim to discover biomarkers for disease 
susceptibility within a specified population. They collect biosamples from huge 
numbers of healthy individuals, mainly germline-DNA isolated from venous 
blood, as well as comprehensive medical, physical measures and epidemiological- 
lifestyle and environmental- data (Holzinger & Jurisica, 2014; Parodi, 2015; 
Riegman et al., 2008). Under this category, Twin cohorts and Twin Registries 
were included (Parodi, 2015). 
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Disease-oriented biobanks, or clinical biobanks, aim to discover and 
validate biomarkers of diseases, genetic and non-genetic, through prospective 
and/or retrospective collections of tumor and non-tumor samples and their 
derivatives, such as DNA, RNA or proteins, from people affected with specific 
diseases. Some collect clinical data, or are sometimes associated with clinical 
trials (Holzinger & Jurisica, 2014; Parodi, 2015; Riegman et al., 2008). Disease-
oriented biobanks may include tissue banks and rare disease biobanks. Rare 
diseases biobanks, also referred to as genetic biobanks, collect biosamples for 
diseases of low prevalence, affecting less than one citizen in 2000.  Most rare 
diseases biobanks work through the active participation of patients and patient 
organizations, and share benefits with them (Parodi, 2015).   
Several studies have shown that there is no standardized agreement or 
definition of the term biobank among biobank personnel and stakeholders. 
However, it is agreed that biobanks are collections of human biosamples stored 
for future research use (Boyer, Whipple, Cadigan, & Henderson, 2012; Edwards 
et al., 2014; Fransson, Rial-Sebbag, Brochhausen, & Litton, 2015; Henderson et 
al., 2013; Hewitt & Watson, 2013; Shaw, Elger, & Colledge, 2014). The 
discrepancies in defining the term 'biobank' were mainly with regards to the nature 
of the collections of related health information, source and number of samples 
collected, years of storing and types of research. This variation explains the 
diversity in the types of existing biobanks having different sample collection 
purposes and research designs. The broad definition of biobank that covers all 
types, was the one stated by the European Commission "Biobanks collect 
biological samples and associated data for medical-scientific research and 
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diagnostic purposes and organize these in a systematic way for use by others." 
(EC, 2012).  
Various entities provided definitions for population-based biobanks. In 
2006, the Organization for Economic Cooperation and Development (OECD) 
defined it as "A collection of biological material and the associated data and 
information stored in an organized system, for a population or a large subset of a 
population" (OECD, 2006).  In 2009, the OCED referred to a biobank as a human 
genetic research database (HGRD) which is "A structured resource that can be 
used for the purpose of genetic research and which include: (a) human biological 
materials and/or information generated from the analysis of the same; and (b) 
extensive associated information” (OECD, 2009). 
In 2006, the Council of Europe provided a legal definition for the biobank. 
Chapter 5, Article 17 of the Ministerial Recommendation on Research on 
Biological Materials of Human Origin, defined it as “A collection of biological 
materials that has the following characteristic: i. the collection has a population 
basis; ii. It is established, or has been converted, to supply biological materials or 
data derived there from for multiple future research projects; iii. it contains 
biological materials and associated personal data, which may include or be 
linked to genealogical, medical and lifestyle data and which may be regularly 
updated; iv. It receives and supplies materials in an organized manner" (Council 
of Europe, 2006). 
Other organizations such as The Biobanking and Bimolecular Resources 
Research Infrastructure—European Research Infrastructure Consortium (BBRI-
ERIC), the largest network of 250 established biobanks from Europe, defined the 
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biobanks as: "Collections, repositories and distribution centers of all types of 
human biological samples, such as blood, tissues, cells or DNA and/or related 
data such as associated clinical and research data, as well as bimolecular 
resources, including model- and microorganisms that might contribute to the 
understanding of the physiology and diseases of humans'' (Fransson et al., 2015).   
The Public Population Project in Genomics and Society (P
3
G), a not-for-
profit international consortium dedicated to support international collaboration 
between population genomics researchers, defined biobanks as "An organized 
collection of human biological material and associated information stored for one 
or more research purposes" (Fransson et al., 2015). 
The International Society for Biological and Environmental Repositories, 
ISBER, a global forum that harmonizes technical, legal, and ethical issues related 
to repositories, defined it as "An entity that receives, stores, processes and/or 
disseminates specimens, as needed. It encompasses the physical location as well 
as the full range of activities associated with its operation” (Fransson et al., 
2015).  
The European Commission and Department of Health Western Australia 
summarized important characteristics of population-based biobanks. Population-
based biobanks are resources, a) that collect and store human biosamples- mainly 
blood, saliva and urine, and related health data, that include detailed personal and 
family health data, environmental exposure and lifestyle data; b) are long-term 
projects that prospectively and continuously collect biosamples and data; c) 
associated with  research projects in the  future that may be undefined at the time 
of the establishment and data collection; d) provide access to researchers, other 
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than the custodians of the biobank, for ethically approved research purposes; e) 
apply coding or anonymization for sample and data to ensure that participants' 
privacy and confidentiality are protected, but at the same time  have, under 
specified conditions with ethical approvals, the option to re-identify participants to 
share clinically relevant information; f) focus on public interest to benefit future 
generations rather than individual participants' benefit; and (g) include established 
governance structures and procedures to protect participants' rights and interests 
and ensure quality operations (DHWA, 2010; EC, 2012).  
2.3 Purposes of Population-based Biobanks 
Population-based biobanks were established in many countries to address 
important public health and economic development challenges such as complex 
chronic diseases and health traits. The aim is to improve the population's health 
and increase the wellbeing of future generations (Al Kuwari et al., 2015; Bravo, 
Napolitano, Santoro, Belardelli, & Federic, 2013; Imboden & Probst-Hensch, 
2013; Kang et al., 2013; Leitsalu et al., 2015; Leitsalu, Alavere, Tammesoo, 
Leego, & Metspalu, 2015; Li et al., 2012; Marko-Varga, Baker, Boja, Rodriguez, 
& Fehniger, 2014; Pang, 2013; Rudan et al., 2011).  Population-based biobanks 
are key resources to enhance and promote epidemiological studies, monitor 
diseases and other health outcomes in the population and accelerate the 
introduction of personalized medicine.   
2.3.1 Enhance and promote epidemiology research  
Until recently epidemiology, research ignored genetic variation across 
populations and subgroups and depended mainly on epidemiological data as well 
as environmental and lifestyle risk factors to understand causes of diseases 
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(Brand, Schulte & Probst-Hensch, 2012).  The availability of data from the 
Human Genome Project, genome wide association study (GWAS), whole genome 
sequencing (WGS) and the genomic revolution shifted the focus to elucidate the 
role of genomics in the development of various complex diseases and response to 
treatment since the 1990's (Khoury, 2001cited in King & Nicolae, 2014; Lockhart, 
Yassin, Weil, & Compton, 2012). Most genetic diseases are caused by multiple 
genetic factors on multiple genes and only some diseases originated from a single 
defective gene (Greely, 2007 cited in Kang et al., 2013).  
Epidemiology research now focuses on understanding the genetic 
variations of diseases (genotypes) as well as the interaction of genotype risk 
factors with environment and lifestyle (phenotypes) risk factors in the 
development of common diseases and other health outcomes (Kang et al., 2013). 
These studies require huge numbers of high quality biosamples collected through 
biobanks (Brand & Probst-Hensch, 2007; GBI Research, 2011; Zielhuis, 2012). 
Furthermore, it has the potential to support international collaborative studies 
(Harris et al., 2012; Zielhuis, 2012).  The biobank of International Agency for 
Research on Cancer (IARC) is an example of international collaboration and 
collection of biosamples from across the world. It contains 5 million biological 
samples from 1.5 million participants (IARC, 2016).  
Biobanks allow multiple uses of their resources, biosamples and data in 
research, and thus promote simultaneous multiple research activity. In addition, 
they continuously generate new knowledge and data through their research 
findings. Secondary data can be used in further research and may provide 
opportunities for new findings beyond the scope of the original research. Further, 
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they reduce the burden and discomfort of repeated recontact of participants for 
data gathering, minimizing breaches to privacy and confidentially and reducing 
levels of approvals required for use of secondary data (Olson et al., 2014).    
2.3.2 Strengthen epidemiological surveillance  
Until recently, biobanks and surveillance systems were considered as 
independent from one another (Brand et al., 2012).  Surveillance by definition is 
"The ongoing, systematic collection, analysis, and interpretation of health data 
essential to planning, implementing, and evaluating public health practice, closely 
integrated with the timely dissemination of these data to those who need to know" 
(McGraw-Hill Concise Dictionary of Modern Medicine, 2002).  
However, population-based biobanks of cohorts with prospective 
collection of phenotype data can efficiently serve as a useful surveillance system 
to quantify disease incidence, and monitor various health outcomes of a target 
population and subgroups of populations (Brand et al., 2012). Such data will 
provide decision makers with the knowledge to plan, implement and monitor 
public health preventive programs, as well as improve clinical care (Bravo et al., 
2013) 
Moreover, many of the established population biobanks were linked to 
other vital national registries such as population, death, disease specific registries 
and health information system, which further enhances surveillance and 
monitoring of disease and health outcomes (Leitsalu et al., 2015; Olson et al., 
2014). 
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2.3.3  Personalized medicine 
Population-based biobanks are novel technologies and tools that could 
pave the way to and accelerate the introduction of personalized medicine (Harris 
et al., 2012; Hewitt, 2011; Husedzinovic et al., 2015; Ioannis, Fotis, Evangelos, & 
Christos, 2015; McHale, 2011; Zielhuis, 2012). Personalized medicine refers to a 
medical practice that uses an individual's genetic profile to guide decisions 
concerning the prevention, diagnosis, and treatment of diseases (Genetic Home 
Reference, 2016). Biobanks could translate genomic and other biomedical 
research into advances in clinical care based on genomic profile, risk stratification 
and advances in pharmaceutical industry (Bravo et al., 2013; Kang et al., 2013; 
Marko-Varga et al., 2014; Olson et al., 2014; Pang, 2013).  Biobanking research 
will advise in planning effective and targeted disease prevention interventions and 
public health promotion messages, beside improving clinical care (Bravo et al., 
2013; Kang et al., 2013; Pang, 2013) 
Clinical genomics requires large sample sizes, such as those in biobanks to 
achieve statistical power and obtain reliable results, as individually, most genetic 
variants are likely to have modest or small impacts on phenotypes (Marko-Varga 
et al., 2014; Olson et al., 2014).  Pharmacogenomics is a science interested in 
determining how new knowledge about human genomes and their products can be 
translated into discoveries and development of improved drugs.  Biobanks help 
find and validate targets for therapies, and validate the expression level of these 
targets through diseases biosamples. The new improved drugs are tailored to 
individualized patient plans based on their genetic makeup, genomic organization 
and level of target protein expression. Larger samples to support the development 
of improved targeted therapy could also be attained through regional and 
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international biobank research collaboration and networks (Branković et al., 2014; 
Marko-Varga et al., 2014). 
 Integration of biobanks into healthcare system and linking their databases 
with other national health databases can support the introduction of personalized 
medicine (Leitsalu et al., 2015; Marsolo & Spooner, 2013; Olson et al., 2014). 
The Estonian model is one example of how to utilize the population-based 
biobank as a resource to support the introduction of personalized medicine.  The 
Estonian population-based biobank, the largest epidemiological cohort in the 
Baltic region, was established in 2000. Later, after several years of 
implementation of the biobank, Estonia linked different national health databases 
with its biobank to enrich the phenotypic content of the biobank database. These 
include databases on population, death, cancer, tuberculosis and myocardial 
infarction registries, National Health Information System and Estonian Health 
Insurance Fund. The vision is to enable the use of such rich data along with 
molecular profiling data of patients to calculate disease risk and likely drug 
response, with the aim of introducing personalized medicine (Leitsalu et al., 
2015).  
2.4 Requirements for Establishing a Population-based Biobank 
To set up a population-based or national biobank, principal requirements 
must be charted out, by the custodian or the operator of the biobank well in 
advance. These requirements must be clearly communicated to all biobank 
stakeholders, including public to ensure that it is in alignment with the interests of 
prospective participants. It include: (a) defining the current and future purpose or 
mission for the biobank; (b) developing a business plan; (c) developing 
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governance structure and operational policies, procedures; (d) considering the 
flexibility of information technology design to enable future collaboration and 
linkage to other databases; (e) carrying out stakeholder consultation; and (f) 
providing solutions to transparently publicize information regarding the biobank 
(DHWA, 2010; Gottweis & Lauss, 2012; Kohane, 2011; Leitsalu et al., 2015; 
Marsolo & Spooner, 2013; OECD, 2009). 
2.4.1 The purpose of the biobank 
 The purpose of population-based biobanks is to carry out genomic and 
epidemiological research to improve the wellbeing of the population and the 
future generations.  Prior to establishing a biobank, the custodian or the operator 
of the biobank should have established criteria for sampling and participant 
selection. This will ensure that the biobank sample size is representative of the 
targeted population, and that the research results are scientifically appropriate for 
their intended use (DHWA, 2010; Olson et al., 2014; UK Biobank, 2006; UK 
Biobank, 2007). Important considerations include a recruitment policy that 
ensures justice, beneficence, transparency and no discrimination.  This is why the 
current population-based biobanks that are founded on study design have disease 
focus, epidemiological parameters and mathematical models, and a vision of 
biobank potentials. They also need to have clearly estimated the size of samples 
required for recruitment, as well as the age range of participants (DHWA, 2010; 
Olson et al., 2014).  
One example is the UK biobank which recruited 500,000 participants aged 
45-69 years. This age group was selected because it involved people at risk of 
developing a wide range of complex diseases, such as cancer, heart disease, 
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stroke, diabetes and dementia, over the next few decades (UK Biobank, 2007).  
Another example is Estonia, where 52,000 participants were recruited, accounting 
for 5% of adult population of 18 years and above and reflecting the age, sex and 
geographical distribution of the Estonian population (Leitsalu et al., 2015; Leitsalu 
et al., 2015). Table ‎2-1, in section 2.9 provides other examples of population-
based and national biobanks and summarizes their sample sizes and participants' 
age ranges. 
2.4.2 The business plan 
The business plan should be comprehensive, and ensure the sustainability 
of financial and human resources, as biobanks are unique and different other 
research facilities, and require a costly infrastructure (O'Doherty & Hawkins, 
2010; Olson et al., 2014; Watson et al., 2014). The business plan should explain 
the financial model throughout the biobank's life span, including the nature and 
source for funding as well as the assumptions, and identify potential risks and 
alternatives options of funding in case one source of funding was terminated. The 
plan should also, carefully estimate and ensure sufficient professional staff 
required to operate the biobank.  In case commercial or international collaboration 
is planned, this needs to be clearly stated in the plan, and communicated to all 
stakeholders, including participants (DHWA, 2010). 
Most existing population-based biobanks are funded by governments or 
large charitable or research organizations (Henderson et al., 2013). Table ‎2-1 in 
section 2.9 provides a review of the source of funding of selected existing 
population-based biobanks.   
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2.4.3 Governance structure, standard operational procedures and 
policies 
The biobank operator should clearly establish its governance structure and 
framework. The governance structure and framework should be designed to 
protect the rights and well-being of research participants and ensure that their 
rights and interests prevail research interests of the biobank operator and users 
(DHWA, 2010; OECD, 2009).   
The biobank operator should have in place a set of standard operational 
procedures (SOP's) and policies, based on international best practices, to guide 
key operational decisions (Womack & Mager, 2014). Important SOPs include 
maintaining records and documenting management procedures; quality assurance 
procedures, including biosafety, training of staff and knowledge transfer, material 
handling and documentation procedures; participant recruitment and management 
procedures, including obtaining informed consent, withdrawal consent and 
recontact; as well as others (BBMRI Stakeholder's Forum, 2010; DHWA, 2010; 
National Cancer Institute [NCI], 2011; OECD, 2007; OECD, 2009). 
The governance structure, SOP's, and policies, of the biobank needs to be 
developed and approved by an independent human research ethics committee 
prior to the establishment of the biobank.  Information on the biobank governance 
and its management should be made publicly available (Critchley et al., 2012; 
OECD, 2009).  
The full potential of biobanks can be achieved only through high quality 
operations (Artene et al., 2013; De Souza & Greenspan, 2013; Harris et al., 2012; 
Hewitt, 2011; Womack & Mager, 2014; Zhou, Sahin, & Myers, 2015). Biobanks 
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should seek certification by accreditation bodies such as the College of American 
Pathologists, CAP (De Souza & Greenspan, 2013; Hewitt, 2011), International 
Organization of Standardization Standard, (ISO) 9001 or others, to ensure quality 
(De Souza & Greenspan, 2013).  
The biobank should have in place oversight mechanism to ensure 
compliance of its management, personnel, collaborators and researchers with  
legal requirements and ethical principles. Public and transparent reporting on 
compliance or faults in compliance is obligatory and it should be available to 
participants and the public (EC, 2012; OECD, 2009; Kaye, 2012b). 
 An effective and transparent governance structure and framework 
reassures stakeholders, including the general public that the biobank operation is 
being managed in an accountable and ethical way (Womack & Mager, 2014). 
2.4.4 Consultation with stakeholders 
Consultation with various stakeholders is a critical step in planning the 
establishment and sustaining population-based biobank (BBMRI Stakeholder's 
Forum, 2010; Critchley et al., 2012; DHWA, 2010; EC, 2012; Olson et al., 2014). 
Biobank custodian or operator should not fear public consultation; instead, they 
need to facilitate it to share information and views, and to learn what are the 
appropriate and acceptable biobank operations and policies (Gaskell & Gottweis, 
2011). Stakeholders may include participants, the general public, patients groups, 
industry, scientists, ethicists, clinicians and researchers. 
The extent and method of consultation would vary according to groups of 
stakeholders (BBMRI Stakeholder's Forum, 2010; DHWA, 2010; Gaskell & 
Gottweis, 2011; O'Doherty et al., 2011; O'Doherty et al., 2012). The biobank 
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operator or the custodians need to communicate clearly the importance and extent 
to which their input may influence the establishment and future aims of the 
biobank.  In general, stakeholder consultation should cover the purpose and design 
of the proposed biobank, its current and future scope, potential risks involved to 
participants and their families, and the governance structure. In addition, it should 
explore any particular cultural, religious or other sensitivities that might be 
important to potential participants (DHWA, 2010).  
2.4.5 Information and education resources 
Information and education resources for the general public and other 
stakeholders on the biobank initiative should be made available, either in the form 
of internet-based communications and publications, or through other means of 
communication. Information on the biobank needs to be easily accessible, 
transparent and culturally accepted. It should be meaningful to the  target 
audience, and cover the most important aspects of the biobank: background on the 
custodian/s and senior management, its governance structure, collaborators and 
the purpose, both current and future, the proposed duration of the biobank, its 
source of funding, operational policies, risks to participants and risk mitigation 
plans, research that is being carried out with the biobank resources and its general 
results, and finally, the contact details for more information (BBMRI 
Stakeholder's Forum, 2010; DHWA, 2010; EC, 2012). 
Publicity plans are essential to increase engagement and participation 
(Gaskell & Gottweis, 2011; Kelly, Spector, Cherkas, Prainsack, & Harris, 2015; 
Platt, Bollinger, Dvoskin, Kardia, & Kaufman, 2014; Platt & Kardia, 2015; 
Watanabe et al., 2011). In order to communicate to the general public and educate 
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them, tailored strategies appropriate for target audience need to be used, and they 
should be ongoing to match the change in research technology advancement 
(Kelly et al., 2015; Platt & Kardia, 2015; Stein & Terry, 2013; Steinsbekk et al., 
2013; Wee, Henaghan, & Winship, 2013; Williams, Nemeth, Sanner, & Frazier, 
2013). There are various forms of communication strategies to raise public 
awareness. These include public forums, events, publications, internet-based 
communications and traditional media among others (Beskow, Burke, Fullerton, 
& Sharp, 2012; Budimir et al., 2011; Knoppers, Deschenes, Mester et al., 2015; 
Zawati, & Tasse, 2013; Wallace & Kent, 2011; Watanabe et al., 2011). 
2.5 Biobank Governance Framework and Structure 
Governance is a new terminology (Hansson, 2011). It is broadly defined as 
any intentional activity that attempts to control, order or influence the behavior of 
others. Regulations and governance are sometimes used interchangeably; 
however, governance is a boarder term (Hansson, 2011; Kaye, 2012b).  
The governance framework and structure of a biobank is influenced by the 
biobank's purpose, design, scale of bioinformatics and communication 
technologies, potential for commercialization, and building regional or 
international hubs and networks (EC, 2012; OECD, 2009; O'Doherty & Hawkins, 
2010). It could vary according to each country in alignment with its economic, 
social, legal development and resources infrastructure, including the research 
capacity of each country (Silverman et al., 2013).  
The governance framework consists of a formal structure, which includes 
the international principles of ethical research, legal instruments and the legally 
constituted regulatory bodies. In addition, it includes less formal structures that 
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influence behavior such as, international guidelines and recommendations from 
professional societies, standard operating procedures (SOP's), professional values 
and may include community advisory boards (EC, 2012; Hansson, 2011; Kaye, 
2012b). 
2.5.1 International principles of ethical research 
Several instrumental documents described the broad principles that should 
govern the research in human and were the basic of all international laws, policies 
and guidance for the protection of human participants. The most famous is the 
Nuremberg Code created in 1949 as a result of the verdict on the 'doctors’‎trial' on 
the World War II prisoners at Nuremberg, Germany.  It was part of an 
international legislation due to a UN resolution in December 1946 that brought the 
Nuremberg trials under the purview of the law. The Code sets ten ethical 
principles for experimentation on humans. It also established the requirements for 
informed consent, absence of coercion, properly formulated scientific 
experimentation, and beneficence towards experiment participants (Health and 
Human Services, 2005). 
Some examples of the most important declarations are, the World Medical 
Association (WMA) Helsinki Declaration and the United Nations Educational, 
Scientific and Cultural Organization (UNESCO) declarations. The Helsinki 
Declaration is considered the gold standard for the conduct of research involving 
human beings. It was adopted by the 18th WMA General Assembly in 1964 and 
amended several times, last in 2013. It applies to biomedical research on human 
subjects and addresses the use of human biosamples. The WMA Declaration of 
Taipei on Ethical Considerations regarding Health Databases and Biobanks, 
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adopted by the 53rd WMA General Assembly, in 2002 and revised recently by the 
67th WMA General Assembly in 2016. It address the collection, storage and use 
of identifiable data and biosamples beyond the individual care of patients (EC, 
2012; OHRP, 2016a; WMA, 2013; WMA, 2016). The UNESCO has released two 
declarations related to human genomic research, both emphasizing the need to 
protect the data derived from the human genome. The first declaration, 'the 
Universal Declaration on the Human Genome and Human Research', was made in 
1997, and the second 'the International Declaration on Human Genetic Data’‎ in 
2003 (EC, 2012; OHRP, 2016a; UNESCO, 2004).   
The Belmont Report is one of the most significant set of principles on 
biomedical research, the 'Ethical Principles and Guidelines for the Protection of 
Human Subjects of Research', prepared by the National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Research in 1979. 
The report provides an analytical framework to guide the resolution of the ethical 
problems related to research with human subjects and sets three core principles for 
research on human subjects: respect for persons, beneficence and justice. It was 
the basis for the federal US regulation for the protection of human participants in 
research, the 'Common Rule', such as the Department of Health and Human 
Services (DHHS) regulations 45 CFR 46 and the Food and Drug Administration 
(FDA) parallel  regulations 21 CFR 50 and 21 CFR 56 (Health and Human 
Services, 1979; OHRP, 2016b).  
2.5.2 International guidance on best practices 
Several entities such as the Council for International Organizations of 
Medical Sciences (CIOMS), the World Health Organization (WHO) and the 
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International Conference on Harmonization for Good Clinical Practice (ICH-
GCP), have established key standards and guidelines for the conduct of 
international research on human participants to encourage best practices and 
harmonization in biomedical. The first international guidance for biomedical 
research was 'International Ethical Guidelines for Biomedical Research Involving 
Human Subjects' prepared by CIOMS in 1982 and subsequently revised in 2002 
and the 'International Guidelines for Ethical Review of Epidemiological Studies' 
in 2009.  The WHO developed 'Operational Guidelines for Ethics Committees that 
Review Biomedical Research' in 2000, the 'Guideline for Obtaining Informed 
Consent for the Procurement and Use of Human Tissues, Cells, and Fluids in 
Research' in 2003, 'Handbook for Good Clinical Research Practice (GCP) 
Guidance for Implementation in 2005' , 'Standards and Operational Guidance for 
Ethics Review of Health-Related Research with Human Participants' in 2011 
(Alahmad et al., 2012; Artene et al., 2013; De Souza & Greenspan, 2013; EC, 
2012; Harris et al., 2012; Kang et al., 2013; Nair & Ibrahim, 2015b; OHRP, 
2016a; Silverman et al., 2013).  
Other internationally recognized organizations and societies have 
established international guidance or statements on genomic research or human 
genomic databases, such as the OCED, the Human Genome Organization 
(HUGO) and ISBER. The OCED developed 'Best Practices Guideline on 
Biological Resource Centers' in 2007, which includes a chapter on using human 
biosamples for research.  Later in 2009, it published another guide that addressed 
the 'use of human biosamples in genetic research titled 'OECD Guidelines on 
Human Biobanks and Genetic Research Databases'. The HUGO developed 
'Statement on the Principled Conduct of Genetic Research' in 1996, 'Statement on 
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DNA Sampling: Control and Access' in 1998 and 'Statement on Benefit Sharing' 
in 2000 (EC, 2012; OECD, 2009; OHRP, 2016a). ISBER published 'Best 
Practices for Repositories: Collection, Storage and Retrieval of Human Biological 
Materials for Research' in 2005 and further revised in 2008 and 2012. It has 
addressed topics such as biobank setup, quality assurance and quality control, 
specimen collection and processing, training, as well as important legal and 
ethical issues, among others (De Souza & Greenspan, 2013).  
2.5.3 Legal Instruments 
Legal instruments include national laws or Acts that were passed 
specifically on biobanking activity such as those in Iceland, Estonia, Fenland, 
Hungary, Denmark, Norway, Sweden, Spain, Bulgaria, Portuguese, Taiwan and 
China. They could also be integrated with other legislation laws such as those in 
the UK, France and the Netherlands (Chen, 2014; EC, 2012; Marko-Varga et al., 
2014; Office of Human Research Protections [OHRP], 2016; Scott, Caulfield, 
Borgelt, & Illes, 2012).  
These laws or Acts were created to ensure the legal basis for biobanks and 
important biobanking activities. They address important aspects related to 
biobanking such as ownership of biobank resources; biosample and data; the form 
and level of stored personal and health  information that could be coupled with the 
biosample; as well as the who, how and where biosamples could be stored and 
used over a long  period of time. 
Other countries such as the US, Canada, and Australia have not passed 
specific laws or Acts on biobanking; instead, there were several laws, acts and  
federal regulatory policies- on biomedical research, privacy of personal 
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information, genetic information non-discrimination, bioinformatics and others- 
that cover aspects of biobanking activity which vary in extent (Marko-Varga et al., 
2014; OHRP, 2016a).   
2.5.4 Regulatory bodies 
Research ethic committee (REC), also named as institutional review board 
(IRB), independent ethics committee or ethical review board, is essential 
governance structures to approve biobank establishment and biobank research 
protocols. The main roles of such regulatory bodies are to oversee the governance, 
management and operation of the biobank and to ensure compliance with 
applicable domestic and international legislation, regulations, policies and 
frameworks. They review the scientific aspect of research or research protocols as 
well as the use of biosamples (DHWA, 2010; EC, 2012; O'Doherty & Hawkins, 
2010). These committees are independent and are formed of experts from the 
various scientific, legal, ethical and clinical domains, as well as representatives of 
participants, and members of the general public. 
 Other regulatory bodies could include a Data Authority Body or its 
equivalent. They could serve as independent bodies to audit compliance of RECs 
or IRBs, to monitor access to and the uses of the biosamples and data, adherence 
to research ethics approvals, as well as access approvals and ensuring that 
participants' approval is granted during the informed consent process (DHWA, 
2010; EC, 2012).  In addition, there can be other oversight bodies including a 
National Health Research Authority or Higher Research Council, or its equivalent. 
The main role is to reassure that research participants' interests and rights are 
protected, as it is done in the UK (EC, 2012).  
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Collaboration and coordination of RECs with such regulatory authorities 
should be encouraged and obligated by national laws (EC, 2012). RECs should 
seek accreditation or certification by recognized international bodies or programs 
to ensure quality and compliance with laws and policies. Several accreditation and 
certification initiatives such as the Strategic Initiative for Developing Capacity in 
Ethical Review (SIDCER), and programs such as the Association for the 
Accreditation of Human Research Protection Programs (AAHRPP) have been 
adopted by some countries. These facilitate registration, self-assessment and 
second external reviews, which will add to the RECs' effectiveness (Silverman et 
al., 2015).  
2.5.5 Community advisory groups 
Community advisory boards (CABs) or equivalent groups are another 
form of less formal governance structure. These groups can be the voice of the 
participants and the general public, and can be part of the decision-making process 
during planning, implementing and maintaining population-based biobanks 
(Olson et al., 2014).  
2.6 Review of medical research and biobank ethics and 
governance in the Middle-East 
The extent of research ethics capacity and their development vary widely 
in the countries of the region (Silverman et al., 2013). Medical research 
experience in the Arab countries of the Middle East region is limited compared to 
other regions of the world (Nair, Ibrahim, & Celentano, 2013); however, it is 
growing rapidly now. The inadequacy of research governance structure in the 
region has attracted pharmaceutical companies to the region and the number of 
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clinical trials has increased dramatically over the last two decades (Alahmad et al., 
2012; Silverman et al., 2015; Silverman et al., 2013).  
A review biomedical research regulations and guidance from the Arab 
countries of the Middle East region is limited. In fact, some countries such as 
Oman and Yemen do not have anything in place, while Syria refers to Helsinki 
Declaration and the CIOMS International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (Alahmad et al., 2012; H. Silverman et al., 
2013). Five countries have national laws that address research on human 
participants.  Two of them had laws specifically on medical research 'Law of 
Clinical Trials' Jordan passed in 2001, and another recent one 'System of Ethics of 
Research on Living Subjects' in Saudi Arabia in 2010.  The other three countries 
have laws on medical ethics or medical liabilities in general, and include some 
language on medical research such the one that the UAE passed in 2008, Lebanon 
in 1994 and in Egypt in 2003 (Alahmad et al., 2012; OHRP, 2016a; Silverman et 
al., 2013). 
In the UAE, the Federal Medical Liability Law No. (10) of 2008, recently 
revised in 2016, and the Cabinet resolution No (33) of 2009 concerning the 
Implementation Regulation of the Federal Medical Liability Law 2008, cover 
some regulations on medical research. Article 8 of the resolution stated, the 
requirement for preauthorization, list the authorizing authorities and mandate that 
research practices must comply with international guidance on best practices and 
Sharia (Islamic) laws. Article 9, stated the approved sites for research, the process 
and conditions of informed consent.  In Abu Dhabi Emirate, HAAD had published 
the Healthcare Policy Manuals, in 2012. Chapter V of the Healthcare Regulator 
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Manual, covered research oversight bodies and their roles, authorization 
requirements for facilities and investigators, and treatment of personal data.  The 
Healthcare Provider, Professional and Insurer policy manuals contains provisions 
that cover protection of personal data and duties relating to data management and 
confidentiality. However, the  implementation of this policy is confined to Abu 
Dhabi Emirate (HAAD, 2016c).    
Regional guidelines on research on human participants are scarce. The few 
available guidelines are the UAE's 'Guidance for Conducting Clinical Trials Based 
on Drugs/Medical Products & Good Clinical Practice' developed in 2006, 'HAAD 
Data Standards and Procedures' developed in 2008 that covers the collection,  
storage, access use and publication of personal and health data and  the obligations 
to respect privacy and confidentiality, 'Standard Operating Procedures for 
Research Ethics Committees'  developed in 2012 that encloses some language on 
biobanking, and 'HAAD Guidelines for Patient Consent' revised in 2016 which 
covers conditions required for informed consent for medical research purpose 
(HAAD, 2016d; Alahmad et al., 2012). Saudi Arabia developed 'Clinical Trial 
Requirement Guidelines' in 2005 and revised it in 2008. Sudan published 
'National Guidelines for Ethical Conduct of Research Involving Human Subjects' 
in 2008, Bahrain 'Ethical Guidelines for Health Research 'in 2009, Kuwait 'Ethical 
Guidelines for Biomedical Research' in 2009 and  Qatar 'Guidelines, Regulations 
and Policies for Research Involving Human Subjects' in 2009 (Alahmad et al., 
2012; OHRP, 2016a; Silverman et al., 2013).  
Generally, the existence as well as the number of RECs in the region is 
limited. It has been observed that as a response to increased clinical trials in the 
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region, the number of RECs is increasing and recently several institutions in the 
region have established departments and units for medical research ethics 
(Silverman et al., 2015; Ten Have, 2006). 
Biobanking has been recently introduced in the Middle East region by a 
few countries such as Qatar, Saudi Arabia and Jordan. There were no specific 
laws or acts on biobanking activities or genomic research (Alahmad et al., 2012; 
OHRP, 2016a; Silverman et al., 2013). The existing guidelines do not cover 
important practices and procedures on biobanking activities. The governance 
structure pertaining to biobanking activity in the Middle East region, in the form 
of legal instruments or guidance is still to be developed (Alahmad et al., 2012).  
2.7 ELSI Challenges of the Population-based Biobanks 
Governance of population-based biobanks is a huge challenge for ethicist, 
scientist and biobank stakeholders, including participants. Existing medical 
research ethics legislation and regulations are not sufficient to address biobank's 
legal and ethical aspects (Marko-Varga et al., 2014; EC, 2012), for the following 
reasons. First of all, population-based biobanks are not seen merely as a research 
infrastructure, it represents major public investment and interests (O'Doherty et 
al., 2011). Secondly, biobanks are long-term prospective projects, and many risks 
pertaining to biobanking operations, future innovations and potentials cannot be 
fully predicted at the time of establishment. Thirdly, they involve complex 
bioinformatics and communication operations, including the potential for linking 
biobank databases with other vital and health databases and registries which 
requires them to ensure that the data remain potentially re-identifiable (EC, 2012; 
Olson et al., 2013; Otlowski, 2012).  A fourth consideration is that biobank 
research involves storage of genetic data that may be considered as personal 
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identifiers (Otwolski 2013) and may involve multiple use of its resources, 
biosample and data,  across various research projects and investigators. And 
fifthly, biobanks have a wide range of stakeholders including participants, public, 
researchers and their research organizations, as well as commercial and 
government entities. This adds to the challenge in terms of complexity of 
governance arrangements required, including laws, protocols, ethical guidelines 
and contracts.  
Finally, there are growing efforts towards globalization as well as building 
regional and international networks for research to increase the efficiency of 
genomic research. This implies sharing biobanks’ resources with other research 
facilities outside the country of donation (Artene et al., 2013; EC, 2012; Gitter, 
2013; Gottweis & Lauss, 2010; Gottweis, Gaskell, & Starkbaum, 2011; Harris et 
al., 2012; Otlowski, 2012; Prainsack & Buyx, 2013; Womack & Mager, 2014). 
Biobank challenges can be broadly classified as legal, ethical and social. These 
challenges will be described below in detail.  
2.7.1 Legal challenges. 
2.7.1.1 Regulations and guidelines 
Major challenges is lack of appropriate or insufficient regulation for 
biobank research. Currently countries that have implemented population-based 
biobanks are either in the process of developing new legislation or revising their 
existing medical ethics legislation to cover important aspect of biobanking 
activities (Budin-Ljøsne et al., 2012).   
Only a few countries have defined and passed new national laws or acts 
specifically addressing biobanking activity, while others have integrated 
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biobanking related laws into other laws, or passed decrees or rules to cover some 
aspects of biobanking (Marko-Varga et al., 2014; OHRP, 2016a).  In the Middle 
East, there are significant gaps in the development of legislation, laws or 
guidelines related to medical research as well as biobanking activity. 
Passing national legislation is often an extensive and lengthy process that 
does not keep pace with the rate of dynamicity and innovation of in the field of 
biobanking, and would not be sufficient to cope with the many risks raised in a 
timely fashion. In addition, revisions and updates of existing laws require 
substantial investments of time. Such was the case of Norway, where their 
existing national legislation needed revision in order to accommodate new 
requirements for genome sequencing that were not covered by their 
Biotechnology law. To this end, the law has to undergo regular revision (Budin-
Ljøsne et al., 2012). 
Moreover, there is little attention being paid to ensuring that these acts or 
laws are flexible and consider the regional and global trends in biobank research 
networks in such way that national legislation is in harmony with other 
jurisdictions (Budin-Ljøsne et al., 2012).  
On the other hand, legislations on biobanking activity may be burdensome 
or restrictive rather than facilitative (Budin-Ljøsne et al., 2012; Stjernschantz 
Forsberg, Hansson, & Eriksson, 2011). An example is the French national 
legislation for biobanking activity that was fragmented and integrated with other 
legislation. The challenges with such fragmentation are that they require obtaining 
separate authorizations for specific biobanking activities which is time consuming 
and burdensome for researchers (Budin-Ljøsne et al., 2012). In Italy, the Italian 
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Personal Data Protection Code for General Authorization for the Processing of 
Genetic Data allows samples to be stored for research, but requires specific 
written consent for each new research study. 
Other regulatory challenges are related to the international codes and 
declarations such as the Nuremberg Code, Declaration of Helsinki and the 
UNESCO Declarations. All these codes and declarations have not been ratified 
into international law, and have no legal force behind them (Alahmad et al., 2012; 
EC, 2012; Marko-Varga et al., 2014). 
 International guidelines for best practices, as mentioned earlier, from 
WHO, CIOMS, ICH-GCP and others from North America, Europe and  those 
developed in the Middle East region, even if available and widely shared to 
encourage standardization and harmonization, do not have legal statements and 
are non-binding in nature (Alahmad et al., 2012; EC, 2012; Marko-Varga et al., 
2014; Silverman et al., 2013). Adherence guidelines are completely voluntary and 
vary in degree across countries, particularly in the Middle East region (Alahmad 
et al., 2012; Lahey, 2013; Nair & Ibrahim, 2015a; Nair & Ibrahim, 2015b; 
Silverman et al., 2015; Silverman et al., 2013).  
A very limited number of regional guidelines based on International 
guidance were developed in the Arab countries of the Middle East. However, 
when compared with the international guidelines such as the CIOMS, ICH-GCP 
and other International guidelines, they have many deficiencies with regard to the 
protection of human participants. These deficiencies vary in type and number 
from one country to another, posing major risks on the protection of research and 
biobank participants (Alahmad et al., 2012).  
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2.7.1.2 Oversight bodies   
One of the common challenges with regards to oversight bodies is that 
these committees usually have no legal status, and as such, no power of 
enforcement (EC, 2012; Kaye, 2012b; Marko-Varga et al., 2014). Only Sweden 
has passed an act to legalize the role of REC (Marko-Varga et al., 2014). 
In addition, the definition and standardization of RECs structure and roles 
vary worldwide. Few countries such as Estonia, Italy, France, Finland, Austria, 
China and India have defined and regulated the structure and roles of RECs 
(O'Doherty & Hawkins, 2010). Some countries have created their own guidelines, 
the UAE is the one and only country from the Arab Middle East region to have 
done that (Nair et al., 2013). 
In the context of regional networks or globalization, IRB or REC decisions 
might vary among regions and countries, and their power of enforcement is 
restricted only to their own jurisdiction. Also, since there is no mutual recognition 
of research ethic committee decisions, each regional or global research protocol 
must be submitted to own country for ethics approval, which duplicates efforts. 
Furthermore, these committees face the challenge of having to investigate non-
compliance by secondary (external) researchers not based in their countries (EC, 
2012).  
Additional challenges from Arab Middle East countries include the low 
number of existing RECs, insufficient training of members in the field of research 
ethics, limited human and financial resources, and lack of diversity in members. 
There are unmet needs for conducting audits or secondary external reviews by 
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independent regulators, or registration to internationally recognized accreditation 
programs or initiatives (Silverman et al., 2015; Silverman et al., 2013).  
Furthermore, there are no gold standard tools to evaluate the effectiveness 
of RECs with regard to ethical quality of reviews or the impact of RECs on 
research practices (H. Silverman et al., 2015).  
2.7.2 Ethical challenges. 
Protection of participants' rights and interests is the central concept behind 
effective biobank governance. The considerable ethical challenges related to 
informed consent, withdrawal of consent, privacy and confidentiality protection, 
return of research results and commercialization will be described below.   
2.7.2.1 Informed consent 
Informed consent is the most frequent ethical issue pertaining to biobank 
research that has been raised and addressed in the literature (Budimir et al., 2011; 
Caulfield et al., 2014; Master  & Resnik, 2013). The fundamental principle of 
research governance that includes biobank research is to ensure autonomy, respect 
and protection of research participants, while keeping the research interests in 
consideration (EC, 2012; OECD, 2009; Otlowski, 2012).  
Informed consent is one‎way‎to‎respect‎a‎participant’s rights and dignity, 
so that they exercise autonomy and make decisions about matters in light of their 
own values. Respect of autonomy implies respect of human dignity and rights. 
The consent process involves protecting research participants through providing 
them with the necessary information transparently and honestly in order to fairly 
assess risks (Otlowski, 2012). It is also seen as a process to honor research 
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participants’ contributions to advance medical research and generate new 
knowledge (Clayton, 2005 cited in Otlowski, 2012).   
Informed consent is a process by which research participants voluntary 
confirm willingness to participate in research after being informed on all related 
aspects pertaining to that particular research that will help them to make a 
decision about participation, and is documented by means of a written, signed, and 
dated form (International Council for Harmonisation [ICH], 1996).  
Informed consent is a requirement of the Nuremberg Code (Health and 
Human Services, 2005) and is reflected in a number of international declarations 
such as, the Declaration of Helsinki and the Universal Declaration on the Human 
Genome and Human Right. For example, article 26 of the Declaration of Helsinki 
states: "In medical research involving human subjects capable of giving informed 
consent, each potential subject must be adequately informed of the aims, methods, 
sources of funding, any possible conflicts of interest, institutional affiliations of 
the researcher, the anticipated benefits and potential risks of the study and the 
discomfort it may entail..." (World Medical Association [WMA], 2013). This 
essential requirement is reflected as well in all national legislations and 
regulations, guidelines on research on human participants.  
The major ethical concern related to informed consent is whether research 
participants are adequately informed about risks and benefits of biobank research.  
The challenges are in the appropriate selection of information-what, how, who and 
the amount- and consent policy (Hansson, 2011).  
The consent form or document could vary by type of research; however, 
guidelines on best practices, such as those of the ICH-GCP, WHO, CIOMS and 
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others, require that the informed consent document should cover specific basic 
requirements in order to provide information needed to make an informed consent 
about participation. This basic information includes title of the research, details 
regarding the researcher and the organization conducting the research, purpose of 
the research, participant responsibility, risks, benefits, duration of research, 
storage of sample and ways it will be discarded, protection of data and 
confidentiality measures, the right to withdraw without penalty or loss of benefits 
and contact details for more information (ICH, 1996; Nair et al., 2013; Nair & 
Ibrahim, 2015a; Nair & Ibrahim, 2015b; WHO, 2002).  
To obtain informed consent about participation at the time of recruitment, 
the research consent form should meet the fundamental requirements of a biobank 
consent form, based on guidelines mentioned above, as well as the legal 
requirements of the country. It is also equally important to ensure that participants 
are able to comprehend the information provided in the form. The consent form 
should focus on providing the most important and relevant information on the 
biobank research from the participants' perspective. It should be in a simple and 
short format; so a one page consent form outlining the most important information 
in a straightforward, easily readable language is suggested (Beskow et al., 2010; 
Sheehan, 2011). More detailed information can be provided to interested 
participants in the form of supplementary information or FAQ's (Beskow et al., 
2010; Beskow, Dombeck, Thompson, Watson-Ormond, & Weinfurt, 2015). 
The consent form needs to be in a readable and simplified language in 
order to address language barriers and ensure health literacy (ICH, 1996; Nair et 
al., 2013; Nair & Ibrahim, 2015a; Nair & Ibrahim, 2015b; WHO, 2002). 
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Moreover, the consent process must ensure voluntary participation and must be 
sensitive to and respectful of the cultural, social, and religious differences of 
participants (Hansson, 2011). 
In the context of regional or international networks or hubs, generic 
consent is often required.  Most countries do not have a generic model of 
informed consent form for biobank research, and the requirement of consent may 
vary according to research studies (Beskow et al., 2015; Budin-Ljøsne et al., 
2012). This issue makes it hard for biobanks to determine from the original 
consent form the specific research purposes for which the resources, biosamples 
and data could be used and shared, as well as an understanding of which resources 
can be considered as intellectual property of the biobank (Budin-Ljøsne et al., 
2012). This issue is even more complicated in cases of resources from deceased 
individuals (Budin-Ljøsne et al., 2012; Tasse, 2011).   
With regard to consent policy, according to WHO's 'Guideline for 
Obtaining Informed Consent for the Procurement and Use of Human Tissues, 
Cells and Fluids in Research', there are three main consent policies in medical 
research on humans. These are fully restricted or 'narrow' or 'specific' consent, 
partially restricted or 'tiered' consent and unrestricted or 'broad' consent. In fully 
restricted consent, the participant consents to the use of the biosamples and/or data 
to the immediate specific research only. In partially restricted, the participant 
consents to the use of the biosamples and/or data in the immediate research as 
well as in future research of a specified type or types, and up to a specified time in 
the future. In the unrestricted, the participant consents to the use of the biosamples 
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and/or data in the immediate research, as well as future research of any kind and at 
any time (Otlowski, 2012; WHO, 2002).  
The assumption made by most scientists and researchers about research 
participants' expectations and interests is that they prefer specific consent policy, 
as this gives them the control over the way their contributions, biosample and data 
will be used, especially genetic data; it is the optimal approach that certainly 
addresses the ethical principles of informed consent (Otlowski, 2012). However, it 
is thought that specific consent maximizes participant autonomy at the expense of 
research expansion and convenience (Master et al., 2015). In addition, specific 
consent would require recontact of participants for every linkage and reuse of their 
samples and data for research. This approach would not be appropriate for large 
scale and long-term operations of population-based biobank research. It is 
burdensome on participants as it might cause inconvenience and unnecessary 
intrusion into their private lives. It might also affect the scientific value of the 
initiative as it increases the risk of high dropout of research subjects and/or 
introduces consent bias. In addition, practicing it is burdensome and impractical 
for the biobank as it implies additional time, logistics and costs to biobanks; 
besides, acquisition of consent is impossible from deceased donors (D'Abramo, 
Schildmann, & Vollmann, 2015; Otlowski, 2012; Porteri, Pasqualetti, Togni, & 
Parker, 2014; Steinsbekk, Kare Myskja, & Solberg, 2013). Ethically, specific 
consent holds participants accountable to understanding risks and benefits of 
research (Beauchamp, 2011; Otlowski, 2012).  
The International Bioethics Committee of UNESCO, WHO, other 
researchers and biobank scientists support broad consent policy as valid and 
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appropriate policy for a population-based biobank research (D'Abramo et al., 
2015; Master et al., 2015; Otlowski, 2012; Sheehan, 2011). In fact, there is a 
growing academic, scientist and international support to broad consent (Master et 
al., 2015; Otlowski, 2012). Those who support broad consent argue that since 
participants are provided with information that covers all aspects relevant to an 
individual's choice, then that is an appropriately informed individual consent. If 
the information given is general, covering all risks and benefits of potential future 
research that might be conducted using biobank resources as specified in an 
agreement or consent form, and if those resources are used only for biomedical 
research and not for any other purpose such as in forensics or by immigration 
authorities, then broad consent is considered to be informed consent (Hansson, 
2011). 
Another supporting argument relies on the precise meaning of informed 
consent, which is enabling participants to choose to accept certain risks for the 
sake of possible benefits according to their plans (Sheehan, 2011). In the case of 
biobank research, it is assumed that the risks, compared to benefits, are generally 
considered as low. The risks are related to privacy and come with the right to 
withdraw, while biobank research itself is socially valuable, and participation in 
biobank research is seen a duty and an expression of solidarity to support medical 
research (D'Abramo et al., 2015; Master & Resnik, 2013; Prainsack & Buyx, 
2013).  
Furthermore, those who support broad consent rely on: (i) the option of 
withdrawal of consent at any time as a granted right for all participants; (ii) the 
role and ethical accountability of governance structure (the REC) in assessing the 
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risks and benefits for participants, and ensuring that adequate privacy protection 
measures and anti-discrimination policies are in place  (D'Abramo et al., 2015; 
Master & Resnik, 2013; Otlowski, 2012; Sheehan, 2011); (iii) ongoing review of 
participants' consent to ensure that the use of samples and data are consistent with 
the consent given, and for approved purposes and governance of the biobank 
(Hansson, 2011); and (iv) ensuring ongoing communication with research 
participants on the biobank research directions and possible use of its resources, 
which gives a sense of control to participants. This communication could be 
through updates on a website, newsletter via emails or other means of 
communication (Otlowski, 2012).  
Some researchers believe that adding 'Exclusion Clauses' to biobank 
participant consent forms gives research participants more control on the use of 
their contributions for research as it enables participants to indicate certain types 
of research that they do not wish to allow their contribution to be used. It also 
limits the sharing of biosamples and data with specific research organizations such 
as international researchers and insurance companies. Another advantage is that it 
increases transparency and promotes accountability to biobank research, thereby 
increasing trust. However, exclusion clauses are written by researchers, and as 
such, participants might have some difficulty understanding it, or they might not 
represent participant concerns (Joly et al., 2015; Master & Resnik, 2013; Master et 
al., 2015). In addition, this model is useful and applicable for small-scale or 
disease-oriented biobanks, and is not practical for population-based biobank 
research (Master & Resnik, 2013; Master et al., 2015).  
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In cohort and retrospective biobank research, the most common types of 
consent policy used are the specific and the broad consents (Fullerton & Lee, 
2011). Table ‎11 provides examples of informed consent policies in the existing 
national and population-based biobanks in selected countries.   
Research participants’ views and preferences regarding biobank research’s 
informed consent policy might differ from theoretical justifications or scientists' 
views (D'Abramo et al., 2015). In fact published studies and systemic reviews 
showed variations across population and subgroups of same population. Some 
studies and systemic showed that the general public prefer the specific one time 
consent approach (D'Abramo et al., 2015; Eder, Gottweis, & Zatloukal, 2012; 
Husedzinovic et al., 2015; Lewis, Clotworthy, Hilton, Magee, Robertson, 
Stubbins, & Corfield, 2013a; Lipworth et al., 2011; Platt et al., 2014; Tauali et al., 
2014),  while other recent studies and systemic reviews, including a study from 
Jordan, Middle East, showed a preference for broad consent (Ahram et al., 2013; 
Allen & McNamara, 2011; Caulfield et al., 2012; Ewing et al., 2015; Garrison et 
al., 2015; Joly, Dalpe, So, & Birko, 2015; Kelly et al., 2015; Lemke, Halverson, & 
Ross, 2012; Lipworth et al., 2011; Platt et al., 2014; Porteri et al., 2014; Simon et 
al., 2011).  
Studies showed that public preference regarding the type of consent 
depended on whether they were offered different options for consent - including 
narrow or specific consent.  It also depended on whether they could clearly 
understand the biobank logistics as well as the research risks and benefits for them 
as individual and as a society (D'Abramo et al., 2015; Garrison et al., 2015; 
Tomlinson et al., 2015). Furthermore, preference to broad consent was determined 
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by certain demographic characteristics such as ethnicity (Ewing et al., 2015; 
Garrison et al., 2015; Joly et al., 2015; Platt et al., 2014), level of education, 
income (Platt et al., 2014) and gender (Garrison et al., 2015). Female respondents 
and those with unfavorable demographic characteristics and minorities favored 
specific consent (Garrison et al., 2015; Lewis, Clotworthy, Hilton, Magee, 
Robertson, Stubbins, & Corfield, 2013a; Platt et al., 2014).  
2.7.2.2 Withdrawal of consent 
The ability to withdraw consent without penalty or loss of benefits is one 
of the rights explicitly established by the Nuremberg Code as well as in all 
research ethics declarations and guidelines, such as Helsinki Declaration, the 
UNESCO International Declaration on Human Genetic Data, HUGO statements 
and CIOMS guidelines and others. These guidelines and declarations agree and 
emphasize that the right to withdraw from research has five characteristics: it is 
immediate, absolute, unconditional, complete and untradeable (Holm, 2011). 
For‎ example,‎ in‎ article‎ 16‎ of‎Helsinki‎Declaration,‎ it‎ was‎ stated‎ that‎ “a‎
potential subject must be informed of the right to refuse to participate in the study 
or‎to‎withdraw‎consent‎to‎participate‎at‎any‎time‎without‎reprisal”‎(WMA,‎1013).‎
The UNSECO International Declaration on Human Genetic Data provided two 
options for complete withdrawal of consent: either to destroy any use of data and 
biosamples, or keep them with full anonymization. In addition, it requires that 
destruction of biosamples and data are done in accordance with the wishes of the 
research participants (Alahmad & Dierickx, 2014; Melham et al., 2014; UNESCO, 
2004) and with due respect to their cultural heritage and religious beliefs 
(Alahmad & Dierickx, 2014; OECD, 2009). The more recent CIOMS 
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International Guidelines for Ethical Review of Epidemiological Studies (2008) 
recognizes that withdrawal of consent in epidemiology or population studies can 
be challenging and might take several forms (Council for International 
Organizations of Medical Sciences [CIMOS], 2008; Melham et al., 2014).    
Withdrawal of consent is granted to all participants in research on human 
subjects, as reflected in all international principles and guidelines, as well as 
national legislations and regulations on research on human participants.  However, 
the extent and characteristics of right to withdraw in the context of biobank 
research is not similar to that of traditional medical or clinical research. Careful 
attention needs to be given to what withdrawing consent actually means in the 
context of biobank research (Melham et al., 2014; Otlowski, 2012).   
The biobank collects and stores biosamples and massive personal, 
genomic, environmental, lifestyle and medical data that is digitized to make them 
easily replicable and distributable, then aggregated and integrated into large sets 
of 'big data' and sometimes are allowed commercial access. The data is then 
shared with a variety of collaborators and networks outside the biobank, which 
makes individual data difficult to trace (Kaye, 2012b; Melham et al., 2014). 
Likewise, data published as part of aggregate data set cannot be meaningfully 
withdrawn from the public domain. Moreover, the previous use of biosample and 
data cannot be undone, therefore withdrawing of consent in the biobank research 
setting in reality means preventing future use of previously collected biosamples 
and data, rather than cessation of intervention (Melham et al., 2014).   
Existing population-based biobanks have defined or adopted various 
policies regarding withdrawal of consent, primarily 'all or none' or 'tiered' 
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strategies.  The adoption of various policies depends on the operational capacity 
of the biobank to deal with withdrawal of consent requests (Melham et al., 2014). 
Withdraw of consent might mean (i) no further contact; (ii)  no further ongoing 
collection of data and no further contact; or  (iii) complete withdrawal of samples 
and data from future use in any new research. Complete withdrawal of consent 
might include complete destruction of samples and data or irreversible 
anonymization. It is important that research participants are aware of these 
implications and understand the meaning of each option of withdrawal of consent 
in the biobank setting in order to make an informed consent about participation in 
the biobank (Hansson, 2011; Melham et al., 2014). 
Also it is important to have an opt-out registry, such as that in Denmark 
and Norway, to monitor informed consent processes and ensure that participants 
understand their right to opt out (Budin-Ljøsne et al., 2012).   
2.7.2.3 Privacy and confidentiality 
Biobanks carry high informational risks as they collect and store huge 
quantities of phenotype and genotype data of many individuals and from various 
sources, and may routinely recontact participants to update their phenotype data 
(Hansson, 2011). The major information risks of  biobanks are (i) risk of misuse 
of data, particularly genetic data, that could result in discrimination of participants 
by third parties such as insurance companies, employers or commercial entities, or 
stigmatization of individuals or subgroups of the populations; (ii) loss of privacy 
as a result of collecting a lot of information including genotype data from various 
sources such as medical records, registries and national database; (iii) potential 
breach of confidentiality as a result of indirect disclosure of data over time, or re-
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identification of research participants (Budimir et al., 2011; Caulfield et al., 2014; 
Evers et al., 2012; Fisher & Harrington McCarthy, 2013; Gitter, 2013; Hansson, 
2011; Laurie et al., 2010; Petrini, 2012).   
Protection of research participant identity is one of the fundamental 
principles of research ethics (Heeney, Hawkins, de Vries, Boddington, & Kaye, 
1011).‎As‎stated‎in‎article‎14‎of‎Helsinki‎Declaration,‎“Every precaution must be 
taken to protect the privacy of research subjects and the confidentiality of their 
personal information”‎ (WMA,‎ 1013).‎ As‎ well‎ as,‎ mandated‎ in all existing 
national legislations and regulations on research on human participants. 
To protect against the misuse of data, several guidelines insist that access 
to biobank data is granted only to researchers, and only for research purposes. For 
example, the OCED 2009 guidelines on HBGRD stated, “These Guidelines set 
out that the HBGRD should not grant access to or disclose participants' human 
biological materials or data to third parties for non-research purposes, except 
when required by law. For example, the operators of the HBGRD should not make 
available participants' human biological materials or data to third parties such as 
insurers, employers, law enforcement agencies or other civil-law agencies for 
non-research purposes” (OECD, 2009). 
Biobanks have the obligation to protect research participant identity while 
maximizing the use of data for research (EC, 2012; Kaye, 2012b). For that, 
biobanks may adopt several levels of protection of personal data, but none 
provides complete protection (Greely, 2007 cited in Budimir et al., 2011). Most 
scientists prefer coding of data in the belief that it is the standard research practice 
and the appropriate solution to protect privacy (Budimir et al., 2011; EC, 2012). 
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Coding means that the biobanks remove participant identifiers and replace it with 
a code. The code is then encrypted for use by researchers.  However, data and 
sample sources must remain potentially re-identifiable to the biobank custodian to 
allow future recontact and ongoing linkage of various sources of data to the 
specific individual (EC, 2012; Kaye, 2012b).  
Anonymization is another privacy protection strategy and considered the 
ideal way to protect personal data (Budimir 2011). Anonymization prevents 
participant re-identification through deleting the coding keys linking data and 
samples to participant's identifiers (OECD, 2009). It provides additional 
confidentiality and privacy protection over coded data. However, it is impossible 
to guarantee anonymity, especially when heath data are used in different contexts 
or genomic data are involved (Mostert, Bredenoord, Biesaart, & van Delden, 
2015). 
'Anonymize or consent' strategies are well-accepted ethical positions in 
research as methods to protect privacy (Laurie et al., 2010; Hansson, 2011). 
Consent respects a participant's autonomy to make decisions regarding privacy 
risks (Kaye, 2012b; Laurie et al., 2010). Anonymization  and coding is another 
conventional approach used to eliminate the need for consent or other legal 
requirements (Mostert et al., 2015), or to justify broad consent policies as it 
eliminates the need for re-consent in future research on the same samples and data 
(secondary research) (Whitley, Kanellopoulou, & Kaye, 2012). However, 
anonymization reduces research utility (Budimir et al., 2011; A. K. Hawkins & 
O'Doherty, 2011; Laurie et al., 2010), makes it difficult to recontact participants 
for future research, return of research results or withdrawal of consent, and is 
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considered disrespectful to participants (Budimir et al., 2011; Thorogood et al., 
2014). 
However, privacy in the context of genomic research poses additional 
challenges. It is believed that the effectiveness of traditional research measures to 
protect privacy, such as coding and anonymization are questionable in the context 
of biobank genomic research, and cannot guarantee absolute protection 
(Greenbaum, Sboner, Mu, & Gerstein, 2011; Heeney et al., 2011; Kaye, 2012b; 
Laurie et al., 2010; Thorogood & Zawati, 2015).  
The new whole genome sequencing technologies produce rich and more 
detailed information that is specific and unique to individuals (Greenbaum et al., 
2011).  The advancements in bioinformatics has made re-identifying research 
participants from a small amount of genetic and/or clinical data increasingly 
possible (Heeney et al., 2011). Additionally, the development of biobank research 
networks and increased data sharing make it difficult to guarantee complete 
confidentiality (McGuire et al., 2011). Similarly, human genome sequence 
datasets and information are increasingly available publicly outside the controlled 
environment of medical research. People can now obtain access to their own 
genome data through direct-to-consumer companies (Lumley & Rice, 2010). They 
can also trace their biological relatives through ancestor-tracing companies (Kaye, 
2012b).   
In addition to scientists' views, published studies on the willingness of 
general public to participate in population-based biobanks report that privacy and 
confidentiality are the most common concerns expressed by the general public 
from various populations and sub-populations, including the Middle East (Ahram, 
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Othman, Shahrouri, & Mustafa, 2013; De Vries et al., 2016; Eder et al., 2012; 
Gaskell et al., 2013; Halverson & Ross, 2012a; Igbe & Adebamowo, 2012; Joly et 
al., 2015; Kerath et al., 2013; Lemke et al., 2010; Melas et al., 2010; Nasrella & 
Clark, 2012; Overby et al., 2015; Pullman et al., 2012; Rahm et al., 2013; 
Ridgeway et al., 2013; Simon et al., 2011; Spruill et al., 2014). 
2.7.2.4 Return of research results 
The return of research findings in the field of medical research is limited to 
general or aggregate outcome of research. As stated in article 26 of Helsinki 
Declaration,‎ “All medical research subjects should be given the option of being 
informed about the general outcome and results of the study.”(Knoppers, Zawati, 
& Senecal, 2015; WHO, 2002; WMA, 2013).  
The return of results in clinical trials on drugs and medicine is the norm, 
however it is challenging in genomic research and biobank research (Knoppers et 
al., 2015). According to researchers, there are four approaches for returning 
genomic results in whole genome sequencing: (i) return only panels of specific 
genes or targeted sequencing to reduce the potential for incidental findings; (ii) 
return results if they meet specific criteria, such as ACA, analytical validity, 
clinical significance and actionability; (iii) ad hoc case-by-case determination; or 
(iv) no return.  
Analytic validity means that the test can accurately and reliably identify a 
particular genetic characteristic; an actionable finding is a finding that is 
considered actionable if there are identified therapeutic or preventive interventions 
that have the potential to alter the course of the disease or condition; and clinical 
significance means an accurate and actionable research finding (Knoppers et al., 
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2013). The most recent conclusion revolving consensus of researcher participants 
and panel experts is that researchers are obliged to return at least some incidental 
results of genomic research to research participants (Appelbaum et al., 2014). 
Existing population-based biobanks typically return two types of results to 
participants: initial assessment and general outcomes results. Initial assessment 
results might include blood pressure, BMI and other tests often in the form of a 
written summary (Al Kuwari et al., 2015; Knoppers et al., 2013; Smith & Aufox, 
2013; Wallace & Kent, 2011; Zawati, Knoppers, & Thorogood, 2014). In case any 
of these results are abnormal or merit clinical interference, participants will be 
recommended to visit their healthcare providers for proper management (Al 
Kuwari et al., 2015; Knoppers et al., 2013; Wallace & Kent, 2011). The aggregate 
and general research outcomes, according to obligation of various research ethics 
standards, should be shared in an ongoing fashion, and through any 
communication channels: website, newsletter, publication or other (Beskow et al., 
2012; Budimir et al., 2011; Knoppers et al., 2013; Wallace & Kent, 2011; 
Watanabe et al., 2011).   
With regard to genetic research results, biobank policies vary (Terry et al., 
2012; Wolf et al., 2012). Most existing population-based biobanks have adopted a 
no return policy, and this should be reflected in the consent form. Other biobanks, 
mostly disease-oriented, have opted to return genetic research results, although 
this option varies widely. Those offering research results may offer either 
incidental findings (IFs) alone to participants, or only individual research results 
(IRRs), whereas others consistently offer both IFs and RRs (Terry et al., 2012). 
IFs are unforeseen research findings that have potential health or reproductive 
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importance, are discovered during the course of research but are beyond its 
objectives. On the other hand, IRR are research results discovered during the 
course of research which concern an individual participant and have potential 
health or reproductive impact (Knoppers et al., 2013). Although the conditions for 
returning IFs and IRRs may be similar, returning IFs might be more challenging 
as it may fall beyond the particular field of expertise of the researcher (Knoppers 
et al., 2013). In the US, in order for biobank research to return individual genomic 
research results, the analysis must be performed in a validated Clinical Laboratory 
Improvement Amendments (CLIA)-certified laboratory (Smith & Aufox, 2013).  
Researchers who support 'restrictive disclosure policy', i.e., no return of 
genetic research results (Bredenoord, Kroes, Cuppen, Parker, & van Delden, 
2011), argue that first, population-based biobank research is epidemiological in 
nature, and intended to produce generalizable knowledge for future potential 
research. Such results are neither validated nor intended for diagnostics nor 
clinical information on individuals, and therefore researchers are not required to 
return individual results (Solberg & Steinsbekk, 2012; Wallace & Kent, 2011) nor 
provide counseling (Budimir et al., 2011). Secondly, biobanks are an 
infrastructure for future research, which means that it is difficult to obtain 
informed consent for participants on undiscovered outcomes which might be 
significant, or of limited value right at the time of recruitment (Wallace & Kent, 
2011). 
Thirdly, the moral obligation to return results in research depends on the 
depth of relationship between researchers and participants (Beskow et al., 2010; 
Bledsoe et al., 2012; Solberg & Steinsbekk, 2012). In the biobank context, most 
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research is secondary, and researchers might be in different facilities, countries or 
occur in the future. Therefore, there may be less obligation to return results 
(Beskow et al., 2010). Fourthly, recontact for returning results requires retaining 
the link for identification of research participants, which increases the risk of 
breaching confidentiality and endangering privacy (Bledsoe et al., 2012).  
A fifth argument is that it might be harmful for research participants 
through causing unnecessary worries of potential future disease in those who 
believe they are healthy (Solberg & Steinsbekk, 2012); there are also chances of 
being psychologically, socially or economically harmed in being informed about 
research findings the clinical utility and accuracy of which is uncertain (Budimir 
et al., 2011; Viberg, Hansson, Langenskiold, & Segerdahl, 2014). Sharing 
research findings after many years of giving consent might cause confusion or 
inconvenience to participants (Viberg et al., 2014). Disclosure of genetic research 
results may yield IRPs and/or IFs that might mislead participants and promote 
therapeutic misconceptions, i.e., inaccurately attributing therapeutic intent to 
research (Bredenoord et al., 2011; Halverson & Ross, 2012c; Solberg & 
Steinsbekk, 2012; Zawati et al., 2014). 
Last, but not least, it may imply the need for additional resources such as 
experts, genetic counselors and funding to do so (Black et al., 2013; Bledsoe et al., 
2012; Bledsoe et al., 2013; Knoppers et al., 2013).  
In contrast, many researchers support a qualified return of individual 
results to participants and consider that not returning results is untenable and 
needs to be challenged. They believe that disclosure of results to participants 
reflects‎ a‎ respect‎ for‎ the‎ participants’‎ autonomy‎ and‎ right‎ to‎ know‎ (Wallace‎&‎
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Kent, 2011). Moreover, there are other researchers who believe that beneficence 
obligates researchers to disclose data for research participants to maximize 
benefits and minimize harms. The information returned in time can change their 
lifestyle and prevent future potential risk of diseases (Viberg et al., 2014). Others 
argue that reciprocity between researchers and participants can be sustained by 
returning individual research results (Gaskell et al., 2013). 
Although returning individual results is not an obligation for traditional 
research, there are ongoing debates whether researchers bear the duty to analyze 
and return genomic research result findings, including the IFs and IRRs. In fact, 
there is recent consensus among experts for an obligation to return genetic 
research results, both the IFs and IRRs, if they meet the ACA criteria, and if, 
during the process of informed consent or subsequently, the research participant 
has opted to receive individual genetic results (Black et al., 2013; Bredenoord et 
al., 2011; Christenhusz, Devriendt, & Dierickx, 2013; Jarvik et al., 2014; 
Knoppers et al., 2012; Knoppers et al., 2015; Lemke et al., 2010; Lemke et al., 
2012; Smith & Aufox, 2013; Terry et al., 2012; Viberg et al., 2014).  
Returning research results is context specific. Although the majority of 
published studies, from various populations and sub- populations, showed that 
there is growing desire and high expectations among research participants and the 
general public to receive their aggregate and individual genetic research results 
(Al-Hussaini & Abu-Hmaidan, 2014; Allen et al., 2014; Bollinger, Scott, 
Dvoskin, & Kaufman, 2012; Haga et al., 2013; Halverson & Ross, 2012a; 
Karlson, Boutin, Hoffnagle, & Allen, 2016; Lemke et al., 2010; Lipworth et al., 
2011; Meulenkamp et al., 2010; O'Daniel & Haga, 2011; Streicher et al., 2011), 
Chapter 2  Literature Review 
62 
 
other studies reported that returning genetic research results, was perceived as a 
concern that would discourage their participation in biobank research ( Al-Jumah 
et al., 2011; Hassona, Ahram, Odeh, Abu Gosh, & Scully, 2016; Rodriguez, 
Torres, & Erwin, 2013).  
2.7.2.5 Commercialization 
Population-based biobanks are often established as publicly funded 
facilities by government or academia (Budimir et al., 2011; Edwards et al., 2014; 
Henderson et al., 2013; Hewitt & Watson, 2013). Nevertheless, biobanks are 
costly resources, both in terms of logistics infrastructure and expertise (Beier & 
Lenk, 2015; Diaferia, Biunno, & DeBlasio, 2011; Gottweis & Lauss, 2012; 
Turner, Dallaire-Fortier, & Murtagh, 2013), while generating minimal short-term 
returns (Kozlakidis, Mant, & Cason, 2012). Therefore, researchers believe that in 
order to manage the costs of establishment and maintenance, biobanks must 
operate as business enterprises as well as being part of a scientific infrastructure 
(McDonald et al., 2014). 
Some researchers believe that commercialization is seen as inevitable 
(Beier & Lenk, 2015; Budimir et al., 2011), first for financial support to ensure 
long-term sustainability of biobank operations (Caulfield et al., 2014; Joly et al., 
2015; Turner et al., 2013). Second, to facilitate the translation of useful 
technologies and practices into biobank research, thereby maximizing research 
potential. This is believed to advance biomedical knowledge, provide improved 
treatment opportunities, and lead to better healthcare - introduction of 
personalized medicine (Caulfield et al., 2014; Evers, Forsberg, & Hansson, 2012; 
Nicol & Critchley, 2012). Both interests, financial support and advancement of 
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technology, while being different, should not be seen as opposing (Evers et al., 
2012). 
 Commercialization of population-based biobanks are globally recognized 
(Evers et al., 2012). Commercialization in biobank research, in its broader sense, 
might involve a number of activities. It could refer to the commercialization of the 
biobank resources, data or samples; commercialization of research results or 
products generated as a result of utilizing the biobank resources (Beier & Lenk, 
2015; Caulfield et al., 2014; Evers et al., 2012); or it might refer to building 
partnerships or receiving funds from private companies such as pharmaceutical, 
medical devices, biotech companies or others (Caulfield et al., 2014).   
The most common ethical concerns raised in relation to commercialization 
are: ownership and benefit sharing. Who should own the property rights to 
biosamples and genetic information and who should share benefits or profits 
generated from the donated or altruistically contributed biosamples and data, the 
researcher, the biobank, companies, research participants or the community. 
(Budimir et al., 2011; Petrini, 2012; Turner et al., 2013; Tutton, 2010).  
The ethical dilemma of ownership raised from debates about human 
biosamples and data including genetic information are whether they are seen as 
proprietary right or extension of personal right (Hawkins et al., 2013). The laws 
and regulations regarding ownership of human biological materials varies across 
countries and in some countries it has not been decided yet (Beier & Lenk, 2015; 
Caulfield et al., 2014). Researchers argue that denying ownership of their own 
biological material and data to research participants might discourage 
participation in biomedical research (Gitter, 2013). 
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In terms of benefit sharing it is important ensure justice to research 
participants and balance commercial interests against public good and values of 
the biobank (Budimir et al., 2011; Nicol & Critchley, 2012; Turner et al., 2013) 
and prevent commercial exploitation against fairness for research participants and 
open science, unrestricted knowledge production and sharing (Birch, 2012; Evers 
et al., 2012; Gitter, 2013; Joly et al., 2015).  
Population-based biobanks are public resources and therefore their benefits 
and knowledge generation should be shared by all, in order to improve the health 
of population (Evers et al., 2012). The HUGO Statement on Human Genomic 
Database,‎ Recommendation‎ 1,‎ stated‎ that‎ ‘‘Knowledge useful to human health 
belongs to humanity. Human genomic databases are a public resource. All 
humans should share in and have access to the benefits of databases’’‎ (Human‎
Genome Organization [HUGO], 2002).  
Commercial rights for patency and intellectual property should not 
dominate or prevent knowledge sharing and open science.  Recommendation 6, of 
the HUGO Statement, stated that researchers and commercial entities are 
acknowledged‎ to‎ ‘‘have a right to a fair return for intellectual and financial 
contributions to databases,’’‎ but‎ ‘‘fees should not restrict the free flow of 
scientific information and equitable access’’‎(HUGO,‎1001).‎ 
Researchers argue that the dilemma of property rights of biosamples and 
data could be resolved by benefit sharing (Ram, 2015). Open science, or sharing 
benefits with individuals and the community at large in terms of knowledge to 
improve the health of the population could be a motivating factor to research 
participants (Gitter, 2013).    
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In terms of other forms of benefit sharing with research participants, the 
HUGO clearly distinguishes two forms of remuneration for research participants: 
direct compensation and benefit sharing (Ram, 2015; Ridgeway et al., 2013). The 
HUGO Statement on the Principle Conduct of Genetic Research, 1996, 
recommends‎prohibiting‎“undue inducement through compensation for individual 
participants, families and population”.‎ ‎ However,‎ as‎ the‎ statement‎ clearly‎
articulates, 'This prohibition does not include agreements with individuals, 
families, groups, communities or populations that foresee technology transfer, 
local training, joint ventures, provision of healthcare or information, 
infrastructures, reimbursement of costs, or the possible use of a percentage of any 
royalties for humanitarian purposes”‎ (HUGO,‎ 1996).‎ With‎ expanded‎
commercialization of genetic research and contribution from private sector that 
exceed government contribution, Recommendation 6 of the HUGO Statement on 
Benefit Sharing in 2000 requires that “profit-making entities dedicate a 
percentage (e.g. 1% - 3%) of their annual net profit to healthcare infrastructure 
and/or to humanitarian efforts”‎(HUGO,‎1000). 
2.7.3 Social challenges  
Existing published studies found that the general public were not familiar 
with biomedical research, genomics nor biobanking (Abou-Zeid et al., 2010; 
Ahram et al., 2014; Al-Hussaini & Abu-Hmaidan, 2014; Al-Jumah et al., 2011; 
Allen & McNamara, 2011; DHWA, 2010; EC, 2012; Eder et al., 2012; Gaskell et 
al., 2013; Godard, Ozdemir, Fortin, & Egalite, 2010; Igbe & Adebamowo, 2012; 
Luque et al., 2012; Millon Underwood, Buseh, Kelber, Stevens, & Townsend, 
2013; Moriya, Inoue, Ikeuchi, Ishii, & Motojima, 2014; Nasrella & Clark, 2012; 
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Rodriguez et al.,. 2013; Simon et al., 2011; Streicher et al., 2011; Tauali et al., 
2014; Tupasela et al.,2010).  
In addition great variation in the willingness to participate in a population-
based biobanks across populations and subgroups within the same population.  
there was also variation in the factors influencing willingness to participate 
(Abou-Zeid et al., 2010; Ahram et al., 2013; Banks et al., 2012; Critchley et al., 
2012; De Vries et al., 2016; Gaskell et al., 2013; Halverson & Ross, 2012a; 
Lewis, Clotworthy, Hilton, Magee, Robertson, Stubbins, & Corfield, 2013a; Ma et 
al., 2012; Millon Underwood et al., 2013; Overby et al., 2015; Ridgeway et al., 
2013; Sanderson et al., 2013; Tauali et al., 2014; Toccaceli et al., 2014; Tupasela 
et al., 2010). These factors will be elaborated later in the discussion and 
comparison with this study results.  
Studies also showed diversity in terms of public's views, preferences and 
concerns about biobank procedures and policies, such as the consent procedure 
(Ewing et al., 2015; Garrison et al., 2015; Joly et al., 2015; Lewis et al., 2013a; 
Platt et al., 2014), privacy and confidentiality protection (Ahram et al., 2013; De 
Vries et al., 2016; Eder et al., 2012; Gaskell et al., 2013; Halverson & Ross, 
2012a; Igbe & Adebamowo, 2012; Joly et al., 2015; Kerath et al., 2013; Lemke et 
al., 2010; Melas et al., 2010; Nasrella & Clark, 2012; Overby et al., 2015; Pullman 
et al., 2012; Rahm et al., 2013; Ridgeway et al., 2013; Simon et al., 2011; Spruill 
et al., 2014), returning individual genetic research results (Al-Hussaini & Abu-
Hmaidan, 2014; Al-Jumah et al., 2011; Allen et al., 2014; Bollinger et al., 2012; 
Haga et al., 2013; Halverson & Ross, 2012a; Karlson et al,  2016; Lemke et al., 
2010; Lipworth et al., 2011; Meulenkamp et al., 2010; O'Daniel & Haga, 2011; 
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Rodriguez et al., 2013; Streicher et al., 2011), as described earlier.  The biobank 
initiator or custodian  in selecting the appropriate biobank policies will need to 
consider the characteristics and perspectives of potential participants (Dove et al., 
2012; Joly et al., 2015; Kaye, 2012b; Kelly et al., 2015; O'Doherty et al., 2011; 
O'Doherty et al., 2012; Platt et al., 2014; Simon et al., 2011). 
The success of biobanks is dependent on public active, long-term  
engagement and wider, voluntary participation (Critchley et al., 2012; 
Husedzinovic, Ose, Schickhardt, Frohling, & Winkler, 2015; Marko-Varga et al., 
2014;  Nobile, Vermeulen, Thys, Bergmann, & Borry, 2013; Olson et al., 2014; 
Porteri et al., 2014; Watson et al., 2014). Public engagement and participation is 
expressed in the ability to make informed decisions regarding participation in 
biomedical research as well as in empowering and taking active role in the 
development of biobank governance framework, such as representation in REC, 
advisory‎ committees‎ or‎ patients’‎ advocacy‎ groups‎ (Silverman‎ et‎ al.,‎ 1015;‎
Silverman et al., 2013).  
 Public engagement and empowerment is greatly influenced by many 
factors. These include the political system and its stability, social and economic 
development, research ethics capacity and bodies (Silverman et al., 2015; 
Silverman et al., 2013), legal and regulatory structure and stage of development 
(Kaye, 2012), healthcare and information technology (Nair et al., 2013), health 
and research literacy- knowledge on diseases, research processes and technologies  
(Budin-Ljøsne et al., 2012; Nair et al., 2013; O'Doherty & Hawkins, 2010; 
O'Doherty et al., 2011; Silverman et al., 2013) and an understanding of their rights 
as participants in research (Nair et al., 2013; Silverman et al., 2013).  
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Public engagement and consultation during all phases of the biobank 
project lifecycle is crucial. Efforts need to be made by the initiator or the 
custodian of the biobank, to ensure that public are actively and transparently 
engaged and empowered. It is believed that public engagement ensure biobank 
research is conducted in an ethical, locally appropriate manner (Lemke et al., 
2010; O'Doherty et al., 2011; O'Doherty et al., 2012). Furthermore, public 
engagement is also one way to reach to a consensus to the long debatable 
discussion on biobank research concerns (O'Doherty et al., 2011; O'Doherty, 
Hawkins, & Burgess, 2012). Last, public engagement increase public trust on 
biobank and ownership and therefore improve participation and long-term 
engagement (Critchley et al., 2012; Husedzinovic et al., 2015; McWhirter et al., 
2014; Nobile et al., 2013; Watson et al., 2014).  
There are various models of community engagement, empowerment and 
meaningful public input on biobank policies and governance. These include 
surveys, forums, focus group discussions, democratic public deliberations, 
innovative web 2.0 communication solutions and others (Dove et al., 2012; Joly et 
al., 2015; Kaye et al., 2015; Longstaff & Burgess, 2010; O'Doherty & Hawkins, 
2010; O'Doherty & Hawkins, 2010; O'Doherty et al., 2012; O'Doherty, Ibrahim, 
Hawkins, Burgess, & Watson, 2012; O'Doherty & Burgess, 2013; Steinsbekk et 
al., 2013; Teare, Morrison, Whitley, & Kaye, 2015).  There is no universal magic 
strategy to establish smooth dialogue with the general public and the potential 
biobank participants, as different cultures and traditions require different 
approaches (Gottweis et al., 2011).  
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Health literacy is another crucial empowerment strategy to increase 
community control over health, and to make appropriate informed decisions 
(Sorensen et al., 2012) including participation in medical research and through 
understanding their rights as research participants.  It gained global attention in 
the last few years due to associations with social determinant of health, health 
behavior and health outcomes, utilization of health care services and the quality of 
healthcare systems (Nutbeam, 2008; Sorensen et al., 2013). Improved health 
literacy leads to gaining skills and capabilities required to engage in a range of 
health-enhancing actions such as skill of social organization and advocacy, skill of 
negotiation and self-management, active engagement in social actions for health, 
and participation in changing social norms and practices (Nutbeam, 2008).  
Public are more likely to participate and engage in population-based biobank 
research if they are aware of its existence, importance and social benefits, and are familiar 
with  its operations (Gaskell & Gottweis, 2011). 
2.8 Models and Solutions for Biobank Governance Challenges 
Many researchers  argue that traditional governance structures cannot deal 
with the unique  challenges of biobank research described  above (DHWA, 2010; 
EC, 2012; Gottweis & Lauss, 2012; O'Doherty & Hawkins, 2010; O'Doherty et 
al., 2011; Olson et al., 2013; Olson et al., 2014). Various models and solutions for 
effective, innovative governance have been proposed to overcome biobank 
governance challenges.  A few will be described below. 
2.8.1 Models  
One model proposed is adaptive governance. This model relies on four 
principles to ensure sustainable and effective governance of biobank. These are: 
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firstly, recognize biobank participants as a collective body. Biobanks are a large 
public investment, and their objectives are for public benefit; therefore, it is very 
important to involve the broad community in active engagement to shape policies. 
Secondly, trustworthiness. Public trust is essential for biobanks to increase 
participation and ongoing engagement. Trustworthy biobanks need to have fair 
recruitment policies and community representation, make available transparent 
reports to the public on compliance or faults to compliance, undergo regular 
auditing by an independent regulatory body to monitor adherence to laws and 
policies, and to ensure financial sustainability. Thirdly, governance structures 
must be adaptive to the dynamic nature of biobank; they should be built up and 
improved over time, and incorporate innovative technology solutions. Finally, 
there must be alignment in the nature of the biobank in terms of purpose, size, 
collaborators and the specific governance structural framework adopted 
(O'Doherty & Hawkins, 2010).  
A second model proposed by a few researchers is the solidarity-based 
governance model. This model originated from the field of politics and social 
science.  It relies on the principle that all individuals are part of this society and in 
return, individuals have an obligation toward the society, which includes helping 
others. This model shifts from a restrictive autonomy-focused one towards a more 
harm mitigating one, and a commitment to veracity without affecting the respect 
for individual values. It implies that researchers can appeal to the solidarity of 
individuals, as these individuals have benefitted from earlier research and will 
possibly benefit from future research. Participants still have the right to refuse or 
withdraw participation at any time.  Solidarity in this model implies that 
participants are willing to accept certain potential costs, the risk of harm and the 
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inconvenience that may rise as result of participation, to assist others (Hens, Nys, 
Cassiman, & Dierickx, 2011; Prainsack & Buyx, 2013). In this context, it is 
assumed that participants agree to allow the use of their samples and data in 
research other than what was originally envisioned, as long as it is consistent with 
the overall values and purposes of the biobank. Therefore, it supports the use of 
broad consent. It also shifts efforts and financial resources from risk mitigation 
strategies to more of educational and research activities. Likewise, from the 
biobank's prospective, this model assumes that the biobank governance structure 
and policies will ensure treating participants as partners in research, to whom the 
biobank owes respect and veracity. Efforts must be made to ensure and maintain 
participants' trust. The idea of open science, as well as data access and sharing 
with various researchers, relies on the principle of solidarity. Data or benefit 
sharing becomes a contractual obligation of researchers towards society at large 
(Prainsack & Buyx, 2013). 
Integrating population-based biobanks into the healthcare system is 
another model to address some challenges associated with biobank governance, 
including financial sustainability and ongoing recruitment and engagement of 
participants (Kaye, 2012a). Furthermore, institutionalization of biobanks supports 
the introduction of personalized medicine, and the translation of research results 
into clinical care (Harris et al., 2012; Kaye, 2012a; Wyld, Smith, Hawkins, Long, 
& Ward, 2014).  One recent example is the Estonia biobank (Leitsalu et al., 2015; 
Leitsalu et al., 2015) described earlier. Another example is the Million Veteran 
Program (MVP), a mega-biobank launched by the US Department of Veterans 
Affairs in 2011 to establish a national longitudinal study of veterans for future 
genomic and other biomedical research (Gaziano et al., 2016). It is summarized in 
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Table ‎21. The successful integration of biobanks into healthcare systems relies on 
early planning and collaboration of all stakeholders (Wyld et al., 2014).   
2.8.2 E-governance solutions 
Several e-governance‎ solutions‎ such‎ as‎ 'ELSI‎ by‎ design’‎ were‎ proposed‎
and designed in order to overcome the ethical, and other legal and social 
implications, and to consider international dimensions. These technology-based 
solutions are built to be integrated with traditional governance structure and not 
replace it (EC, 2012; Kaye, 2012b; Kaye et al., 2015; Williams et al., 2013). 
Examples of such solutions are Dynamic Consent, Wiki-governance and 
DataSHIELD. 
Dynamic Consent is one of the models proposed to overcome ethical 
concerns related to one-off static consent. Dynamic Consent requires governance 
mechanisms that involve information and communication technologies (ICT) 
solutions such as Web 2.0, which allow participants to engage as much as they 
choose. Participants, through digital communication, can interface and control 
different privacy settings and decide who is allowed to access their de-identified 
information and/or contact details. In addition, this system allows researchers to 
streamline recruitments, and enable participant recontact (Kaye et al., 2015; 
Steinsbekk et al., 2013; Teare et al., 2015). 
 Dynamic Consent is not a replacement for existing consent approaches, 
but rather a tool that could facilitate the process of obtaining consent (Kaye et al., 
2015; Williams et al., 2013). This approach is believed to address a few ethical 
concerns, as well as the public preference to specific consent. This increases 
transparency, which in turn increases trust in biobank activities, and an ongoing 
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engagement and communication with biobank will align with the ongoing nature 
of biobank research (Gottweis et al., 2011; Platt & Kardia, 2015; Stein & Terry, 
2013; Steinsbekk et al., 2013; Watanabe et al., 2011; Wee et al., 2013; Williams et 
al., 2013). 
However, they do not address the concept of reciprocity as a feature of 
engagement as participants contribute their samples and data, and in return they 
are interested in being aware of how their contributions are used in research. They 
also like to receive information on general research results that utilize their 
samples and data (Hobbs, Starkbaum, Gottweis, Wichmann, & Gottweis, 2012; 
Nobile et al., 2013; Steinsbekk et al., 2013; Wee et al., 2013). Additionally, this 
model is subject to privacy regulation within the country, the information 
technology infrastructure, and the availability of‎its‎management‎cost‎(D’Abramo‎
et al., 2015).   
Wiki-governance is another collaborative solution recently proposed for 
large scale, population-based biobanks to avoid the issues raised with small 
biobanks including the top-down governance structure, and to ensure a more 
active and ongoing participation from all stakeholders.  It is a web 2.0-based 
solution, using a social-media driven HTTP Secure online digital forum through 
which registered stakeholders, mainly research participants, and others such as 
researchers and collaborators can submit their proposal for digital governance 
structure, research protocols, strategies and policies online. Suggestions received 
as comments, or as part of discussion then shape the policy content that will be 
modeled into workable policies and guidelines with the help of policy experts and 
the biobank management committee. This collaborative ongoing effort is believed 
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to increase buy-in of all stakeholders to the biobank governance structure and 
policies, and to ensure that it is crafted in partnership with the research 
participants and other stakeholders rather than imposed by others (Dove et al., 
2012; Joly et al., 2015).  Nonetheless, some researchers argue that this solution is 
complex, abstract and time-consuming (Joly et al., 2015).  
DataSHIELD is another e-governance solution, especially valuable for 
collaborative studies and global governance. This solution is designed to protect 
research participant privacy and confidentiality, while facilitating and promoting 
collaborations and access of researchers to individual-level data (EC, 2012; Gaye 
et al., 2014; Wallace & Kent, 2011). Further, DataSHIELD has the potential to 
protect the intellectual property of researchers in biobanks (Gaye et al., 2014).  It 
enables simultaneous parallelized analysis of the individual-level, harmonized 
data of several studies, without the need for these data to leave the database. It 
also enables the return of data inquiries in the form of anonymous summary 
statistics or aggregate results (Dove et al., 2012; EC, 2012; Gaye et al., 2014; 
Wallace & Kent, 2011; Wolfson et al., 2010). 
This solution requires the setup of a dedicated data computer (DC) at each 
collaborating center. The DC is set up with the necessary softwares such as OPAL 
instance or R instance, and appropriate firewall protections.  OPAL is the core 
database application which has been developed by OBiBa, and R is an open 
source software for statistical computing. The commands are sent from a central 
analysis computer (AC) to several DCs (Gaye et al., 2014; Murtagh et al., 2012; 
Wallace & Kent, 2011). 
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2.9 Regional Experience and Summary of Selected International 
Biobanks 
Biobanking was introduced recently in the Middle East region by a few 
countries. Iran has a disease-oriented National Tumor Biobank, Israel and Cyprus 
established biobanks including a national population-based biobank 
(SpecimenCentral.com, 2016). Turkey is planning a national biobank soon (Daily 
Sabah, 2015). The experience from the Arab countries of the Middle East region 
is also new.  Described below are existing biobanks in the region.   
The first experience in the Arab countries was Qatar biobank. Qatar is a 
small country, with total population of 2.5 million in 2015, of which Qataris, at 
300,000 formed 14% of the total population (Al Kuwari et al., 2015; Qatar 
Biobank, 2016). The Qatar biobank was established in 2010 by the Qatar 
Foundation, in collaboration with Hamad Medical Corporation and the Supreme 
Council of Health. It is supported by experts from Imperial College London. Qatar 
biobank is a population-based biobank that aims to study the influence of genes, 
environment and lifestyle in common diseases. It targets 60,000 participants (one 
fifth of Qatari population), both Qataris and long-term residents (>15 years) aged 
18 years and above. Recruitment started in December 2012, and is ongoing. These 
invitations are planned to be extended to younger population between 14-17 years 
(Al Kuwari et al., 2015) at a later stage. Participation involves completing a health 
and lifestyle questionnaire, collection of biosamples (blood, urine and saliva), and 
a series of noninvasive measurements such as anthropometry, body composition, 
bone health, cognitive function, grip strength, retinal and disc imaging, 
measurements of cardiovascular, respiratory and lung functions. Participants are 
informed about the possibility of recontact or invitations for subsequent future 
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visits. Qatar biobank follows international and national ethical guidelines, and is 
compliant with Islamic religious principles. Qatar biobank is working in 
partnership with Rice University in Huston, Texas, to develop policies on the 
ethical implications of biomedical research.  Qatar biobank implements ISO 9001 
QMS (Al Kuwari et al., 2015; Qatar Biobank, 2016).  
Another example is the Saudi biobank. It was established in 2011 by the 
King Abdullah International Medical Research, which is a part of the National 
Guard Health Affairs (NGHA) in affiliation with P
3
G. The Saudi biobank is 
funded by two governmental organizations: the King Abdul Aziz City for Science 
and Technology and King Abdullah International Medical Research. The NGHA 
serves a community population of 2.5 million with nearly 60,000 patients a year, 
and has 4 large hospitals and 60 health centers. It is a population-based and 
disease oriented biobank, and aims to collect from the catchment area 100,000 
samples from the public aged 10-70 years, in addition to 100,000 patients with 
certain diseases. The population-based biobank collects health and lifestyle data, 
non-invasive measurements, and samples of blood and urine. Recruitments started 
in 2013 and was ongoing until 2016. Saudi biobank follows international and 
national ethical guidelines, and is compliant with Islamic principles (Alahmad & 
Dierickx, 2014; Alahmad, Hifnawy, & Dierickx, 2015). The establishment and 
development of the biobank SOPs were supported by P
3
G (Public Population 
Project in Genomics and Society, 2012).  
The third example is from Jordan. The King Hussein Cancer Centre 
Biobank (KHCCBIO),‎Jordan’s‎first‎biobank,‎was‎established‎in‎November‎1011‎
in one of the most well-known, comprehensive cancer care centers in the Middle 
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East, which caters to 3500 cancer patient annually. It is a disease-oriented 
biobank, specifically for cancer, and aims to collect 10,000 samples over 10 years 
from cancer patients in Jordan and neighboring countries. Samples and related 
clinical data will be collected and used in research for the purpose of developing 
biomarkers and potentially diagnostic products. The KHCCBIO is supported by 
the Seventh Framework Programme (FP7) and funded by the European Union 
(Barr et al., 2014; Chen & Pang, 2015).  The SOPs were developed based on the 
guidelines‎ of‎ the‎ Molecular‎ Medicine‎ Ireland‎ (MMI),‎ St‎ James’‎ Hospital‎ and‎
Trinity College Dublin. It will also implement ISO 9000 QMS to ensure high 
quality research, and meet any future regulatory requirements (Barr et al., 2014).   
Table ‎2-1, summarizes the regional experience, besides providing 
examples of some selected international population-based or large-scale biobanks 
(>200,000 participants). It provides information on the year of establishment, 
number of participants, their age ranges, recruitment status, source of funding and 
integration with the healthcare system. Moreover, presents comparisons of 
policies pertaining to informed consent, withdrawal application, future contact and 
individual genetic research results return. 
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Table ‎2-1:  Examples of existing national and large-scale population-based biobanks in selected counties. 















Estonian Genome Project 
(Estonia) 
geenivaramu.ee 
2000 PB 52,000 
(18  + y) 
Target 1 million 
Ongoing  
Non-profit 




2 stages, 1) before coding 
right to withdraw/ 2) after 










Leitsalu et al., 
2015&  Leitsalu 
et al., 2015, Al 
Ahmad et al. 
2014, Website 




2004 PB & 
DO 
NA Non-profit Broad 
consent 
Destruction or 
anonymization of the 
sample 
NA NA Yes.  
NHS 
Morente et al, 
2011, Sak et al., 
2012 
UK biobank  
(UK) 
ukbiobank.ac.uk 








3 options; No further 
contact/No further 
access/No further use  
 
Yes No  Yes.  
 NHS 
Website, Al 
Ahmad 2014b   
Canadian Partnership for the 




2008 PB 300,000  




No further use of data, 




No No Website, Fortin 
et al. 2011 
Research Program on Genes, 
Environment, and Health  
(US) 
2009 PB 500,000  






Kaiser Foundation  
Broad 
consent 
Right to withdraw 
authorization to use 
protected health 
information 






Swedish National Biobank 
Program  (Sweden ) 
bbmri.se 
 






3 options; No further 
contact/ No further 
access/No further use  
NA NA No Scott et al., 
2012, website 
Million Veteran Program 
(US) 
research.va.gov/mvp/ 









NA Yes NA Yes. VA 
Healthcare 
System 
Gaziano et al., 
2016 
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  Continue Table 2-1 
Name , Country 
website 
Year  Type Size 















 ( Japan) 
biobankjp.org 
 
2003 DO 300,000 patients 
affected with 47 




NA NA NA Yes 
 
Lee et al., 2012, 
Yoshizawa 2014,  
Kang et al., 
2013, Scott et 
al., 2012 



















NA No Yoshizawa 2014, 






2005 PB & 
DO 
200,000 








cease providing any 
biological specimen, 
withdraw, or change the 
scope of the use 
NA NA No Fan et al,  2015 
P3G website 
Yoshizawa 2014 
Korea Biobank Project  
(S Korea) 
/koreabiobank.re.kr 
2008 PB & 
DO 
300,000 
















(18 + y) 








NA Yes No. Assessment 








2011 PB & 
DO 
Target 100,000 
(10-70y) & 100,00 







3 options. No further 
contact, No further and  
access, Use of fully 
irreversible anonymized 
samples & data 
Yes NA Yes.  NGHA 
Network 
Al Ahmad et.al 
2014 & 2015, 
P3G Newsletter 
2012 
PB: Population-based,  DO: Disease Oriented, NA: Not available, NHS; National Health Services, NGHA; National Guard Health Affairs 
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2.10 Summary of the Literature Review 
To summarize, there are different types of biobanks, which can be broadly categorized 
into population-based and disease-oriented biobanks.  Most of existing biobanks are disease-
oriented. Population based biobanks are more common in Europe than other parts of the 
world; however, it is expanding worldwide since the 1990s.   
Population-based biobanks aim to discover biomarkers for disease susceptibility 
within a specified population through collection and storage of biosamples and 
comprehensive data on personal and family health, as well as environmental exposures and 
lifestyle from‎ a‎ large‎ number‎ of‎ healthy‎ individuals.‎ It‎ focuses‎ on‎ publics’‎ interests‎ and‎
benefits‎rather‎than‎individual‎participants’‎benefits.‎ It‎aims‎to‎improve‎wellness‎and‎health‎
of future generations. 
Population-based biobanks are invaluable resources to promote epidemiological and 
genomic research to improve populations' health, monitor diseases and other health outcomes, 
and pave the way to accelerating personalized medicine. Biobanks will advise on planning 
effective and targeted disease prevention interventions and health promotion messages for 
public health, as well as on methods to improve clinical care, based on genomic profiles and 
risk stratification.   
To establish a population-based biobank, a number of basic requirements need to be 
developed, approved well in advance, and communicated to all stakeholders. These 
requirements must be developed based on guidance best practices, in compliance with 
international regulations, and in consultation with stakeholders: most importantly potential 
biobank participants and the general public.   
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Biobank governance structures include formal and less formal structures. The 
governance‎framework‎of‎a‎biobank‎is‎influenced‎by‎the‎biobank’s‎purpose,‎design,‎scale‎of‎
bioinformatics and communication technologies, potential for commercialization, and 
building regional or international networks.  The development of biobank legal instruments 
varies across countries, and there is a huge gap in the Middle East region. The role of RECs is 
important in order to oversee research and the use of biobank resources. Other important 
oversight bodies might include National Research Council or Data Protection Committee or 
its equivalent that could regulate REC's. Others such as community advisory groups are 
important to present the voice of research participants.  
Population-based biobanks are unique initiatives, and their governance is a huge 
challenge worldwide. Ethicists have raised several ethical, legal and social concerns. Legal 
instruments have their own challenges. There are a number of international gold standards 
declarations and guidelines on best practices; these could be used as references to ensure high 
quality operations and protection of participants' rights, but they do not have legal standing. 
Most common ethical challenges include ensuring informed consent of participants, ability to 
withdraw consent and its implications, privacy protection of personal and genetic data, return 
of individual genetic research results, and the potential for commercialization of biobanks. 
Important social challenges include the engagement and empowerment of general public in 
terms of informed consent participation and active involvement in biobank governance.   
A majority of researchers argue that the traditional biobank governance structure 
cannot deal with the unique challenges of modern biobanks research. Various models and e-
solutions for effective and innovative governance have been proposed to overcome biobank 
governance challenges.  
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Biobanking experience of Arab countries in the Middle East is humble yet growing.  
Qatar biobank, established in 2010, is the first and only true national population-based 
biobank in the region, and offers promising regional experience. This is followed by the 
Saudi biobank established in 2013, which is both population-based and disease-oriented.
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3 Chapter 3: Methods 
This chapter describes the study methodology, including the main research 
questions, study design, recruitment of study participants, sampling of participants 
and sample survey size, survey development and administration, study 
independent variables and main outcome variable, coding of data, statistical 
analysis and data limitation. In addition, it highlights matters pertaining to the 
protection of research participants and related issues.  
3.1 Research Questions and Hypothesis 
3.1.1 Research questions 
Our main research questions concerned about (i) estimating the overall 
probability, at the population level, of‎the‎Emirati‎general‎public’s‎willingness‎to‎
participate in a population-based biobank for genomic research and (ii) 
elucidating factors associated with their decision to participate.   
3.1.2 Hypothesis 
We assumed that there would be a significant difference in the probability 
of willingness to participate in the proposed population-based biobank, by gender. 
This assumption was based on findings from a regional study from Saudi Arabia, 
a country which has a similar context and cultural background as Abu Dhabi, 
UAE. There it showed that being female was associated with willingness to 
participate in biomedical research. It increase likelihood of participation by two 
and a half folds (Adjusted OR=2.53, 95%CI; 1.69 -3.77, P < 0.01). (Al-Jumah et 
al., 2011).  
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3.2 Conceptual Framework 
To guide this study, a conceptual model was created as given in 
Figure ‎3-1. It describes major factors that could influence the general public's 
engagement and participation in a population-based biobank. The conceptual 
framework guided the development of a survey questionnaire as well as the 
interpretation of results, their implications for policy development and 
recommendations of future research.  
The conceptual model was developed on the basis of reviewing the 
literature as well as on my understanding of the issues related to governance 
challenges of population-based biobank. In particular, it looked at the social 
challenges and factors influencing the general public engagement and 
participation in biobank research, as well as the key requirements for the setup of 
a biobank and innovative models and e-solutions to overcome governance 
challenges. It was also based on my observations and experience in planning, 
implementing and monitoring various public health programs and initiatives in 
Abu Dhabi, in addition to several other factors, which are included in the 
framework.   
The conceptual framework groups identify relevant factors into proximal 
and distal factors, and illustrate some of the complex relationships among these 
variables. Proximal (direct) factors are subcategorized into individual and 
biobank-related factors. Individual factors include (i) socio-demographic 
characteristics such as age, gender, education level, income, marital status, 
parental status, insurance, place of residence, religion, ethnicity and others; and 
(ii) perceived risks and benefits of biobanking for future research to self, family 
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and society at large, including a history of family or personal chronic diseases that 
might motivate participation in biobank research. 
 The biobank related factors include: (iii) biobank model or design features 
of purpose, method of  recruitment and collection of  biosample  and data, type of 
biosample to be collected, initiator, custodianship, collaborators, source of 
funding including potentials for commercialization, and integration with 
healthcare system or accompanying clinical services provided at time of donation. 
It also includes (iv) biobank standard procedures and governance, consent and 
withdrawal of consent, protection of participants' privacy and confidentiality, 
methods to recontact, return of research results, as well as ownership and benefits 
sharing, among others.  
Distal factors include: (i) health and medical research literacy; (ii) 
healthcare system factors, experience with healthcare services and trust in key 
actors such as the government, healthcare providers, research institutions and 
researchers; (iii) health information and communication  technologies, strategies 
used in biobank operation, governance, and communication with various 
stakeholders, most importantly participants and the general public; and (iv) the 
social, economic and legal development of the country and socio-cultural context 
and influences. 






Figure ‎3-1: Conceptual framework: Factors influencing public's participation and engagement in population-based biobanks 
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3.3 Study Design 
The study in Abu Dhabi was cross-sectional and emirate-wide. Data was 
collected through telephone interviews using a structured survey questionnaire. 
Eligible participants comprising adult Emirati volunteers were drawn at random from 
a list of individuals who underwent Weqaya screening as the prospective participants 
of the biobank project. The study was conducted over 11 months, from April 2015 to 
March 2016. 
3.4 Study Participants 
Participants eligible for this study were those who underwent Weqaya 
screening during the period of July 1, 2012- March 31, 2015. They were adult 
Emiratis 18 years and above, residing or working in the emirate Abu Dhabi, and 
covered by Thiqa insurance plan.  Thiqa is the Arabic word for 'trust' and is a single-
payor health insurance plan for UAE nationals. 
3.5 Sampling and Sample Size 
The study subjects were selected through the random sampling of a list of 
individuals who underwent Weqaya screening during the above-mentioned period, 
using Stata Statistical Data Analysis software version 11.2. The list was derived from 
Daman Insurance Company which administers the Thiqa insurance plan. Since two-
thirds of the list comprised females, a stratified sampling method was used to adjust 
for gender in order to ensure that the samples represent the true population gender 
distribution (1:1) and would be eligible to test the specified hypothesis. Within each 
gender, an equivalent set of random samples were selected.  A sample size of 600 
individuals was considered adequate for the purpose of this study. 




The sample size calculation is shown in detail in Appendix II. The sample size 
was estimated based on various assumptions. First, it was based on an overall 
estimated true population proportion of willingness to participate in the population-
based biobank. Several estimated true population proportions were assumed, both 
lower and higher than the two regional studies from Jordan and Saudi Arabia. The 
study from Jordan was recent, and it showed that 64% of the Jordanian adults in a 
national-wide survey were willing to participate in a biobank (Ahram, Othman, 
Shahrouri, & Mustafa, 2013). The Saudi study showed that 78.4% of Saudi 
participants, outpatients at a hospital in Riyadh City, were willing to donate their 
leftover samples for biomedical research (Al-Jumah et al., 2011). Assuming an 
accepted margin error of the true population proportion of 3% or 4%, the sample size 
was calculated using the equation, SE of p^= square root of p*(1-p)/n.   
Another estimate of sample size was based on the hypothesis. The null 
hypothesis assumes no gender-based difference in the proportion of willingness to 
participate in population-based biobank. The sample size for two sample proportions 
was calculated using Stata, assuming a 5% level of significance and a study power of 
90%, the various assumed overall population proportion used above, and the various 
assumed differences in proportions by gender.  
The final sample size decided was based on an overall probability of 
willingness to participate was close to that of the study from Saudi Arabia, at 78.4%, 
assuming difference by gender of 10 to 12%, as this was closer to our proposed 
method for acquiring biosample and health information that were left over. The 
sample size was then inflated, assuming a response rate of 70% for the telephone 
survey. This assumption was based on a recent small-scale experience of a phone 




survey conducted by HAAD - Public Health team on Emiratis' satisfaction regarding 
the Weqaya screening program in 2013.   
It is worth highlighting that during the first month of conducting the surveys, 
we experienced a high rate of invalid telephone numbers. Re-sampling of a larger 
sample size on the original list was done in order to account for that, and to reach the 
target of 600 completed surveys.    
3.6 Survey Development and Administration  
This section describes in detail the survey questionnaire development and 
refinement, as well as its administration. Arabic and English versions of the final 
survey questionnaire are provided in Appendix III.   
3.6.1 Survey development and refinement 
3.6.1.1 Survey development 
The data were collected using a structured questionnaire.  The development of 
the survey questionnaire was first informed by the literature. The initial version of the 
questionnaire was adapted from published instruments used in studies that focused on 
reported‎ factors‎ influencing‎ the‎ general‎ public’s‎ decision‎ to‎ participate‎ in‎ a‎
population-based biobank (Ahram, Othman, & Shahrouri, 2013; Kerath et al., 2013; 
Kettis-Lindblad, Ring, Viberth, & Hansson, 2006; Lewis, Clotworthy, Hilton, Magee, 
Robertson, Stubbins, & Corfield, 2013a; Sanderson et al., 2013; Simon et al., 2011; 
Wells et al., 2014).   
3.6.1.2 Review by experts 
The questionnaire was revised for content validity and for clarity of language 
by the Thesis Advisory Committee, a panel of experts that have the knowledge and 




expertise in bioethics, health behavior, epidemiology, biostatistics and public health 
from Johns Hopkins University and UAE University. 
3.6.1.3 Translation 
The survey was initially developed in English, and a forward translation into 
Arabic was done by the primary investigator. The translation was first done using 
Google translation, and refined by the primary investigator and the research project 
team using simple and concise wording and paraphrasing to ensure that the translation 
was conceptually the equivalent of the original. It was then sent to an independent 
bilingual expert in English literature whose mother tongue is Arabic, along with 
background information on the purpose of this study in order to revise and match the 
Arabic and English versions. The final step of the translation was a backward 
translation by another independent bilingual public health staff who was not involved 
on this research and has no knowledge of the initial English version of the 
questionnaire.  Both English versions were compared and found conceptually similar.  
3.6.1.4 Cognitive testing interviews 
Cognitive testing using face to face interviews was conducted on a small 
group of Emirati adults: 16 men and women that have characteristics similar to those 
of the study participants, in term of age, level of education and socioeconomic level, 
to pretest the questionnaire. The cognitive interview questionnaire is provided in 
Appendix IV. The group that participated in the interviews comprised the family, 
relatives and colleagues of the research team from HAAD, who are outside the 
medical or public health profession. The primary investigator developed a cognitive 
testing interview guide, and trained the research assistants to conduct the interviews 
and collect information. The cognitive testing interviews process and guide was 




informed by the literature (Wells et al., 2014; Willis G, 2005). The purpose of these 
interviews was to test respondents' understanding of each question and their ability to 
provide accurate answers.  It tested the questionnaire for clarity of the questions, and 
helped to tailor response options.  In addition, it ensured the cultural and contextual 
appropriateness of the survey questions, responses and instructions. 
Based on the findings from the cognitive testing interviews, and taking into 
consideration the mode of administration as telephone survey, it was decided that the 
questions needed to be refined further in order to make them simple and concise. 
Some questions and responses were paraphrased or shortened, and some deemed 
unnecessary, and introductory paragraphs and complex, problematic questions were 
deleted. The changes were incorporated into both Arabic and English versions of the 
questionnaire. The English version was then reviewed for a final time for language by 
a public health professional colleague who is a native speaker of English.  
3.6.1.5 Presetting 
Finally, the questionnaire was field pretested by the research assistants on a 
sample of 15 individuals - friends and colleagues - through conducting a phone survey 
to check for the reliability of the questionnaire, to assess the average time needed to 
complete the survey, as well as to ensure that study participants answered all of the 
questions during the field calls.   
3.6.1.6 Final questionnaire 
The final questionnaire, Appendix III, comprised 29 questions, the majority of 
which were closed-ended, multiple-choice questions. The question on age was open-
ended, and in some questions, the participants were given the opportunity to provide 
comment or responses other than those listed. At the end of the questionnaire, 




participants were also given the opportunity to provide general comment if any. All 
questions had the option of 'don't know/not sure' and 'refused to answer'.  
The questions were designed to assess the factors described in the conceptual 
framework. It captured nine major domains: 1) demographic profile of the study 
participant; their 2) awareness of biomedical research and biobanking; 3) attitudes 
towards biomedical research and biobanking; 4) willingness to participate in a 
population-based biobank; 5) perception of risks and benefits of biobank research and 
health status; 6) socio-cultural context and influence; 7) healthcare system experience 
and trust; 8) public's views concerning recontact and return of research results; and 9) 
preferred  health information and communication strategies.  
To ensure better understanding of the research participants about the topic of 
the research, some questions, particularly those related to biosamples, biomedical 
research and genomics, included explanations of some terms. In some cases, an 
introductory paragraph was given prior to asking questions. This step was particularly 
important to overcome the anticipated biomedical research and biobanking illiteracy. 
For‎ example,‎ biomedical‎ research‎ was‎ explained‎ as‎ “the‎ medical‎ research‎ that‎
involves the use of biological samples such as blood, urine‎or‎tissue”.‎‎Participation‎in‎
medical‎ research‎was‎ explained‎as,‎ “donating‎blood‎or‎ tissue‎ for‎ research‎or‎ taking‎
part‎ in‎a‎ trial‎ for‎ testing‎an‎experimental‎ treatment”.‎Genomics‎was‎defined‎as‎“the‎
relation‎of‎human‎genes‎with‎health.” 
To ensure better understanding and informed decision-making regarding 
willingness to participate in population-based biobank, the following introductory 
paragraph was included. This paragraph defined a biobank, explained the proposed 




model for establishing it, explained what participation in biobank research entailed, 
and reviewed the process of consent and its withdrawal.  
“Biobanks are like a library that stores large numbers of samples along with 
related health information for several years for the purposes of medical research.  
The Health Authority is planning to establish a population-based biobank in 
Abu Dhabi during the year. It will be managed by a healthcare provider. The purpose 
of the Biobank is to provide a resource that can support a diverse range of research, 
intended to improve the health of the Emirati population. Through this research, we 
hope to identify the genetic causes and variations of diseases common to the Emirati 
population. These include diabetes, heart disease, cancer and asthma, among others. 
It will also help to find new ways to prevent and treat these diseases in ways that are 
specifically tailored to Emiratis. It is hoped that this research will benefit current and 
future generations.  
Blood and urine samples collected during the Weqaya screening program, 
which would otherwise have been discarded, would instead be retained, matched with 
the health information collected via a questionnaire, and deposited in the biobank. 
The biobank will store samples and health information in a de-identified manner. 
Personal identifying information such as name, insurance number or date of birth will 
be removed and replaced by codes. The researchers using the samples will not know 
whom they came from.  
All adults 18 years and over in the emirate of Abu Dhabi will be invited to 
participate in the biobank. Participation in the biobank will be voluntary, and 
participants must give their permission for their samples and health information to be 




included in the biobank. Participants have the option to withdraw from the biobank at 
any time in the future without giving any reason.” 
3.6.2 Survey administration 
3.6.2.1 Data collection team 
The survey was administered by trained volunteers. Majority of volunteers 
were university students from the College of Medicine, UAE University (UAEU). 
Others were from Abu Dhabi University (ADU), New York University Abu Dhabi 
(NYAD), the Higher Colleges of Technology (HCT), and the Petroleum Institute.  
Volunteers also included interns in the course of their rotation to acquire the required 
training skills within the Department of Non-communicable Disease (NCD) — Public 
Health Division, Health Authority - Abu Dhabi. Additionally, some researchers were 
members of HAAD, NCD Department, Cardiovascular Diseases Section. Volunteer 
listings are provided in, Appendix V.  
3.6.2.2 Recruitment of volunteers 
The UAEU student volunteers were recruited through the Head of Public 
Health Institute, Faculty of Medicine, the co-investigator of this study. Other 
university student volunteers were recruited through their coordinators in their 
respective universities, as the HAAD training section had an established 
communication with several universities for internship programs or training rotations.  
Email communication was sent to the coordinators of public health/health science 
institutes within these universities. The email communication provided background 
information on the study, the specific roles and responsibilities of the volunteers, 
expectations and appreciation. The co-investigator and coordinators of other 
universities sent an email communication with these details to all their students to 




sign up as volunteers. The confirmed list was sent to the research assistants at HAAD 
to start the process of communication and training. The department interns were 
recruited by direct invitation. Signing up was completely voluntary, and there was no 
momentary reward offered for participation in the research study.  
Although a few male volunteers signed up for this study, none completed the 
process of training. All volunteers who conducted the interviews were females, which 
was believed to give a sense of reassurance to the survey respondents. 
3.6.2.3 Training of volunteers 
All volunteers were supervised and supported by the research assistants 
throughout the period of data collection. All volunteers received training, signed a 
confidentiality agreement and received all the necessary documents including a 
summary presentation on the study, copies of the survey questionnaire in Arabic and 
English, the consent form, the participant information form and data dictionary. All 
these documents are available in, Appendices III, V, VI, and VII. The training session 
was interactive and lasted two hours. The training presentation provide background on 
the Weqaya Screening program, the proposed plan for the biobank, details of the 
study, acceptable conduct during the telephone interviews and how to respond to 
difficult situations that might occur. At least three pretesting telephone interviews 
were conducted by each volunteer with a research assistants member. The first field 
call of each volunteer was attended by the research team. Ongoing supervision and 
support was provided by the research team. 
3.6.2.4 Data collection tool and data entry 
The selected method for data collection was telephone surveys as it is a 
convenient, as well as time and money saving method for data collection, particularly 




recommended for large and geographically scattered sample. It is a common tool for 
data collection, and is being increasingly used worldwide, especially by business and 
market research companies (Szolnoki & Hoffmann, 2013).   
 Unlike face-face interviews, self-administered surveys or online surveys, the 
telephone surveys minimize interviewer effects including social desirability bias, and 
allow for complex issues or questions to be clarified, thus ensuring understanding of 
the questions. It also provides a high level of anonymity which was extremely 
relevant in this study, given the unfamiliarity and sensitive nature of the topic and 
questions (Szolnoki & Hoffmann, 2013). 
The data were collected directly into the online survey during the telephone 
interviews. The aim was to ensure good quality data (reducing the errors of manual 
data entry) and a faster method for processing, handling and storing the data gathered 
from telephone interviews. 
All the telephone interviews were conducted in Arabic, and data were captured 
and entered using the Arabic online version of the Survey Monkey® tool.  Volunteers 
receive an active link of the study Survey Monkey®.  Each interview had a unique 
I.D. number that was entered in the online survey once consent was granted. These 
unique numbers were shared with volunteers through the same excel sheet that 
contained the list of potential participants and their contacts details.   
3.6.2.5 Telephone interview procedure 
Each volunteer received a weekly list of participants to first contact by email. 
The lists were sent using password protected Excel® sheets. All calls were attempted 
using fixed line telephones of either HAAD or the University. HAAD allocated 




workstations for volunteers, and each participating university provided an office for 
their volunteers to conduct the calls. 
The list contained two or three phone numbers for each potential participant. 
Volunteers called only the mobile phone numbers of participants and the phones were 
allowed to ring until they disconnected.  If an alternative mobile number was 
available, the volunteer tried that as well. A maximum of three contact attempts were 
made for each participant. The calls were made between 9:00am and 1:00 pm, and 
4:00 - 7:00 pm on weekdays, avoiding prayer and lunch times. These times were 
anticipated to be convenient for most participants. The weekly list of contacts was 
then returned to the research assistants by each volunteer at the end of the week with 
remarks in order to monitor the outcomes of calls and number of surveys conducted.   
3.6.2.6 Confidentiality and study verification procedure 
At the beginning of each call, the procedure for selection of the telephone 
numbers was briefly explained to potential participants. Volunteers read out the 
consent to each participant, and on receiving the same, the volunteer signed a 
hardcopy of the consent form. If the interviewee agreed to participate but at another 
time, or did not complete the survey at the time but was willing to continue later, the 
information, time and date were recorded on the consent form, and they were 
contacted later. Telephone numbers were not recorded on the consent form or the 
online survey questionnaire. Instead, unique survey numbers were recorded. 
On obtaining consent to take part in this study, additional information on the 
study, including the study verification procedures, was offered to participants. Where 
an interviewee showed interest knowing more about the study, volunteers either 
shared the information written in the participant information form verbally, or gave 




participants the option to have a copy sent by e-mail. The participant information 
form included the details of the primary investigator and their phone numbers in order 
to allow participants to verify the authenticity of the calls.  
 A couple of callbacks to volunteers were made during the course of data 
collection, mainly asking for other general inquires. These callers were referred to 
HAAD customer care.    
3.6.2.7 Appreciation for volunteers  
At the end of data collection, the volunteers as well as HAAD research team 
received a 'Thank you' letter signed by the primary and co-investigators, which is 
provided in Appendix VIII. Both volunteers and research assistants were duly 
mentioned and acknowledged in this study. Additionally, enthusiastic and high 
performing volunteers received small gifts in recognition of their extraordinary 
efforts. 
3.7 Variables  
3.7.1 Independent variables  
3.7.1.1 Demographic characteristics 
Demographic variables included gender, age, education level, employment 
and average monthly household income, region of residence, marital status, and 
parental status. Data on gender and region of residence were already provided in the 
Daman original list. Gender was confirmed during calls, as well as by the name 
printed on the consent form. Both variables were then entered manually along with 
the other collected data.   All demographic question response options were multiple 
choice, except age assessed with an open-ended question and subsequently 
summarized into categories.   




3.7.1.2 Health and medical research literacy 
Health and medical research literacy were assessed by 8 questions. Three 
questions asked about the level of self-rated knowledge on biomedical research or 
medical research that involves human biosamples, understanding of genomics or the 
relation between human genes and health, and familiarity with the term 'biobank'. The 
responses were on a three-point Likert scale ranging from 'no knowledge' to 'good 
knowledge'. The other two questions assessed previous experience of blood donation 
or participation in medical research.  The responses options included 'yes', 'no' and 
'don't know/not sure'. Attitudes towards biomedical research and biobanking were 
assessed through three questions. Participants were asked to agree with the statement 
'medical research improves patient health' and the response options were on a five-
point Likert scale ranging from 'strongly disagree' to 'strongly agree'. Participants 
were also asked about the importance of donating biosamples for medical research, 
and the value of the biobank in generating new information to improve health.  The 
response options to these questions were also on a five-point Likert scale ranging 
from 'not at all important/valuable' to 'extremely important/valuable'.   
3.7.1.3 Socio-cultural context influence 
The influence of social norms or socio-cultural context affecting public 
engagement and participation in the biobank was assessed through two questions. The 
first question asked about the willingness of other family members to participate in 
the biobank. The response options were on four-point scale of 'definitely yes', 
probably yes, 'probably no' and 'probably yes'.  The other question asked about 
influencers on making the decision about participation. The response options were, 
'entirely by yourself,' 'with the help of a family member or a friend', or 'with help from 




a doctor or other healthcare provider'. There was also an option to state other 
influencers on their decision to participate. 
3.7.1.4 Perceived benefits and risks of biobanking for research 
Perceived benefits and risks related to participation in a population-based 
biobank were assessed by exploring reasons that would motivate them (perceived 
benefits) or make them concerned (perceived risks) about taking part in the biobank. 
The response options to both questions were a list of risks and benefits to society, self 
or family, including an option to provide additional reasons. Survey respondents were 
encouraged to select up to three reasons. Perceived benefits (motives) were then 
grouped in three major categories: (i) altruistic motives such as improving the 
wellness and health of future generations or supporting medical research; (ii) moral 
motives such as donation being a charitable act; (iii) egoistic (personal) benefits such 
as obtaining cure or better treatment for the condition of self or family members. 
Health status of participants or their close family relative - with regards to 
diagnosis with chronic diseases, such as diabetes, asthma, heart disease, cancer, 
genetic condition or others - was assessed. Health status could be a motivator for 
participation, and might be associated with therapeutic misconception. The responses 
to health status questions included 'yes', 'no' and 'don't know/not sure'.   
3.7.1.5 Healthcare system: Public trust and experience  
The healthcare system related factors public trust and experience were 
assessed in three questions. The first asked about experience with healthcare services 
in the emirate of Abu Dhabi and the responses were on three-point Likert scale 
'mostly negative', 'neutral' or 'mostly positive'. The second asked about trust in 
healthcare providers and the response was on a three-points Likert scale 'low', 




'moderate' and 'high'. The third question asked about Trust in HAAD as a government 
entity supervising the biobank initiative, in terms of assessing risks and benefits of the 
biobank to the Emirati population. The response was on five-point Likert scale 
ranging from 'strongly disagree' to 'strongly agree'.   
 
3.7.1.6 Public views on future recontact and return of research results  
Participants were asked to imagine the scenario where they have agreed to 
participate in the biobank, then were asked the following three questions about certain 
biobank procedures: (i) if they would accept to be recontacted in the future (ii) if they 
like to receive general information regarding biobank research, and (iii) if they would 
like to receive information regarding their own genetic risk of health condition. The 
response options were on a four-point scale: 'definitely yes', 'probably yes', 'probably 
no', 'definitely yes'.  
3.7.1.7 Health information and communication technologies 
Preferred health information communication strategies was assessed in two 
questions. The first question asked about the preferred source for health information, 
particularly to learn more about the biobank, and the second question asked about the 
preferred means of communication to receive general research results of the biobank 
and updates.  Participants were given the option to select up to three sources. The 
response to both questions was a list of sources, including an option to provide 
additional responses.  
3.7.2 The outcome variable 
The main outcome (dependent) variable is willingness to participate in a 
population–based biobank. Participants were given an introductory paragraph about 




the proposed model for the future biobank, the purpose, the likely method of 
recruitment and requirements for participation. It was emphasized that participation in 
the biobank is voluntary. Willingness to participate was assessed by a single question.  
To ensure a clear position toward participation, a four-point scale was provided 
'definitely would participate', 'probably would participate', 'probably would not 
participate' and 'definitely would not participate'.   
3.8 Data Management and Interpretation  
Before data collection, few validation rules and warning messages were built 
in the online Survey Monkey®, to ensure that all values were within accepted ranges, 
all questions were answered, and that the skipped questions jumped to the next 
relevant question. Online messages warned interviewers about entering invalid values 
or leaving incomplete answers. Volunteers were trained and provide with data 
dictionary. The data dictionary was considered essential to enhance the consistency of 
the data collected, minimize intrapersonal variation and standardize responses to 
participants’‎queries‎(if‎any). 
During data collection, online survey interviews data were regularly 
monitored, almost on weekly basis. Duplicates surveys were removed. Volunteers 
were encouraged to complete incomplete interviews, one additional call attempted 
was tried only. Data was downloaded and saved on monthly basis, to avoid data loss.  
After data collection, complete data were exported from Survey Monkey® as 
an excel spreadsheet.  All the raw responses data were in Arabic. Responses were then 
coded‎ as‎ per‎ the‎ survey’s‎ original‎ category‎ codes.‎ Gender‎ and‎ region‎ data‎ were 
entered manually into the excel spreadsheet. Data was assessed for completeness, 
anomalous values and duplicates.  Data were lined up in proper columns and rows and 




then imported to Stata Statistical Data Analysis software version 11.2 (Stata Corp, 
College Station, TX). An identifier was created, variables were named and labeled 
and duplicates were assessed. Finally, summaries were conducted to identify outliers 
and check for completeness and consistency of data.   
Variables were subsequently recoded into new categories based on the 
literature of similar studies, and to ensure adequate number per category to run the 
statistical analysis. Table ‎3-1, below summarize the new categories and labels. 
Ordinal data from Likert-like variables were collapsed and dichotomized into two 
categories. All five-points Likert scale variables on attitudes were dichotomized into:  
agree (include strongly agree or agree) versus disagree (strongly disagree, disagree, 
neutral or not sure), important (include very or extremely important) versus not 
important (include not at all, somewhat, moderately important or not sure), and 
similarly, valuable versus not valuable. 
All three-points scale Likert variables on trust in healthcare providers and 
experience on healthcare services were dichotomized into high trust or mostly 
positive, versus others (include moderate/neutral, low/mostly negative or not sure). 
Data on knowledge was dichotomized into good knowledge versus limited knowledge 
(include no, some knowledge or not sure). All four-point yes/no scales were 
dichotomized into definitely yes versus others (include probably yes, probably no, 
definitely no or not sure), while in the two-point yes/no scale, the 'no' included no and 
not sure.  Age was presented as continuous data as well as categories: 18-24, 25-34, 
35-54, 55-64, 65 years and above. Region of residence was collapsed into two 
categories since only five participants were from the Al Gharbia (Western) region. 
The codes were Abu Dhabi City versus other regions.    




Table ‎3-1: Recoding and interpretation of study variables. 
Variable name  Interpretations 
Independent Variables  









Region of residence 1= Abu Dhabi City 
2= Other regions  
Highest education attained   1=Lower education (<Secondary ) 
1=Higher‎education‎(≥Secondary) 
Current employment status 1=Others (including household duties/ students /retired/ unemployed) 
2= At work 
Monthly household income  1= Lower income (< 20,000 AED)  
2= higher income‎(≥20,000 AED) 
Marital status 1= Others ( include single/widow/divorced) 
2=Married  
Parental status 1= No 
2=Yes 
Ever diagnosed with chronic 
diseases: Personal/Family  
 
1=No (include No/NS) 
2=Yes 
Ever donated blood/ Ever 
participated in medical research  
 
1= No (include No/NS) 
2=Yes 
Familiar with 'biobank'  1=No (include No/NS) 
2=Yes 
Knowledge on:  Biomedical 
research/ genomics  
 
1= Limited (No, some knowledge  & NS) 
2= Good knowledge  
Experience with healthcare services  1=Others (include mostly negative/neutral/NS) 
2=Mostly positive 
Trust in healthcare providers 1= Others (include low/ moderate/NS) 
2=High 
Medical research improves patients’‎
health  
 
1=Disagree (include strongly disagree/disagree/neutral/NS) 
2= Agree (include agree/ strongly agree) 
Trust HAAD to assess risks & 
benefits of biobank 
 
1=Disagree (include strongly disagree/disagree/neutral/NS) 
2= Agree (include agree/ strongly agree) 
Donating biosamples for research is 1= Not important (include not at all /somewhat /moderately important/ NS) 
2= Important (include very/extremely important)  
Biobank as a resource is‎….. 1= Not valuable (include not at all /somewhat /moderately valuable/ NS) 
2= Valuable (include very/extremely valuable) 
Decision to participate is made  1= Help of others ( family members or friends/a doctor or healthcare 
provide /others) 
2=Entirely by myself 
Accept future recontact 1= Others (include definitely no/ probably no/probably yes/ NS) 
2= Definitely yes 
Desire for feedback 1= Others (include definitely no/ probably no/probably yes/ NS) 
2= Definitely yes (strong desire) 
Family participation 1= Others (include Definitely no / probably no/ probably yes/ NS) 
2= Definitely willing (Definitely yes). 
Outcome Variable  
Willingness to participate  1= Others (include Definitely no / probably no/ probably yes/ NS) 
2= Definitely willing (Definitely yes). 




3.9 Statistical Analysis  
Quantitative analysis of the data was conducted using Stata Statistical Data 
Analysis software version 11.2 (Stata Corp, College Station, TX).  Basic descriptive 
summary statistics and complex statistical analysis were conducted to address the 
research questions and objectives.  
 Most of the variables were categorical data, nominal or ordinal. Age was a 
continuous variable, and was subsequently categorized. Few questions have 'other' as 
a response to explore probe further responses. Those responses were subsequently 
summarized into categories and presented in the results. 
Descriptive summary statistics were estimated for all variables using numbers 
and frequencies for categorical data, as well as mean and standard deviation for 
continuous data in order to identify outliers and other distributional characteristics 
that may influence regression, and to describe basic features of the data.  
Comparison by age, gender and education was conducted for all study 
variables. Additional comparisons, where appropriate and relevant, were conducted 
for some variables to examine the difference by other demographic characteristics, 
health status, knowledge and attitudes towards biomedical research or healthcare 
system experience and trust. 
Comparisons between groups were tested using Chi-squared‎(χ1)‎test‎or‎using 
Fisher's exact test where appropriate for non-ordered categories, Kruskal-Wallis for 
ordinal non-parametric distribution (Likert-type variables) and Students' t-tests for 
differences in continuous group means. A two-sided P-value of less than 0.05 was 
considered to assess statistical significance.  




It is worth mentioning that the analysis of the five-point Likert scale attitudinal 
variables using both Kruskal Wallis test (using all the five categories and not sure 
categories) and Chi-squared‎ (χ1)‎ test‎ (using‎ two‎ categories)‎ yielded‎ same‎ statistical‎
significance associations. Therefore, final analysis presented in the results section was 
for Chi-squared‎(χ1)‎test. 
The association of the independent variables with the outcome variable, i.e., 
the willingness to participate in a population-based biobank, was examined by 
conducting univariate (binary logistic regression) and multivariate (multiple logistic 
regression) analysis. From the univariate analysis, the crude odds ratios (OR) with 
95% confidence intervals (95% CI) on all independent variables were estimated. Wald 
P value was determined from testparm and considered significant if it was less than 
0.05.  
Associations that were found to be significant at univariate analysis were then 
entered into a multivariate analysis to generate the final model of factors that were 
independently associated with the willingness to participate in a population-based 
biobank.  
Before running the final model, multicollinearity among the significant 
independent variables from the univariate analysis was first examined by running 
multiple regressions instead of logistic regression, and calculating the variance 
inflation factors (VIF). There were no significant correlations among the independent 
variables, and the mean VIF was below 2.0.   
Secondly, the final model was selected through the use of both forward and 
then backward stepwise procedures, with P=0.05 as cut-off for inclusion or exclusion 
of variables. The candidate sets of significant independent variables entered into the 




model were:  gender,  education, employment status, ever donated blood, knowledge 
on biomedical research, attitudes: to HAAD ,biomedical research, donation of 
biosamples and the value of the  biobank, accept recontact, desire for return individual 
genomic research results , family participation (influence), influencers on decisions 
about participation, and  the perceived benefits 'improve the health and wellness of 
future generation', 'support medical research', and 'donation is a charitable act'.  Since 
gender is a key variable to test the pre-specified hypothesis, it was forced into the 
model using lock in term.  The final  model selected from backward and forward 
stepwise procedure  included: gender,  knowledge on biomedical research, attitudes 
towards the biobank, accept recontact, desire for return individual genomic research 
results, family willingness (influence),  perceived benefits:  'improve the health and 
wellness of future generation' and 'support medical research'.   For double checking, 
the Akaike's Information Criteria (AIC) was calculated for several models with 
different variables, the final model selected had the lowest AIC. 
Thirdly, the overall fitness of the model was assessed using Hosmer-
Lemeshow test. The observations were partitioned into 10 equal-sized groups 
according to their predicted probabilities. The observed and expected numbers of 
predictor variables were compared, and the chi-square statistics suggests that there is 
no evidence of lack of fit: P= 0.28. 
Lastly, a sensitivity analysis for missing data was conducted by including the 
missing‎data‎as‎a‎separate‎category‎in‎the‎model‎as‎‘unknown',‎and‎by‎analyzing‎only‎
the complete data to decide the final model. The results were almost the same.   




Both the crude and adjusted odds ratios for significant independent variables 
associated with the willingness to participate were summarized and compared in a 
table.   
3.10 Data Limitation 
A few issues arose during data collection. While conducting phone surveys, 
the online Survey Monkey® skipped two pages for 47 participants. As a result, the 
responses to questions 15-20 (recontact, return of individual and general research 
results, preferred communication technology, personal and family history of diagnosis 
with chronic disease) were missing for 47 participants. These as well as the ‘refused 
to answer’ questions were treated as missing data. Missing data was included as a 
separate category ‘unknown’, and accounted for during the sensitivity analysis for 
final model selection. 
The denominator (N) was slightly different for each variable as during the 
analysis and tabulation, only complete data, including 'don't know/not sure' as a 
response were included. In addition, few questions were skipped; for example, Q 26 
on parental status was not asked of singles for cultural reasons. Question 11 on 
motives was limited to those who were willing to participate (probably/definitely yes 
or not sure about participation), question 12 on concerns were asked only to those 
who were not willing to participate (probably/definitely no). Question 18 on 
communication technology was limited to those willing to receive general information 
on biobank research.  




3.11 Ethical Consideration and Protection of Research Participants  
This study was reviewed and approved by Al Ain Medical District Human 
Research Ethics Committee (AAMDHREC) on February 15, 2015. The IRB approval 
is included in Appendix IX.   
Study participants were well informed about the study prior to participation, 
and their verbal consent was taken and documented by volunteers. All consent forms 
were collected by the primary investigator at the end of the study. Consent forms were 
scanned and stored in a secured file as soft copy format. Hard copies were shredded.  
The study risks were minimal: there was no intervention, nor access to 
medical records.  Inconvenient times were avoided, and calls were limited to three 
attempts in case of no response or a response of call later.  The survey was 
anonymous, and no identifiers were attached to individual responses. Participation 
was completely voluntarily, and participants were informed that they could refuse to 
answer any question, stop and continue at another time, or withdraw at any time 
without any consequences. 
The survey questions and responses were tested to ensure cultural sensitivity. 
During the pretest period, the telephone surveys were piloted to assess the average 
time required to complete each survey.   
The primary investigators had successfully completed a research ethics 
training course. The training received by the volunteers included fundamentals of 
research ethics as well as signed confidentiality agreements. The study participants' 
list was received from Daman in a password protected CD. Contact details were 
shared with the volunteers as a password protected excel sheet through e-mail 
communication. A generic password code was created and sent once in separate email 




to all volunteers. At the end of the survey, the primary investigator instructed all 
volunteers and research assistants to delete all previous email communications that 
contains the protected excel sheet for lists of contacts.   
The Survey Monkey® surveys were uploaded to secure file, and the online 
survey data were deleted. After completing this study, the survey raw data, scanned 
copy of the consent forms, and the participants contact list will be stored for two years 
in a secure location, to be accessed only by the primary investigator.  
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4 Chapter 4: Results 
4.1 Response Rate  
3,758 phone numbers were called in this study. A maximum of three 
attempts were made for each participant, during varying days and times. We 
experienced high rates of invalid telephone numbers. This was undoubtedly due to 
the duration between the original Weqaya screening, and the timing of this sample 
survey. Figure ‎4-1, summarizes the phone numbers attempted and outcomes. 
A total of 603 telephone interviews were conducted with 313 men and 290 
women.  The overall response rate was 71.7%, which is considered satisfactory in 
the light of the low exposure of the general public to any type of research, and the 
newness and possible sensitivity of the topic addressed. It was close to what was 
anticipated during sample size estimation. 
Of the 603 interviews, six participant interviews (1%) were stopped 
abruptly, and the participants refused to continue the survey. One stopped at the 
main research outcome question regarding the willingness to participate in the 
proposed biobank. The other five participants stopped at question number 13, 
which was related to family participation in the biobank. Interestingly, for those 
five participants, the surveyors were able to capture the perceived concerns and 
benefits of participation in a biobank for future research, as outlined in questions 
number 11 and 12.   
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In general, the survey questions were well tolerated by participants. The 
questions that survey respondents refused to answer were primarily those related to 
demographic data about education, employment, marital and parental status, family 
history of chronic diseases and the monthly household income. For these reasons, 
these questions were kept until the end of the interview. The refusal rate was very low 
for all questions ranging from 0.1% to 0.7%. The question on income had the highest 
refusal rate of 27%. 
4.2 Demographic Profile of the Survey Respondents  
Table ‎4-1, describes the demographic profile of the survey respondents, and 
provides comparisons with the overall Emirati general population of the emirate of 
Abu Dhabi based on latest population estimates of mid-2014 as reported by the 
Statistics Center of Abu Dhabi (SCAD, 2016). All comparisons, except for education, 
were made among adult Emiratis between the ages of 20 to 79 years, where the 
population estimate for educational attainment of Emiratis aged 10 years and over, as 
well as that of the labor force was used, which included the employed and 
unemployed estimates for the Emirati population of 15 years and over.  Further 
comparisons of the demographic profile by gender was conducted and presented in 
Table ‎41. 
Ages of the survey respondents ranged from 19 to 79 years, and their mean 
age was 37.9 (SD ± 10.9 years). The most frequent age group represented in the study 
sample was 35-54 (47.8%), followed by the age group 25-34 years (36.3%). 
Compared with the general Emirati population, the younger age group of 18-24 years 
was less represented in the study (7.1% versus 19.3% of total Emirati population in 
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the age group 20-24). The middle aged group (35-54 years) was therefore over-
represented (47.8% versus 34.3% of total Emirati population).  
Although the study sample was stratified by gender, and equal number of 
random samples were taken from both genders, males appeared to be slightly more 
enthusiastic, curious, and therefore accepting of taking part in the study than females; 
the study samples were 51.9% males versus 48.1% females. The gender distribution 
of the survey respondents was consistent, and considered representative of the general 
Emirati population which was 51.3% males and 48.7% females. Female participants 
were generally younger than males (mean age for females was 35.6 years compared to 
39.9 years for males, (P<0.001).   
Regarding the highest educational attainment, the largest proportion of survey 
respondents, 214 out of 590 (36.4%), completed college or university, followed by 
206 (34.9%) who reported that they had completed secondary school.  While 47 of the 
survey respondents (7.9%) had completed higher education, i.e., Masters or PhD, 
there were a few, 27 (4.6%), who did not attend school or had less than primary 
education. Compared to the general population (10 years and older), survey 
respondents were better educated. The proportion of survey respondents with higher 
education, completed secondary school or higher, was higher (79.1% versus 47.2% of 
the general Emirati population).  It was noticed that those with higher education were 
more likely to be males (84% of all males versus 75% of all females, P=0.006) and 
younger than those with lower education, less than secondary school, (mean age was 
35.7 years versus 45.9 years, P<0.001). 
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Table ‎4-1: Demographic profile of the survey respondents and comparison with Abu 
Dhabi Emirati general population, (20-79 years). 
Characteristics 
 
N (%) Emirati Population (%)  
Gender  N=603 (%)  
Male 313 (51.9) (51.3) 
Female 290 (48.1) (48.7) 
Age (years) N=603 (%)  







25-34 219 (36.3) (36.4) 
35-54 288 (47.8) (34.3) 
55-64 36 (6.0 ) (6.4) 
65+ 17 (2.8) (3.5) 
Region of residence  N=603 (%)  
Abu Dhabi City 261 (43.3%) (51.6) 
Al Ain (Eastern) Region  337 (55.9%) (42.5) 
Al Gharbia) Western Region  5 (0.8%) (5.8) 
Highest education attained  N=590 (%) ^ 
Did not attend school or less than primary 27 (4.6) (16.1) 
Completed primary school 30 (5.1) (15.8) 
Completed intermediate school 64 (10.9) (19.6) 
Completed secondary school  206 (34.9) (24.4) 
Completed college or university 214 (36.3) (19.9) 
Completed Master or PHD 47 (7.9) (3.2) 
DK/NS 2 (0.3) (1.0) 
% Employed of  the total labor force  N= 392 (%) # 
At work 367 (93.6) (88.5) 
Unemployed  25  (6.4) (11.5) 
Monthly Household income in AED  N=436 (%)  
< 20,000  92 (21.1) - 
20,000 to 39,999  186 (42.7) - 
40,000 to 59,999  53 (12.2) - 
60,000 to 79,999  16 (3.7) - 
> 80,000  15 (3.4) - 
DK/NS 74 (16.9) - 
Marital status N=592 (%)  
Single  86 (14.5) - 
Married 481 (81.3) - 
Separated/divorced 17 (2.9) - 
Widowed  8 (1.35) - 
Parental status  N=506 (%)  
No 37 (7.5) - 
Yes  469 (92.5) - 
*SD= Standard Deviation 
^ The population Estimate present education attainment of Emiratis 10 years and over 
# Emirati labor force, age 15 years and over. 
  




Table ‎4-2: Demographic profile of the study participants, by gender. 
Characteristics Males              
313 (51.9%) 
Females                   
290 (48.1%) 
P value† 
Age (years) N=603 (%)   
Mean ±SD 39.9 ±11.6 35.6±9.7 <0.001 
Age groups   0.002 
18-24 14 (4.5) 29 (10.0)  
25-34 103 (32.9) 116 (40.0)  
35-54 159 (50.8) 129 (44.5)  
55-64 24 (7.7 ) 12 (4.1)  
65+ 
 
13 (4.2) 4 (1.4)  
Region of residence  N=603 (%)  0.04 
Abu Dhabi City  148 (47.3) 113 (39.0)  
Al Ain (Eastern) Region 161 (51.4) 176 (60.7)  
Al Gharbia) Western Region 4 (1.3) 1 (0.3)  
Highest education attained  N=588 (%)  0.006 
Did not attend school or less than primary 8 (2.6) 19 (6.7)  
Completed primary school 9 (3.0) 21 (7.4)  
Completed intermediate school 32 (10.5) 32 (11.3)  
Completed secondary school  110 (36.2) 96 (33.8)  
Completed college or university 111 (36.5) 103  (36.3)  
Completed Master or PHD 34 (11.2) 13 (4.6)  
Current employment status  N=590 (%)  <0.001 
At work 248 (81.9) 119 (41.5)  
Unemployed  8 (2.6) 17 (5.9)  
Student  8 (2.6) 21 (7.3)  
Retired  37 (12.2) 5 (1.7)  
Home duties/(other)  2 (0.7) 125 (43.5)  
Monthly Household income in AED  N=362(%)  0.01 
< 20,000  42 (18.0)  50  (24.6)  
20,000 to 39,999  108 (46.4) 78 (38.4)  
40,000 to 59,999  36 (15.5) 17 (8.4)  
60,000 to 79,999  12 (5.2) 4 (11.9)  
> 80,000  8 (3.4) 7 (43.5)  
Marital status N=592 (%)  0.001 
Single  35 (11.5) 51 (17.8)  
Married 263 (86.2) 218 (76.0)  
Separated/divorced 6 (2.0) 11 (3.8)  
Widowed  1 (0.3) 7 (2.4)  
Parental status  N=506 (%)  0.2 
No 16 (5.9) 21 (8.9)  
Yes  254 (94.1) 215 (91.1)  
*SD= Standard Deviation  
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Most of the survey respondents, 337 out of 603 (55.9%), were residing in Al 
Ain (Eastern) region, 261 (43.3%) in Abu Dhabi city, and only five (0.8 %) in the Al 
Gharbia (Western) region. Participants from Eastern region were slightly over-
represented in the study sample (55.9 % of all participants, compared to 42.5% in the 
general Emirati population), and there was less representation from the Western 
region (0.8 % versus 5.8% in the general Emirati population). There were gender 
differences by region: Abu Dhabi residents were 56.7% males versus 43.3% females, 
(P=0.04). No difference of education attainment was seen by age (P=0.06) or by 
region (P=0.36).  
The distribution of survey respondents by employment status revealed that 
most of them, 367 out of the 590 (62.2%), were gainfully employed, followed by 
those doing home duties 127 (21.5%). Only 67 (11.3%) were unemployed or retired, 
and 29 (4.9%) were students.  According to SCAD, the labor force includes employed 
and unemployed individuals aged 15 years and above. The percentage of employed 
survey respondents was higher than that of the general Emirati population (15 years 
and above), 93.6% compared to 88.5%.  In addition, those employed were 
predominantly males (81.9% of males versus 41.5% of all females, P<0.001), younger 
than those of other employment status (mean age was 36.9 years compared with 39.1 
years, P=0.009), and tended to be highly educated (90% of those had higher education 
were at work versus 75% lower education, P<0.001).  
As anticipated, the question on monthly household income was the most 
sensitive one; of the 597 survey respondents who completed the survey, 161 refused 
to answer this question. Of those who answered (N=436), 92 participants (21.1%) 
reported a monthly household income of less than 20,000 AED (<$5,450), 186 
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(42.7%) reported 20,000-39,000 AED ($5,450-10,627), 53 (12.2%) reported 40,000-
59,000 AED ($ 10,900- 16,075) 31 (7.1%) reported 60,000 AED or more (>$ 16,350), 
and 74 (16.9%) were not sure. Those with monthly household income of 20,000 AED 
or more were more likely to be males (60.7% males versus 39.3% females, P=0.01), 
younger (mean age 37.1 years compared with 42.4 years for those of income of 
<20,000 AED, P<0.001), having higher education (88.5% higher education compared 
with 54.4% lower education, P<0.001), and were employed (82.8% versus 58.4% 
other employment status, P<0.001). 
The majority of study participants, 481 out of 592 (81.3 %), were married, 86 
(14.5%) were single, and 25 (4.2%) were either divorced or widowed.  There were 
significant differences in marital status by gender. Those who were married were 
more likely to be males (54.7% males compared with 45.3% females, P=0.001) and 
older (mean age 39 years versus 32.6 years for other marital status, (P<0.001). No 
difference in marital status was found by education status (P=0.46). 
Parental status was assessed by asking the survey respondents whether they 
had children. This question was answered only by those who were ever married, 
including widows or separated, N=506. Singles were not asked this question for 
cultural reasons. The vast majority of ever married survey respondents, 469 (92.5%) 
indicated that they have children; only 37 (7.5%) had no children. Those who 
indicated that they have children were older than those who did not: mean age 39.9 
years compared to 32.3 years, (P<0.001). There were no differences in parental status 
by gender or education (All P>0.05). 
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4.3 Health and Medical Research Literacy 
4.3.1 Knowledge on biomedical research and biobanking    
Participants were asked to self-rate their own level of knowledge on 
biomedical research - medical research that involves the use of human biological 
samples such as blood, urine or tissue, their understanding of genomics - the relation 
between human genes and health, and how familiar they were with the term 'biobank'. 
Figure ‎4-2, illustrates that vast majority of the survey respondents, 573 out of 
the 602 (95.2%), had limited knowledge about biomedical research or were not sure, 
and only 29 (4.8%) indicated that they had good knowledge. There were no 
differences in knowledge about biomedical research by age, gender or education (All 
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Similarly, the majority of study participants, 505 out of the 602 (83.9%), 
reported limited knowledge on genomics, while only less than one-fifth (16.1%) 
reported having good knowledge. Those reported to have good knowledge on 
genomics had higher education (P<0.001).  There were no gender or age differences 
found in this regard (P= 0.47). 
Concerning the familiarity with the term 'biobank', only 99 out of the 603 
(16.4%) survey respondents were familiar with it; however, the vast majority were not 
familiar, as 493 (81.8%) had never heard about this term before and 11 (1.8%) were 
not sure. Those who were familiar with the term biobank tended to have good 
knowledge on biomedical research (P=0.02) and genomics (P=0.001), higher monthly 
household income of >20,000 AED (P=0.02), positive attitude to donation of 
biosamples for research (P=0.05), and a family history of chronic diseases (P=0.02). 
No association with gender, age, education status, knowledge on biomedical research, 
genomics or previous participation in medical research or blood donation (All 
P>0.05) was found.   
4.3.2 Previous donation and participation in medical research 
Previous experience with donation of blood and participation in medical 
research was assessed. Of the 603 study participants, 256 reported previous donation 
of blood (42.5%), while 336 (55.7%) had never donated blood and 11 (1.8%) were not 
sure. Those who gave a history of a prior blood donation were more likely to be male 
(P<0.001), older (mean age 39 years versus 37 years for those who never donated, 
P=0.03) and have higher education (P<0.001).   
Only 36 out of the 603 (6.0%) survey respondents indicated that they had ever 
participated in medical research, such as donation of blood or tissue for research or 
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taken part in a trial for testing a new experimental treatment. The vast majority 562 
(93.2%) had never participated, and five (0.8%) were not sure. No difference in prior 
history of being a research participant was found for age, gender or education (All 
P>0.05).  
Further analysis of previous participation in medical research by previous 
blood donation, healthcare system experience and trust, knowledge and attitude 
towards biomedical research and biobanking, as well as personal or family history of 
chronic diseases showed that survey respondents who indicated previous participation 
in medical research were more likely to donate blood (P=0.007), and have high trust 
in healthcare providers (P=0.01). However, no difference was shown by experience 
with healthcare services, trust in HAAD, knowledge and attitude to biomedical 
research and biobanking, and health status (All P>0.05). 
4.3.3 Attitudes towards biomedical research and biobanking  
Participants were asked about their attitudes towards biomedical research, the 
importance of donation of biosamples for medical research, and the value of 
biobanking to generate new information to improve health. In general, the majority of 
the survey respondents had a positive attitude towards biomedical research and 
biobanking for research. Figure ‎4-3, graphically displays the responses. 
The vast majority of survey respondents, 548 out of 603 (90.9%), agree that 
medical research leads to improvement in patients' health. Very few disagreed, 15 
(2.5%), were neutral, 18 (4.6%), or were not sure, 12 (2.0%). Those who had positive 
attitudes towards medical research had good knowledge of genomics (P=0.02) and 
had trust in HAAD, (P<0.001). Gender, age, education, personal and family history of 
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chronic diseases, and knowledge of medical research or biobank did not seem to 
influence survey respondents' attitudes towards medical research (all P>0.05).  
Moreover, a majority of survey respondents believed that it is important that 
people donate biosamples for medical research, 508 out of the 603 (84.3%). The rest 
believed that it is moderately important 55 (9.1%), not important, 19 (3.2%), or were 
not sure 21 (3.5%). Those who believed that it is important to donate biological 
samples for research were older than others (mean age 38.3 years versus 35.6 years, 
P=0.03), had good knowledge in genomics (P=0.008), had a positive attitude to 
medical research (p<0.001), and had higher rates of chronic diseases than others 
(P=0.02).  Attitudes toward donation of biosamples for research did not vary by 
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A vast majority of survey respondents, 552 (91.6%), believed that the biobank 
would be a valuable resource to generate new information to improve the health of 
Emiratis. Others believed that it is moderately valuable 29 (4.8%), not valuable, six 
(1.0%), or were not sure, 16 (2.7%). Those with a positive attitude to the value of the 
biobank had positive attitude to medical research and donation of biosamples (both 
P<0.001), had high trust in healthcare providers (P=0.01) and HAAD (P<0.001), and 
mostly positive experience with healthcare services in Abu Dhabi (P=0.008). 
Attitudes toward the biobank did not vary by gender, age, education, knowledge on 
biomedical research and biobank, personal or family history of chronic diseases (all 
P>0.05). 
4.4 Healthcare System Experience  
Healthcare system experience factors were assessed using three questions. 
Figure ‎4-4 graphically illustrates the main findings.  
Participants were asked to describe their general experience with healthcare 
services in the Emirate of Abu Dhabi. A large proportion of participants, 334 out of 
547 (61.1%), reported mostly positive experiences, while 181 (33.1%) were neutral 
and 21 (3.8%) thought it was mostly negative.  Only 11 (2.0%) survey respondents 
were not sure.  Those with mostly positive experience were slightly older than others, 
mean age 38.5 years versus 36.5 years (P=0.03). Experience with healthcare services 
in Abu Dhabi did not vary by gender, education, personal or family history of chronic 
diseases (all P>0.05).  
Participants were further asked to rate their trust in healthcare providers. Only 
198 out of the 546 survey respondents (36.3%) indicated that their trust in healthcare 
providers was high. The largest proportion 289 out of the 546 (59%) indicated that 
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they were moderately trustful, further 8.3% had low trust and 2.6% were not sure.  
Gender, age, education, personal and family history of chronic diseases did not 
influence survey respondents' trust in healthcare providers (all P>0.05).  It was 
observed that those who have high trust in healthcare providers were more likely to 
report mostly positive experiences with healthcare services (P<0.001), have positive 
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questions related to the healthcare system experience and trust. The vast majority of 
the study participant had trust in HAAD, 452 out of the 548 (82.5%). Others were 
either neutral (10.0%), disagreed (2.6%) or were not sure (2.6%). Those who have 
trust in HAAD had mostly positive experience with healthcare services in the emirate 
of Abu Dhabi (P<0.001), high trust in healthcare providers (P<0.001), and a positive 
attitude to medical research (P<0.001), donation for research (p=0.01) and the value 
of the biobank (P<0.001). Gender, age, education and personal or family history of 
chronic diseases did not influence trust in HAAD (all P>0.05). 
4.5 The Socio-Cultural Context and Influence 
Social-cultural influences on decision-making regarding possible participation 
in the biobank was assessed by asking survey respondents whether they think that 
other family members would be influenced by their participation and would be willing 
to do the same, as well as by assessing the influencers on their own decision to 
participate.  
Out of the 597 survey respondents, 247 (41.4%) reported that their family 
members would definitely be willing to participate in the biobank. Of the others, 246 
(41.2%), reported that they would probably be willing, 38 (6.4%) were not willing, 
and 66 (11.1%) were not sure, as shown in Figure ‎4-5. Gender, age and education did 
not seem to influence family willingness to participate in the biobank (All P>0.05).  
When asked about people that might be help in making a decision regarding 
biobank participation, the majority, 422 out of the 594 (71.0%), preferred to make the 
decision entirely by themselves, 81 (13.6%) preferred to make the decision with help 
from family members or friends, 83 (14%) with help from a doctor or other healthcare 
provider, and 7 (1.2%) were not sure.  Those who preferred to make the decision 
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about participation with help from others - family members, friends, a doctor, or 
healthcare providers - were more likely to be females (P<0.001), those with  lower 
education status (P=0.001), are not employed (P<0.001),  and  had a monthly 
household income of less than 20,000 AED  (P=0.001). No difference was seen by 
age. 
 
   
 




Further assessment by family participation was done to explore the possible 
influences of social network on decisions regarding participation in the proposed 
biobank. Those who preferred to make the decision about participation with help from 
others (family members, friends, a doctor or healthcare providers) were more 
confident about family participation than those who made decision by themselves, 
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4.6 Perceived Benefits and Risks of Biobanking for Future Research 
Personal and close family relative history of chronic diseases was assessed as 
a potential motivator for participation in the biobank.  Perceived benefits and risks of 
biobank for future research were assessed by exploring reasons that would motivate 
(perceived benefits) or concern (perceived risks) them when it comes to the decision 
to take part in the future biobank.  Survey respondents were encouraged to select up to 
three possible reasons.   
4.6.1 History of chronic diseases 
Almost one-quarter (25.7%), 141 out of the 549 survey respondents, reported 
that they had been diagnosed with a chronic disease, 408 (73.6%) were free of chronic 
diseases, whereas four (0.7%) were not sure. No gender differences were found for 
self-reported history of a personal chronic disease (P=0.18). Those with personal 
history of a chronic disease were older (mean age 43.3 versus 35.9 years, P<0.001), 
more likely to have a close family relatives with chronic diseases (P=0.02), and had 
lower education (P<0.001). 
On the other hand, a majority of survey respondents, 369 out of 544 (67.8%), 
indicated a positive history of a close family relative with a chronic diseases, 172 
(31.6%) had no family history, and three survey respondents (0.6%) were not sure. No 
differences were found by gender, age or education in family history (all P>0.05).  
4.6.2 Perceived benefits of biobanking for future research  
Perceived benefits can be broadly clustered into: (i) altruistic motives such 
helping future generation  or support medical research; (ii) moral motives such as 
believing that donation is a charitable act; or (iii)  personal (egoistic) motives such as 
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therapeutic benefits to self or family members, as categorized by researchers (Luque 
et al., 2012; Nobile et al., 2013 ).   
The most common motive to participate in a biobank was altruistic: to 
improve the health and wellness of future generations, (72.7%), and to support 
research (60.9%), followed by moral motives, e.g., donation is a charitable act 
(51.4%).  Less frequent reasons cited by survey respondents were therapeutic 
benefits; reasons such as obtaining better treatment or cure for family members 
motivated only one-third‎ (31.0%),‎ and‎ obtaining‎ better‎ treatment‎ or‎ cure‎ for‎ one’s‎
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Twenty-seven participants (4.8%) pointed out other motives such as   
development opportunities for the country, reduced need to travel abroad for 
treatment, and personal curiosity: gaining knowledge and better understanding of the 
biobank and its function.  
Overall rankings of motives by gender were relatively similar, except for the 
motive 'donation is a charitable act' which ranked third for males while it was the 
second most common motivator for females. In addition, it was observed that 
'improving the health and wellness of future generations' motivated those with higher 
education (P=0.005), having a good knowledge of genomics (P=0.001) and a positive 
attitude towards donation of biosample for research (P=0.005), biobanking (0.006) 
and trust in HAAD (P0.001). No differences by age, gender or history of chronic 
diseases (P>0.05) were seen in the factors that motivated them to participate in the 
proposed biobank. 
Similarly, 'support medical research' tended to motivate males (P=0.02), those 
with higher education (P<0.001), had good knowledge on genomics (P=0.007) and 
biobanking (0.04), as well as those who had a positive attitude to donating biosample 
for research (P=0.005) and biobanking (0.006), and had previously donated blood 
(P0.004). There was no association with age or history of chronic diseases (All 
P>0.05). 
Furthermore, 'Donation is charitable act' motivated those who had positive 
attitudes towards the donation of biosample for research and understood the value of 
the biobank (P<0.001). No association with age, gender, education, previous donation 
of blood, or history of chronic disease was found for this motivator (all P>0.05). 
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 Obtaining better treatment for family members tended to motivate females 
more than males (P=0.03), those with good knowledge on genomics (P=0.01), and a 
history of close family members with chronic diseases (P=0.004).  No association of 
this motivator was found with age, education, or personal history of chronic diseases 
(all P>0.05). 
Likewise,‎ obtaining‎ better‎ treatment‎ or‎ cure‎ for‎ one’s‎ own‎ condition‎
motivated older participants (mean age 40.8 years versus 37.3 years, P=0.005) and 
those who had a personal history of chronic diseases (P=0.01). No association with 
gender, education or family history of chronic diseases (all P>0.05) was found for this 
motivator. 
4.6.3 Perceived risks of biobanking for future research 
As illustrated in Figure ‎4-7,  a substantial proportion (38.2%) of those who 
were not willing to participate in the biobank, N= 34, were also not sure about the 
potential concerns regarding donation of biosamples, and health information for 
future biomedical, particularly genomic, research.  Nonetheless, the most frequent 
concerns reported were those regarding genomic research (23.5%), lack of belief in 
medical research (23.5%), concerns regarding loss of privacy (14.7%) and breach of 
confidentiality (5.9%). 
 Other concerns pointed out by survey respondents were concerns such as 
being too sick or not healthy (11.8%),  lack of knowledge about risks and benefits of 
the biobank (8.8%), being too busy (5.9%), transportation barriers (5.9%), lack of 
trust in healthcare services (2.9%), or being too old (2.9%) or were only willing to 
donate biosamples (2.9%) and not information. 
Chapter 4  Results 
131 
 
Those who 'were not sure' about the potential concerns of taking part in the 
biobank research were mainly those who had limited knowledge on genomics 
(P=0.01), had never donated blood (P=0.002), had negative attitude to donation of 
biosample for research (P=0.02) and the biobank (P<0.001).  No association with 
other variables assessed were found (All P>0.05).  
Those who did not believe in medical research had limited knowledge on 
biomedical research (P=0.05), had negative attitudes on the biobank (P=0.003), and 
did not trust HAAD (P<0.001). No association with other variables addressed was 




Figure ‎4-7: Perceived risks of biobanking for future research, N=34. 
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valuable as resource, and did not trust HAAD (all P<0.05). No association with other 
variables tested were found (All P>0.05). 
4.7 Public Views on Future Recontact and Return of Results 
Participants were asked to consider a hypothetical situation where they agreed 
to participate in the biobank. They were then asked whether it would be acceptable for 
them to be contacted in the future by the biobank to ask for new information, 
additional assessments and tests, or to donate more blood, and whether they wanted 
feedback on individual genomic or general research results. A large proportion of the 
study respondents, 402 out of 594 (67.7%), indicated that it is definitely acceptable 
for them to be recontacted by the biobank sometime in the future. Others found this 
probably acceptable 136 (22.9%), and only a few found this to be not acceptable 42 
(7%) or were not sure 14 (2.4%). Those who indicated that they would definitely 
accept to be recontacted by the biobank were more likely to be males (P=0.004), 
highly educated (P=0.007), had previously donated blood (P<0.001), were familiar 
with the term biobank (P= 0.047) and had positive attitudes towards medical research, 
donation of biosamples and the biobank (All P<0.001), and had trust in HAAD 
(P=0.01). No differences by age were noted (P=0.77). 
There was a strong desire for the return of individual research results; 499 out 
of the 595 (83.9%) stated that they definitely wanted to receive information on any 
condition that could be a risk in the future.  Others responded probably yes, 48 
(8.0%), did not want to receive such information, 36 (6.1%), or were not sure, 12 
(2.0%).  Those who had a strong desire for the return of individual research results 
were found to be more likely to have higher education (P=0.005), good knowledge on 
genomics (P=0.008), were familiar with the term biobank (P=0.009), had previously 
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donated blood, and had positive attitudes to medical research, donation of biosamples 
for research, the biobank and HAAD (All P<0.001). No other differences in response 
were found by gender or age (All P>0.05). 
Similarly, there was a strong desire for feedback on general information on the 
research conducted by the biobank; 421 out of 595 (70.8%) indicated that they 
definitely‎wanted‎to‎receive‎such‎feedback.‎Other‎indicators‎included‎‘probably‎yes’ 
107‎(8.0%),‎‘do‎not‎want‎to‎receive‎such‎information’, 55(9.2%), or were not sure 12 
(2.0%). Those who expressed a strong desire for feedback or general information on 
research conducted by the biobank were more likely to have higher education 
(P=0.001), were familiar with the term biobank (P<0.001), had previously donated 
blood (P<0.001) and had a positive attitude toward donation of biosamples for 
research (P<0.001), the biobank, (P=0.004), and HAAD (P<0.001). No differences in 
response were found by gender or age (All P>0.05).   
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4.8 Willingness to Participate in the Population-Based Biobank 
Participants were given an introduction about the proposed plan for 
establishing the population-based biobank in Abu Dhabi, and were asked whether 
they would participate in the biobank, voluntarily donating for future genomic 
research, the residual biosamples (blood or urine) and the health information collected 
during their Weqaya screening visit. 
One participant did not answer this question and decided to end the survey at 
this point, while 602 of the survey respondents answered this question. Error! 
eference source not found., illustrates the responses. Remarkably, the vast majority 
of the survey respondents did not mind donating residual biosamples and 
accompanying health information to the proposed biobank; 458 out of 602 (76.1%) 
indicated that they would definitely participate in the proposed biobank, and a further 
100 (16.6%) indicated that they would probably participate. Only a minority 34 
(5.7%) were not willing to participate or were not sure 10 (1.7%).  
Males were more likely to participate in the proposed biobank compared to 
females; 80.8% of males were definitely willing to participate in the biobank versus 
71.0% of females (P=0.005).  
 




Figure ‎4-9: Willingness to participate in the population-based biobank, N=602. 
 
 
4.9 Factors Associated with Participation in a Population-based 
Biobank 
 As‎ mentioned‎ earlier,‎ the‎ outcome‎ variable,‎ ‘willing‎ to‎ participate‎ in‎ the‎
proposed population-based‎biobank’,‎was‎dichotomized‎into‎two‎categories:‎definitely‎
willing to participate versus others, which included those who responded with 
probably yes, probably no, definitely not or were not sure.  Those definitely willing to 
participate were the majority, 458 out of the 602 study respondents (76.1%), while 
others were 144 (23.9%).    
Explored below are the independent variables that were associated with the 
definite willingness of the Emirati general public to participate in the proposed 
population-based biobank, based on factors described in the conceptual framework 
presented in Chapter 2.  As the model was described in the introductory paragraph to 
our study participants, we had not explored the association with various biobank 
models in our study.  In addition, the health information and the preference for 
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strategies to improve health and research literacy, and to increase the publicity of the 
biobank. 
 Table ‎4-3, presents the significant independent variables associated with the 
definite willingness to participate in a population-based biobank, from both the 
univariate analysis as well as after adjustment from the multivariate analysis. 
Significant demographic factors associated with increased willingness to 
participate in the proposed biobank were gender, higher education attainment and 
employment status. Being a male increased the likelihood of willingness to participate 
by 71% (Crude OR=1.71: 95% CI: 1.17 to 2.05, P=0.005). Higher education, having 
completed secondary school or higher, increased the likelihood of willingness to 
participate by 72% (Crude OR=1.72: 95% CI: 1.10 to 2.67, P=0.02). Currently 
employed increased the likelihood of willingness to participate in the biobank by 84% 
(Crude OR=1.84: 95% CI: 1.25 to 2.69, P=0.002). 
Altruistic and moral motives were significantly associated with an increased 
likelihood of participation of the Emirati general public in the proposed biobank. The 
likelihood of willingness to participate in the biobank showed a three-to-fourfold 
increase among those who were motivated by the benefits 'improving the health of 
future‎generations',‎'support‎medical‎research'‎and‎‎'donation‎is‎charitable‎act’‎(Crude‎
OR=4.0: 95% CI: 2.70 to 5.92, P<0.001) , (Crude OR=3.73: 95% CI: 2.50 to 5.54, 
P<0.001) and  (Crude OR=2.68: 95% CI: 1.80 to 4.00, P<0.001) respectively.  
Factors related to biobank operations and policies were all associated with a 
willingness to participate in the biobank. Accepting recontact increased the likelihood 
of willingness to participate in the biobank almost six-folds (Crude OR=5.69: 95% 
CI: 3.79 to 8.55, P<0.001), returning individual genomic research results also 
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increased it six-folds (Crude OR=5.84: 95% CI: 3.67 to 9.28, P<0.001), and returning 
general biobank research results increased it by almost fourfold (Crude OR=3.66: 
95% CI: 2.46 to 5.46, P<0.001).  
Only two factors related to knowledge and attitudes towards biomedical 
research and biobanking were significant in our study. Self-reported good knowledge 
on biomedical research increased the likelihood of willingness to participate in the 
biobank fourfold (Crude OR=4.42: 95% CI: 1.04 to 18.8, P=0.04), and previous 
donation of blood increased it by 96%, (Crude OR=1.96: 95% CI: 1.31 to 2.92, 
P=0.001).  
Among factors related to healthcare system, only trust in HAAD, the 
government authorities supervising the biobank, as key actor increased the likelihood 
of willingness to participate by 82% (Crude OR=1.82: 95% CI: 1.12 to 2.98, P=0.02). 
Other factors such as trust in healthcare providers and experience with healthcare 
services in Abu Dhabi were not associated. 
Social influence in terms of family participation increased the willingness to 
participate in the biobank almost six-folds (Crude OR=5.69: 95% CI: 3.45 to 9.36, 
P<0.001), and a preference to make decision by own self increased it almost threefold 
(Crude OR=2.63: 95% CI: 1.76 to 3.92, P<0.001). 
After adjusting for other covariates, the significant independent factors 
associated with a willingness to participate in the biobank were: being a male 
(Adjusted OR=1.52; 95%CI: 0.96 to 2.39, P=0.07), having good knowledge on 
biomedical research (Adjusted OR=10.4; 95%CI: 1.11 to 97.8, P=0.04), perception of 
altruistic benefits such as 'improve health of future generation' (Adjusted OR=2.17; 
95%CI: 1.44 to 3.63, P<0.001) and 'support medical research' (Adjusted OR=2.11; 
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95%CI: 1.36 to 3.46, P=0.001), having a positive attitude towards the biobank (OR= 
2.62; 95%CI: 1.27 to 5.39, P=0.009), willingness to definitely accept recontact 
(Adjusted OR=3.25; 95%CI: 2.03 to 5.19, P<0.001), having an expectation of 
individual genomic research findings being returned (Adjusted OR=3.16; 95%CI: 
1.84 to 5.54, P<0.001), and family influence on participation (Adjusted OR=3.19; 
95%CI: 1.84 to 5.53, P<0.001). 
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Table ‎4-3: Factors associated with definitely willingness to participate in a population-based  
biobank.  
Independent factors Crude Adjusted* 
OR 95% CI P- 
value† 
OR 95% CI P 
 value† 
I. Demographic characteristics       
Gender  
(Male vs. Females) 
1.71 1.17-2.05 0.005 1.48 0.94- 2.36 0.07 
Highest education attained  
(Higher vs. Lower education) 
 
1.72 1.10-2.67 0.02    
Current employment status  
(At work vs. Others) 
1.84 1.25-2.69 0.002    
II. Health and medical research literacy       
Ever donated blood 
(Yes vs. No) 
 
1.96 1.31-2.92 0.001    
Knowledge on biomedical research  
(Good vs. Limited knowledge) 
 
4.42 1.04-18.8 0.04 10.4 1.11-97.8 0.04 
Biobank as a resource would be.  
(Valuable vs. Not valuable) 
 
4.99 2.77-9.02 <0.001 2.56 1.23-5.32 0.01 
Medical‎research‎improves‎patients’‎health‎‎ 
(Agree vs. Disagree) 
 
1.95 1.08-3.49 0.03    
Donating biosamples for research is. 
Important vs.  Not important) 
3.39 2.14-5.38 <0.001    
III. Healthcare system experience and trust       
Trust HAAD  
(Agree vs. Disagree) 
1.82 1.12-2.98 0.02    
IV. Perceived benefits of biobanking for future research 
 
 
Improve the health future generation 




4.0 2.70-5.92 <0.001 2.11 1.31-3.38 0.002 
Support medical research 
(Yes vs. No) 
 
3.73 2.50-5.54 <0.001 2.19 1.37-3.49 0.001 
Donation is a charitable act 
(Yes vs. No) 
2.68 1.80-4.00 <0.001    
V. Biobank related procedures and policies  
Accept future re-contact  
(Definitely yes vs. Others) 
 
5.69 3.79-8.55 <0.001 2.80 1.74-4.51 <0.001 
Desire for feedback on own genomic results 
(Definitely yes vs. Others) 
 
 
5.84 3.67-9.28 <0.001 2.55 1.45-4.49 0.001 
Desire for feedback on general information 
(Definitely yes vs. Others 
 
3.66 2.46-5.46 <0.001    
VI. Social-cultural context and influence       
Family influence (participation ) 
(Definitely willing vs. Others) 
 
5.69 3.45-9.36 <0.001 3.19 1.83-5.57 <0.001 
Decision to participate is made by:   
Myself  vs. Help of others 
 
2.63 1.76-3.92 <0.001    
*Final model adjusted for male gender, good knowledge on biomedical research, positive attitudes towards 
the biobank, altruistic motives, accept recontact, strong desire for return of individual research results and 
family influence. 
†Wald‎p‎value‎determined‎from‎testparm. 
Chapter 4  Results 
140 
 
4.10 Preferred Health Information and Communication Channels 
Figure ‎4-10 and Figure ‎4-11, present preferred health information and 
communication channels. They rank them by survey respondents' preference.  
4.10.1 Preferred sources for health information 
All participants responded to this question, N=603.  The top three preferences 
for sources for health information and to learn about the biobank were internet-based 
communication including websites or social media (62.9%), followed by personal 
communication by a doctor or other healthcare providers (39.6%) and printed 
educational materials in the form of booklets or a brochure (23.5%). An additional 
few preferred television (19.5%) or public seminars (11.8%).  
A small minority of survey respondents (2.7%) pointed to other sources of 
information. These were mobile text messages such as the short message service 
(SMS), and publications such as articles in magazines or newspapers. One of the 
survey respondents was not interested at all to search for information on the biobank.  
The analysis of preference of various sources of health information by gender 
revealed that the overall rankings of preferred sources of health information were 
quite similar for both genders. However personal communication by a doctor or other 
healthcare provider and booklets or brochures were preferred by females more than 
males (all P<0.001), while publications such newspapers were preferred by males 
more than females (P=0.04).  
Preferences by age revealed that internet-based communications as a source of 
health information were what younger survey respondents (mean age was 35.6 years 
compared with 41 years, P<0.001) preferred, while print media (newspapers) and 
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television were preferred by older participants (mean age 41 years compared with 37 
years, all P <0.05).   
Preference for sources of health information vary by highest education 
attained and employment status, wherein highly educated participants and those 
employed preferred websites or social‎media‎(both‎P≤0.001).‎On‎the‎other‎hand,‎less‎
educated participants preferred personal communication by a doctor or other 
healthcare provider (P=0.006), or family members, friends or neighbors (P=0.03), and 
television (P=0.03). Those employed also preferred the website as the primary source 
of information (69% versus 53% other employment status, P=<0.001). No difference 
were found by geographical region (All P>0.05). 
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4.10.2 Preferred health communication channels 
The preferred communication technology for general information on research 
and updates of the biobank and feedback on the same was SMS (68.8%), followed by 




Figure ‎4-11: Preferred health communication channels, N=598. 
 
 
A very few survey respondents (6.4%) mentioned other communications 
channels. These were direct phone calls from the biobank staff, or through personal 
communication by a doctor or trusted healthcare providers, social media or 
publications such as newspapers or magazines.  
Overall rankings of preferred communication technologies was quite similar 
for both genders. However it was noticed that females tended to prefer SMS as a 
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females compared with 48.8% males, P=.03), while males tended to prefer emails 
more than females (58.9% of males compared to 41.6% females, P=0.01). Highly 
educated participants preferred email (P<0.001), followed by websites (P=0.049), 
while those who were gainfully employed preferred emails (P=0.001). No difference 
in preference for communication technology was found by age (All p>0.05).   
4.11 Summary of Results 
The overall response rate to the study was 71.7%, considered satisfactory and 
close to what was anticipated during sample calculation. A total of 603 telephone 
surveys were conducted among 313 men and 290 women.  Of the 603 interviews, 597 
interview were completed, while six interviews were stopped abruptly, and 
participants refused to continue the survey.  Overall, the survey questions were well 
tolerated by participants. Questions that survey respondents refused to answer were 
those related to demographic data, particularly monthly household income. 
The age of survey respondents ranged from 19-79 years and the average was 
37.9 years (±10 years). The demographic profile of the study respondents revealed 
that they were older, more likely to be residing in Eastern Region, were employed and 
better educated compared to the general Emirati adult population of Abu Dhabi. By 
design, the gender distribution mirrored the general population.  Nonetheless, men 
were more likely to be married, older, living in Abu Dhabi city, better educated, 
employed and therefore had higher household income.  Those with higher education 
were more likely to have had a history of previous blood donation, and a good 
knowledge in biomedical research and genomics.   
In general, awareness on biomedical research and biobanking in terms of 
previous experience and knowledge was very limited. Only 6% of survey respondents 
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reported ever having participated in medical research and 42% had ever donated 
blood. Those reported as having ever participated in medical research were more 
likely to donate blood, and had high trust in healthcare providers. 
Regarding self-rated knowledge, only 4.8% indicated good knowledge of 
biomedical research, 16.1% had good knowledge of genomics and 16.4% were 
familiar with the term biobanking. Those who were familiar with the term biobank 
also tended to have good knowledge on biomedical research and genomics, higher 
monthly household income (more than 20,000 AED), a positive attitude to donation of 
biosamples for research, and a family history of chronic diseases.  
In general, there were very positive attitudes towards biomedical research and 
biobanking for future research. The vast majority of the survey respondents believe 
that the biobank would be valuable as a resource to generate new information to 
improve the health of Emiratis (91.6%), that medical research leads to improvements 
in patients' health (90.9%), and that it is important to donate biosample for research 
(84.3%). Those who had positive attitudes towards the biobank tended to have a 
positive attitude to medical research and donation of biosamples for research, trust in 
HAAD, high trust in healthcare providers, and mostly positive experience with 
healthcare services in Abu Dhabi.    
With regard to the health care system experience and trust, overall experience 
with healthcare services in the Emirate of Abu Dhabi was not satisfactory, as only 
61.1% considered it a mostly positive experience. Those who had a mostly positive 
experience were slightly older than others, and had high trust in HAAD. In addition, 
only 36.3% of the survey respondents had high trust in healthcare providers. High 
trust in healthcare providers was associated with previous participation in medical 
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research, mostly positive experiences with healthcare services, trust in HAAD and a 
positive attitude to medical research and the value of the biobank. Moreover, trust in 
HAAD, the custodian of the biobank, to assess risks and benefits of biobanks to 
improve the health of Emirati population was high (82.5% agree). Those who had 
trust in HAAD also had mostly positive experience with healthcare services in the 
emirate of Abu Dhabi, reported having high trust in healthcare providers, and had a 
positive attitude to medical research, donation of biosample for research, and the 
value of the biobank.   
A majority of survey respondents (83%) believed that their participation in the 
biobank might be seen as positive gesture, and would encourage their family to 
participate as well, and 41.4% reported that their family would definitely participate 
in the biobank. Majority (71%) preferred to make the decision about participation by 
themselves; others with the help of a doctor or other healthcare provider, or other 
family member/s (14%). Those who preferred to make the decision about 
participation with the help of others were more likely to be female, having lower 
education status, not employed, and having lower monthly household income (less 
than 20,000 AED). 
The most common perceived benefits of biobanking for future research as 
cited by the survey respondents were altruistic: improving the health and wellness of 
future generation, and supporting medical research. The common characteristics of 
survey respondents who mention these motives had higher education, an 
understanding of genomics, and a positive attitudes towards donation of biosamples 
for research and the value of the biobank. Moral motives such as donation being a 
charitable act were mentioned next, mainly by survey respondents who had positive 
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attitudes towards donation of biosamples for research, and understood the value of the 
biobank. Perceived therapeutic benefits such as obtaining better treatment or cure for 
family members or their own condition were cited less frequently. It motivated mainly 
those with a family and personal history of chronic diseases respectively.  
On the other hand, when it came to perceived concerns of those not willing to 
participate, it seemed that the larger proportion were not sure about the potential 
concerns of the biobank research.  These respondents lacked the knowledge of 
genomics, had never donated blood, had negative attitudes towards donation of 
biosamples, and questioned the value of the biobank. Nonetheless, survey respondents 
pointed out three common concerns, mainly about genomic research: not having 
belief in medical research, and concerns about privacy and confidentiality. Apparently 
the common characteristics for those who raised these concerns were negative 
attitudes to HAAD and the biobank (all P<0.05).  
When assessing survey respondents' views regarding recontact and desire for 
feedback on biobank research, a large proportion (67.6%) indicated that they would  
definitely accept recontact in the future by the biobank staff for additional assessment, 
donation or information. They had a strong desire for feedback on their own genomic 
risks of diseases: 83.9% indicated that that would definitely want to receive such 
feedback. They also had a high interest in receiving general information on biobank 
research, with 70.8% indicating‎ ‘definitely‎ yes’.‎ Common‎ characteristics‎ of‎ those‎
who definitely accepted future recontact, and had high expectations for both 
individual and general research results had higher education, familiarity with the term 
biobank, had previously donated blood, and had a positive attitude towards donation 
for biomedical research, the value of the biobank and trust in HAAD.   
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The proposed model of biobanking was introduced to the survey respondents; 
i.e., incorporating the biobank project into the existing Weqaya screening program. A 
vast majority of the survey respondents (92.7%) did not mind donating biosamples 
and health information to the biobank for future research, and majority (76.1%) were 
very optimistic and definitely willing to participate in the same, voluntarily donating 
residual biosamples (blood or urine) and the health information collected during their 
Weqaya screening visit for the biobank for future genomic research. The overall 
probability of willingness to participate in the proposed biobank was higher in males 
compared to females; 80.8% of males were definitely willing to participate in the 
biobank compared with 71.0% of females (P=0.005).  
After adjusting for other covariates, willingness to participate in a population-
based biobank were significantly associated with being male, having good knowledge 
of biomedical research, altruistic motives, a positive attitude towards the biobank, 
acceptance of future recontact, a desire for feedback on of individual research results, 
and family influence on participation. These factors were independently shown to 
have positive associations with a willingness to participate in a population biobank.   
The top three sources for health information were website or social media, 
personal communication by a doctor or healthcare provider, and printed materials 
(booklets or brochures). The top three communication technology to share general 
information on biobank research were SMS followed by emails and mobile phone 
applications. In general, health information and communication channel preferences 
varied by gender, age, level of education and employment status. No association was 
found by region of residence or other demographic characteristics. Overall, internet-
based communications such as website, social media and emails as well as SMS were 
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found to be popular and preferred as trusted channels for health information and 
communication, particularly by highly educated Emiratis. Those with lower education 
levels preferred personal communication by a doctor, other healthcare providers, 
family members or friends, public seminars and TV reports. These communication 
channels are important to consider while planning publicity strategies for the biobank, 
as well as to improve medical research literacy among general public.   
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5 Chapter 5: Discussion and Implications 
Population-based biobanks are invaluable as national resources and 
infrastructure to advance biomedical research, monitor diseases and other health 
outcomes, and accelerate the introduction of personalized medicine. They have been 
implemented in many countries to improve the wellness and health of future 
generations. Population-based biobanks focus on population benefits and interests 
rather than directly assisting individual participants. 
The successful launch, sustainable operations and broad applicability of 
population-based biobank research relies primarily on public engagement and 
widespread voluntary participation. In order to ensure higher, wider and longer-term 
public engagement and participation, biobank information resources, communication 
strategies, as well as biobank regulations and policies need to be tailored to local 
contexts that respect the specific interests of the general public and their preferences, 
and meet local expectations. 
This cross-sectional study was the first of its kind, a large-scale study 
representative of the entire Emirati population of the emirate of Abu Dhabi. The study 
aimed to establish the first emirate-wide data regarding the Emirati public's 
knowledge and attitudes towards biobanking for genomic research, assess their 
willingness to participate in a proposed population-based biobank for future genomic 
research, and explore factors associated with their willingness to participate.   
The overall response rate to the study was 71.7%, considered satisfactory and 
close to what was anticipated during sample calculation. The data collection method 
of telephone interviews was the first reported experience from the region, and what 
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we had wanted to explore for use in future sociological and public health research. It 
can be recommended for use in future studies. 
Overall, our study demonstrated that the Emirati general public are very 
positive about biomedical research, optimistic about the potential value of the 
population-based biobank for the Emirati population, and had high trust in HAAD, the 
custodian of the biobank. They were enthusiastic about participation in the biobank, 
voluntarily donating residual biosamples (blood or urine) and health information to 
the biobank for future genomic and other biomedical research. The overall probability 
of participation in the proposed biobank was 76.1%. Males were more willing to 
participate in the proposed biobank than females, 80.8% compared with 71.0%, 
(P=0.005).  
After adjusting for other covariates, factors that were significantly and 
positively associated with the willingness of the Emirati general public to participate 
in a population-based biobank were: being male, having good knowledge of 
biomedical research, positive attitudes towards the value of the biobank, altruistic 
motives – to improve the health and wellness of future generation and support 
medical research, family influence on participation, accepting future recontact and a 
desire for the return of individual genomic research results. 
In the following sections, we will discuss findings addressing our study 
objectives in relation to other regional and international studies that explored public 
knowledge and attitudes towards biobanking for future research: willingness to 
participate in a population-based biobank,  perception of the benefits and risk of 
participation, public view on recontact and the return of research results, factors 
associated with public decision to participate in a population-based biobank, and 
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views on preferred health and information communication technologies to promote 
and update on biobank research. In addition, we will highlight our study strengths and 
limitations, and conclude with their implications for practice and recommendations 
for future follow up research.   
5.1 Knowledge and Attitudes towards Biomedical Research and 
Biobanking  
The‎ Emirati‎ general‎ public’s‎ understanding‎ about‎ biomedical‎ research‎ in‎
general, genomics and biobanking in particular, was very limited. Only few people 
reported good knowledge on biomedical research (4.8%), and genomics (16.1%), or 
having heard about the term biobank (16.4%).  These findings were expected, and 
consistent with all studies reviewed from various populations and socioeconomic 
subgroups in the US, Canada, Europe, Australia, Asia, and Africa, including Arab 
countries of the Middle East region. Majority of these populations and subgroups 
reported having limited or no knowledge about biomedical research (Allen & 
McNamara, 2011; Eder et al., 2012; El Obaid et al., 2016; Gaskell et al., 2013; 
Godard, Ozdemir, Fortin, & Egalite, 2010; Igbe & Adebamowo, 2012; Nasrella & 
Clark, 2012; Rodriguez et al., 2013), particularly genetics and genomic research 
(Allen & McNamara, 2011; Godard et al., 2010; Luque et al., 2012; Millon 
Underwood et al., 2013; Moriya et al., 2014; Streicher et al., 2011), and unfamiliarity 
with the term biobank (Eder et al., 2012; Gaskell et al., 2013; Hassona et al., 2016; 
Igbe & Adebamowo, 2012; Nasrella & Clark, 2012; Ridgeway et al., 2013; Simon et 
al., 2011; Tauali et al., 2014; Tupasela et al., 2010).  
Previous engagement or participation of the Emirati general public in medical 
research, such as donating blood or providing tissue for research or taking part in a 
trial for testing an experimental treatment, was very low: only 6% of survey 
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respondents had ever participated in medical research.  This was expected from an 
Arab country of the Middle East, as highlighted by Nair on research capacity of the 
region (Nair et al., 2013).  Similarly, a study from Egypt reported that only 6% of 
patients attending urban and rural hospitals and clinics had ever participated in health-
related research, which included taking part in surveys (Abou-Zeid et al., 2010). The 
study in Saudi Arabia reported that 20.7% of the outpatient surveyed had ever 
participated in health-related research (Al-Jumah et al., 2011). On the contrary, rates 
from samples of the general public from the UK and the US- including studies on 
under-represented  subgroups such as African Americans- were higher compared to 
our study. In the UK, a study by Lewis, Clotworthy, Hilton, Magee, Robertson, 
Stubbins, & Corfield (2013b) reported 14% of  a sample of the general public have 
ever participated in medical research,  and in four studies across the US which 
included underserved communities, 14-33% gave such history (Lemke et al., 2012; 
Millon Underwood et al., 2013; Rodriguez et al., 2013; Simon et al., 2011).  
Furthermore, 42.5% of the Emirati general public reported previous blood 
donation. Blood donation is a proxy act for altruism (Ewing et al., 2015). Our findings 
were consistent with a regional and two international studies, from Saudi Arabia and 
the US, where it was reported at 43.1%, 45.5% and 53.5%, respectively (Al-Jumah et 
al., 2011; Kerath et al., 2013; Overby et al., 2015). It is worth mentioning that these 
three studies were based on convenience samples of patients from outpatient clinics 
and were not representative of population surveys.   
Our study indicated that the vast majority of the Emirati general public were 
very positive about the potential role of biomedical research in improving patient' 
health (91%, agreed) and the importance of donation of biosamples for medical 
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research (84% believed it is important).  This finding was consistent with all other 
studies across various populations: Arabs, Africans, Asians, Europeans, Australians, 
Canadians and Americans (Abou-Zeid et al., 2010; Ahram et al., 2012; Ahram et al., 
2013; Al-Hussaini & Abu-Hmaidan, 2014; Al-Jumah et al., 2011; Hassona et al., 
2016; Igbe & Adebamowo, 2012; Lewis, Clotworthy, Hilton, Magee, Robertson, 
Stubbins, & Corfield, 2013b; Ma, Seals, Tan, Lee, & Toubbeh, 2014; Ma et al., 2012; 
McWhirter et al., 2014; Moodley, Sibanda, February, & Rossouw, 2014; Overby et 
al., 2015; Porteri et al., 2014; Sanderson et al., 2013; Toccaceli et al., 2014; Tupasela 
et al., 2010); including underrepresented subgroups- such as African American or 
Hawaiian communities (Sanderson et al., 2013; Tauali et al., 2014). This was also the 
same specifically with respect to support of genetic or genomic research (Kerath et 
al., 2013; Melas et al., 2010; Moriya et al., 2014; Streicher et al., 2011). 
Overall, the vast majority of the Emirati general public were supportive of the 
establishment of a population-based biobank and optimistic about the potential value 
of the biobank as a resource of generating new information to improve Emiratis' 
health (91.6% believe it would be a valuable resource). This finding was similar to 
that of other studies from Saudi Arabia, Qatar, Jordan, Nigeria, Finland, Australia, the 
US and Canada, where a majority of the general public were very positive about the 
value of biobanks, and believed that population-based biobanks have potential 
benefits to improve community health (Ahram et al., 2013; Al-Jumah et al., 2011; 
Critchley et al., 2012; Godard et al., 2010; Halverson & Ross, 2012b; Igbe & 
Adebamowo, 2012; Kerath et al., 2013; Lemke et al., 2012; Lewis, Clotworthy, 
Hilton, Magee, Robertson, Stubbins, & Corfield, 2013b; Pullman et al., 2012; Simon 
et al., 2011; Tauali et al., 2014; Tupasela et al., 2010).  
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5.2 Perceived Benefits and Risks of Biobanking for Future Research  
We found great commonality with other studies in commonly cited reasons for 
perceived benefits and risks of biobanking for future research. However, the rankings 
of these perceived benefits or risks differ across populations and subgroups, in 
addition to a few specific benefits and risks that are particular to some population or 
subgroups. We believe that these differences mirror the countries social and economic 
development, healthcare system model and insurance coverage, biobank model 
(particularly methods of collection of biosample and health information), biobank 
governance framework, advancement of health information and communication 
technologies, health and medical research literacy.  
5.2.1 Perceived benefits of biobanking for future research 
Commonly cited perceived benefits that motivate the public to participate in a 
population-based biobank can be grouped into three main categories: altruistic, moral 
and egoistic (personal) benefits. 
Overall, the Emirati general public seems to report similar perceived benefits 
commonly cited in the literature. Largely altruistic benefits were the primary and the 
most frequently cited, mainly improving the health and wellness of future generation 
(72.7%) and supporting medical research (61%). This was particularly evident among 
highly educated Emiratis. Altruistic benefits were followed by moral motives. More 
than half of the study participants (51.4%) cited it as a charitable act to participate, 
which was evident among those with positive attitudes regarding donation of 
biosamples for research and the value of the biobank.  
However, our study also reported a few misconceptions regarding perceived 
benefits to biobank research, mainly therapeutic misconceptions (expectations of 
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treatment in return for donation) due to confusion between clinical care and medical 
research (Halverson & Ross, 2012b; Halverson & Ross, 2012c; Nobile et al., 2013) . 
Some of the Emirati general public cited therapeutic benefits to family members 
(32%) or self (15.8%) as the perceived benefit for participation. Therapeutic benefits 
motivated mainly those with personal or family history of chronic diseases. Similarly, 
another participant believed that the biobanks would reduce traveling abroad for 
medical care. Diagnostic misconception was cited by one participant 'to discover a 
medical concern, if any'. Diagnostic misconception means there is an expectation for 
personal health-related information in return for the donation (Nobile et al., 2013).   
Table ‎5-1, summarizes and compares perceived benefits cited by the literature 
as motives for the general public to participate in a population-based biobank. 
Consistent with our study findings, altruistic motives were the most commonly cited 
ones (primary motives) by most of the studies from various populations in the UAE, 
China, Italy, France, Australia Canada and the US (Allen & McNamara, 2011; El 
Obaid et al., 2016; Godard et al., 2010; Lemke et al., 2012; Luque et al., 2012; Ma et 
al., 2012; Overby et al., 2015; Pullman et al., 2012; Rahm et al., 2013; Spruill, Gibbs, 
Laken, & Williams, 2014; Streicher et al., 2011; Toccaceli et al., 2014). Many of 
these studies include underrepresented groups such as African American, Hispanic, 
Latinos and native Hawaiians (Halverson & Ross, 2012b; Rodriguez et al., 2013; 
Sanderson et al., 2013; Tauali et al., 2014). This was also consistent with researchers' 
conclusions which acknowledged that the public would tend to view population-based 
biobanks as public goods established primarily for public benefits, and thus tend to act 
altruistically (Pullman et al., 2012).  Moral motives were cited in the literature as 
secondary motives, similar to our study findings (El Obaid et al., 2016; Ma et al., 
2012; Porteri et al., 2014).   




Table ‎5-1: Perceived benefits of biobanking for future research, cited in the literature.  
 
 Perceived benefits (motives) 
 
Cited by 
Benefits cited by our and other studies   
Altruistic motives  
 Improve the health and wellness of future generation 
 helping others (same race, others in general, future  
patients) 
 Support or contributing for research 
 Opportunity to develop new drugs 
 Betterment of humanity/ Help human kind 
 
Frequent motives, cited by 17 other  
studies from: UAE,  China, France, 
Italy, Australia Canada and the US 
(including sub-populations-African 
American, Hawaiian, Hispanic, 
Latinos) 
Moral motives 
 Donation is charitable act 
 Religious permission 
 Citizenship/ national obligation/ Patriotism/ 
Responsible citizen 
 Humanistic gesture 
 Personal worth and empowerment 
 
Frequent motive , cited in  seven 
other studies from  UAE, Qatar, 
Jordan,  Qatar, China, France and 
Italy and Australia 
  
Egoistic (personal) motives 
 Therapeutic benefits (misconception)- obtain better 
treatment or cure for own condition / for family 
members 
 Improve understanding of personal/family chronic 
diseases  
 
Cited by five other  studies from 
Nigeria, UK,  Netherland and  two 
from the US 
Others motives 
 Development opportunity for the country 
  Personal curiosity and improve understanding on 
biobank and genomic research. 
 
Cited by studies from ,  Qatar, Jordan 
and US 
Benefits cited by other studies, but not our study participants 
Other Egoistic (personal) 
 Free healthcare: clinical encounter /check ups  
 Financial incentive 
 
Cited by four studies,  from the UAE, 
Jordan, and the US 
 
Benefits reported only by  our study participants 
 Reduce traveling abroad for medical care 
 Diagnostic benefits ( misconception) 
 
Our study only 
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In contrast to our findings, moral motives were the primary ones for other 
Arabs, from Jordan and Qatar as well as samples studied from Australia. Moral 
motives cited by these studies were religious permission, national obligation and 
being a responsible citizen, respectively (Ahram et al., 2013; Nasrella & Clark, 2012). 
Egoistic benefits mainly those of therapeutic nature and diagnostic advantage or 
clinical assessment associated with donation- were mentioned as primary motives in 
studies from Nigeria, the UK and the Netherlands (Igbe & Adebamowo, 2012; Lewis, 
Clotworthy, Hilton, Magee, Robertson, Stubbins, & Corfield, 2013b; Meulenkamp et 
al., 2010), and as secondary motives from the US (Halverson & Ross, 2012b; Lemke 
et al., 2010; Streicher et al., 2011; Teare et al., 2015), while there were the least 
frequent motives mentioned by Emiratis in our study. 
Other motives mentioned by our study participants and cited in other studies 
were, personal curiosity to improve the understanding of biomedical research and 
biobanking, as reported from the US (Sanderson et al., 2013). Some also identified 
this as a development opportunity that raises the profile of the country, as reported 
from Qatar (Nasrella & Clark, 2012). Motives not cited in our study included 
financial compensation (Hassona et al., 2016; Luque et al., 2012; Rodriguez et al., 
2013). 
5.2.2 Perceived risks of biobanking for future research 
Common perceived risks of biobanking for future research cited in the 
literature by various populations and research ethics advocates were informational 
risks to privacy and confidentiality, unlimited future research, managing and returning 
results, and commercialization concerns of ownership and benefits sharing. Our study 
indicated the Emirati general public has limited understanding of the risks of donation 
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of biosamples and health information for biobank future research; this could be 
explained by the limited knowledge and participation in medical research in general. 
More than one-third (38.2%) of those unwilling to participate were not sure about 
potential risks. Others have reported concerns, consistent with those commonly cited 
in the literature. These were, concerns about genomic research (23.5%); negative 
attitudes to medical research (23.5%); concerns of loss of privacy- sharing private 
information regarding self or family members; medical or genetic data (14.7%); and 
concerns of breach of confidentiality- through a leak of personal information or 
identification (5.9%). 
 Table ‎5-2, summarizes perceived risks (concerns) cited in the literature as 
barriers for the general public to participate in a population-based biobank. Consistent 
with our study, common concerns reported in the literature were confidentiality 
concerns of leakage of personal identification or misuse of data (stigma or 
discrimination by third party: insurer, government or employer). These have been 
reported by many other studies from the UAE, Qatar, Jordan, Nigeria, European 
countries, US and Canada (El Obaid et al., 2016; Gaskell et al., 2013; Halverson & 
Ross, 2012a; Hassona et al., 2016; Igbe & Adebamowo, 2012; Joly et al., 2015; 
Nasrella & Clark, 2012; Overby et al., 2015; Rahm et al., 2013; Ridgeway et al., 
2013; Simon et al., 2011; Spruill et al., 2014). Privacy concerns have also been 
reported in Jordan, Europe, the US and Canada (Ahram et al., 2013; De Vries et al., 
2016; Eder et al., 2012; Gaskell et al., 2013; Halverson & Ross, 2012a; Kerath et al., 
2013; Lemke et al., 2010; Melas et al., 2010; Pullman et al., 2012). Concerns about 
genomic research (misconduct by unethical use of biosamples, contradictory to 
religious belief, integrity, or mistrust in researcher, fear of genetic research results) 
were reported from Nigeria, China, Sweden, the UK and the US (Igbe & 
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Adebamowo, 2012; Lemke et al., 2010; Lewis, Clotworthy, Hilton, Magee, 
Robertson, Stubbins, & Corfield, 2013b; Luque et al., 2012; Ma et al., 2012; Overby 
et al., 2015; Rodriguez et al., 2013; Sanderson et al., 2013; Simon et al., 2011; Tauali 
et al., 2014). Other commonly reported concerns were negative attitudes towards 
medical research in general (Lemke et al., 2010; Overby et al., 2015), concerns of 
lack of knowledge on biomedical research as reported from a study  from the UAE 
and two from the US (El Obaid et al., 2016; Luque et al., 2012; Spruill et al., 2014), 
and practical barriers of time, transportation or logistic as reported from our study 
participants, as well as in studies from the US (Ridgeway et al., 2013; Sanderson et 
al., 2013). 
In contrast to our study findings, common concerns that were cited in the 
literature, but not by our study participants, were: concerns of commercialization - 
public versus commercial interests in terms of ownership of biosamples, benefits 
sharing and data sharing, which were reported from several studies from South Africa, 
the UK, the US and Canada (Godard et al., 2010; Joly et al., 2015; Moodley et al., 
2014; Tauali et al., 2014). Concerns were also raised about unlimited future research 
as reported in Jordan and South Africa (Ahram et al., 2013; Moodley et al., 2014). In 
addition, less common concerns reported include exporting biosamples or research 
being conducted outside the country or by foreign researchers, as reported from 
Egypt, as well as from Nigeria, South Africa, the UK and Hawaiian communities in 
the US  (Abou-Zeid et al., 2010; Igbe & Adebamowo, 2012; Lewis, Clotworthy, 
Hilton, Magee, Robertson, Stubbins, & Corfield, 2013b; Tauali et al., 2014); lack of 
personal relevance or benefits as reported from the samples from the UAE, Jordan, 
Sweden and the US (Ahram et al., 2012; Ahram et al., 2013; El Obaid et al., 2016; 
Melas et al., 2010; Rodriguez et al., 2013; Sanderson et al., 2013); concerns regarding 
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the procedure- such as drawing blood as reported from Jordan and the US (Hassona et 
al., 2016; Luque et al., 2012; Sanderson et al., 2013); and finally, sustainability of 
resources and infrastructure of the biobank, as reported from Nigeria (Igbe & 
Adebamowo, 2012). 
 
Table ‎5-2: Perceived concerns of biobanking for future research, cited in the literature.   
 Perceived risks (concerns) 
 
Cited by 
Concerns reported by our study participants and other studies 
 Concern of confidentiality- data insecurity (leakage of 
identification)  or  miss use of data ( stigma or  
discrimination by third party: insurer, government or 
employer) 
Frequent concern, reported by our 
study as well as 12  other studies 
from  UAE, Qatar, Jordan, Nigeria, 
Europe , US and  Canada 
 Concerns of loss privacy- sharing private information 
regarding personal or family, medical or genetic data 
Frequent concern, reported by our 
study and other eight  studies from 
Jordan, Europe, the US and Canada 
 Concern about genomic or biomedical research- miss 
conduct (unethical use of biosamples, contradicting to 
religious believes)/ Integrity or miss trust in researcher 
/fear of genetic research results 
Our study, as well as studies from 
Nigeria, China , Sweden, US and UK 
 Negative attitudes to medical research- Do not believe 
/do not trust   
 
Our study and two studies from the 
US. 
 Practical barriers: time (too busy), transportation or 
other logistics barrier  
 
Our study and two studies from the 
US. 
 Lack of  knowledge on biomedical research Our study and another three studies 
from UAE and  US 
Concerns reported by other studies but not our study participants 
 Concerns of commercialization: public versus 
commercial interests : ownership of biosamples and 
benefits and data sharing  
 
Cited in 6 studies from South Africa, 
UK, US, and Canada. 
 Exporting biosamples outside the country, research 
conducted outside the country 
Cited in 5 studies from Egypt, 
Nigeria, South Africa, UK and 
Hawaiians 
 Lack of personal relevance/benefits - non disclosure 
of research results/ compensation  
  
Cited in six  studies from UAE, 
Jordan, Sweden,  and the US  
 Unlimited future research  Cited in two studies from Jordan and, 
South Africa 
 Concerns or negative perception about  the procedure 
- example: blood draw/needles 
Cited in three studies from Jordan 
and the US 
 
 Sustainability of biobank infrastructure and resources 
 
Cited in one study from Nigeria  
Concerns reported by our study participants but not by other studies  
 I am not healthy (too sick)/too old 
 Lack of trust in healthcare diagnostic services 
 
Our study only 
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5.3 Public Views on Recontact and Return of Research Results 
Although recontact and re-identification of research participants is one of the 
major ethical and legal challenges frequently mentioned, the vast majority of the 
Emirati general public did not perceive future recontact as a negative concept or 
barrier, and did not object.  In fact, a majority (68%) of the Emirati general public 
were definite about accepting future recontact by the biobank staff for additional 
assessment tests, donation of more blood or the provision of new information, other 
than that collected routinely through the periodic Weqaya screening program. 
Emiratis were definite about accepting future recontact were more likely to be males, 
highly educated, had previously donated blood, were familiar with the term biobank, 
and had positive attitudes towards medical research, donation of biosamples and the 
biobank, and trusted HAAD.   
Consistent with our study, high acceptance was also reported from a study in 
the US, from participants of a biobank, where vast the majority (93%) had no 
concerns about updating researchers with health information (Mester et al., 2015). 
However, in contrast to other studies from Arab countries, in Jordan and Egypt many 
respondents favored no future recontact (Abou-Zeid et al., 2010; Ahram et al., 2013; 
Hassona et al., 2016). 
Managing and returning research results have raised ethical and legal 
concerns. However, a vast majority of the Emirati general public had high 
expectations and a strong desire for returning biobank research results, both individual 
genomic and general aggregate research results, with higher interest in individual 
research results (i.e., their own genomic risk findings). The characteristics of Emiratis 
who had  high expectations for returning biobank research results, both individual and 
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general research results, were those who had previously donated blood, were familiar 
with the term biobank and had positive attitudes towards medical research, donation 
of biosamples and the biobank,  and trusted HAAD.   
  In fact, the public in various populations and subgroups had a high interest 
and expectations for returning both individual genomic and general aggregate 
research results. This was reported in most studies conducted on samples from various 
populations; including other Arabs in Saudi Arabia, Jordan and Egypt (Abou-Zeid et 
al., 2010; Ahram et al., 2013; Al-Hussaini & Abu-Hmaidan, 2014; Al-Jumah et al., 
2011; Alahmad, Hifnawy, Abbasi, & Dierickx, 2016; Allen & McNamara, 2011; El 
Obaid et al., 2016; Mester et al., 2015; Meulenkamp et al., 2010; Moriya et al., 2014; 
Porteri et al., 2014; Sanderson et al., 2013; Streicher et al., 2011; Tauali et al., 2014). 
Updating the public and research participants on the aggregate research results 
reflected the respect the biobank accorded to the participants. It increased public and 
participants’‎ trust‎ in‎ biobanks,‎ besides increasing awareness, and therefore 
participation (Mester et al., 2015). Furthermore, recently there has been widespread 
consensus among experts about the obligation to return individual genomic research 
results, both the incidental findings and individual research results, if it  met the ACA 
criteria of analytical validity, clinical significance and actionability, and if the 
research participant had opted to receive individual genomic results during the 
consent process or subsequently (Black et al., 2013; Bredenoord et al., 2011; 
Christenhusz et al., 2013; Jarvik et al., 2014; Knoppers et al., 2012; Knoppers et al., 
2015; Lemke et al., 2010; Lemke et al., 2012; Smith & Aufox, 2013; Terry et al., 
2012; Viberg et al., 2014).  Some studies probed the preferences of individual 
genomic research results based on the actionability or clinical significance of the 
findings (Beskow et al., 2012; Watanabe et al., 2011), explored public attitudes 
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towards disclosing genomic data with various third parties (Alahmad et al., 2016), or 
further probed on the frequency about communication of general research results 
(Mester et al., 2015). This was not explored in our study and can be evaluated later in 
future research.    
In contrast to our study findings, few studies one in the US on a sample from a 
Latino community, and two in Jordan and Saudi Arabia on outpatients, favor no 
feedback on individual genomic research results. In fact they perceived it as concern 
that would discourage their participation in biobank research (Al-Jumah et al., 2011; 
Hassona et al., 2016; Rodriguez et al., 2013).  
5.4 Willingness to participate in a Population-based Biobank 
A vast majority of the Emirati general public (92.7%) did not mind donating 
residual biosamples and health information to the biobank for future genomic 
research. A recent small-scale qualitative study on participants enrolled in a 
biomedical research in Abu Dhabi reported that 95% of the 42 participants did not 
mind having their biosamples and blood stored for future research (El Obaid, et al., 
2016). 
The overall probability of willingness, definitely willing, to participate in the 
proposed biobank was 76.1%. Willingness to participate in the biobank in our study 
refers to voluntarily donating residual biosamples (blood or urine) and the health 
information collected during their Weqaya screening visit to the biobank for future 
genomic research and other biomedical research. 
When comparing other studies, the Emirati general public were more 
enthusiastic about participation in the biobank compared with other Arabs. Two 
studies from Jordan reported that 64% of the general public were willing to be a 
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biobank donors (Ahram et al., 2012) and another recent reported 55.9% (Hassona et 
al., 2016). In Saudi Arabia,  although overall probability of those willing to donate 
blood or allow use of excess surgical samples in future biomedical research was on 
average 78.4%, those who were  strongly willing were only 48.9% on average, 57.3% 
for blood and 34.4% for surgical samples (Al-Jumah et al., 2011). In China, one 
study, reported that 61.7% of the general public were willing to donate clinical 
leftover biosamples to biobank for future research (Ma et al., 2012). Our findings 
were close to those of the studies from Italy, Finland and the United States, which 
cited rates of 86%, 83%  and 78%, and 80% (with  opt in consent), respectively, with 
regards to their willingness to donate to a biobank for research  (Kaufman, Bollinger, 
Dvoskin, & Scott, 2012; Lemke et al., 2012; Porteri et al., 2014; Tupasela et al., 
2010).   
A possible explanation to high willingness to participate compared with other 
Arabs, is that the proposed biobank model, is planned to be integrated to a running 
screening program,  that already collect comprehensive data, provide free checkups 
and assessments, as well as the method of collection of biosamples is convenient, 
residual blood or urine instead of direct donation or surgical tissues.  
5.5 Factors Associated with Public's Willingness to participate in a 
Population-based Biobank 
Factors associated with public's willingness to participate in a population-
based biobank were summarized in the conceptual framework presented in Chapter 2. 
This section will describe the significant factors associated with the willingness to 
participate in a population-based biobank from our study as well as from the reviewed 
literature.  
  




Table ‎5-3: Summary of literature on significant independent factors associated with public's' 




 Consistent findings 
Significant in our and/or other studies 
 
 Contrasting findings 
Significant  in other studies 
Demographic 
characteristics 
  Higher education  
 Employment  
 Gender* 
  Age 
 Annual household income 
 Region of residence/Rural: urban 
distribution 









  Motive: improve wellness and 
health of future generation* 
 Motive: support research * 
 Motive: donation is charitable act 
  Motive: therapeutic/health benefits 
  Motives: financial compensation  
 Concerns: privacy and 
confidentiality 
 Concern: misuse /misconduct of 
research 
Biobank operations 






  Accept recontact * 
 Desire for returning individual 
generic results * 
 Desire for returning general 
aggregate  results ~ 
  








  Ever donated blood  




 Donation of biosample for research 
is important 
 Biobanks are valuable resources to 
generate new information to 
improve health * 
 
  Previous participation in medical 
research 
 Familiarity with biobank 
 Self-reported good knowledge or 
understanding  genomics  
Healthcare system 
factors- Trust & 
experience  
 
  Trust government /entity supervise 
the biobank - HAAD 
  Trust healthcare 
institution/providers 





  Family influence (participation)*~ 
 Decision is made with help of self-
versus  others~ 
  
*Remained significant at multiple logistic regression 
~Not explored for association with willingness to participate  in other studies  
^ not explored in our study 
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Overall, compared with other studies from other populations, including other 
Arabs there were great variation in factors associated with the willingness to 
participate in a population-based biobank. Table ‎5-3, provides a summary of the 
significant independent factors associated with public' willingness to participate in a 
biobank as gleaned from the reviewed literature, and compares them with those from 
our study. It highlights significant independent factors that were not explored in our 
study or in other studies, and those that remained significant in our study after 
adjusting for other covariate.  
5.5.1 Demographic characteristics 
Demographic characteristics that were associated with the Emirati general 
public's willingness to participate in a population-based biobank were also reported in 
other studies. Higher education attainment, i.e., completion of secondary or higher 
level of education, was positively associated with the likelihood of willingness to 
participate (Crude OR=1.72: 95% CI: 1.10 to 2.67, P=0.02). Higher education was the 
most frequently reported significant demographic characteristic, cited in the studies 
from eight other countries: Jordan, Saudi Arabia, Egypt, China, as well as from 
Europe, Australia and the US (Abou-Zeid et al., 2010; Ahram et al., 2012; Ahram et 
al., 2013; Al-Jumah et al., 2011; Critchley et al., 2012; De Vries et al., 2016; Gaskell 
et al., 2013; Ma et al., 2012; Toccaceli et al., 2014).  
Similarly currently employed had significantly associated with the willingness 
of the Emirati general public to participate in the biobank (Crude OR=1.84: 95% CI: 
1.25 to 2.69, P=0.002). Employment had also been reported as a significant factor 
associated with increased willingness to participate in studies from three countries: 
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China, Australia and the US (Banks et al., 2012; De Vries et al., 2016; Ma et al., 
2012). 
A third significant demographic factor was gender; being a male increased the 
likelihood of willingness to participate (Crude OR=1.71: 95% CI: 1.17 to 2.05, 
P=0.005). Gender was found to be significant in three other studies. The study from 
Europe - on 32 countries- was consistent with ours, it shows that being male was 
associated with an increased likelihood of participation in population-based biobank 
research (Gaskell et al., 2013), while  the study from Saudi Arabia-conducted on out-
patient volunteers, and another from the US recoded that being a female increased the 
likelihood of participation in biomedical research  or biobank  (Al-Jumah et al., 2011; 
Ridgeway et al., 2013).   
Factors such as age, annual household income, ethnicity, religion and rural-
urban distribution were found significant in studies from Jordan, China, the UK, the 
US and Australia (Ahram et al., 2012; Ahram et al., 2013; Al-Jumah et al., 2011; 
Banks et al., 2012; De Vries et al., 2016; Lewis, Clotworthy, Hilton, Magee, 
Robertson, Stubbins, & Corfield, 2013b; Ma et al., 2012; Ridgeway et al., 2013), but 
unexpectedly and in contrast, did not show significant association in our study. 
Religion and ethnicity were not explored in our study participants, as all were Emirati 
and universally Muslim.  
5.5.2 Perceived benefits and risks of biobanking for future research 
In our study, altruistic and moral motives had significant association with an 
increased likelihood of participation of the Emirati general public in the proposed 
biobank. Altruistic motives such as, 'improve the health of future generations' and 
'support medical research' increased the likelihood of willingness to participate in the 
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biobank four-folds (OR=4.0: 95% CI: 2.70 to 5.92, P<0.001) and (OR=3.73: 95% CI: 
2.50 to 5.54, P<0.001), respectively. Moral motive, i.e., 'donation is charitable act', 
increased the willingness to participate three-folds (OR=2.68: 95% CI: 1.80 to 4.00, 
P<0.001).  
Consistent with our study, altruistic motives were found to be positively 
associated with willingness to participate in a biobank in a study from the US (Overby 
et al., 2015). Also moral motives- religious permission, was found to be positively 
associated with willingness to be a biobank donor in a study from Jordan (Ahram et 
al., 2013; Al-Jumah et al., 2011). 
In contrast to our findings, a sample studied in Jordan reported personal 
(egoistic) motives such as financial compensation as an independent factor associated 
with the increased willingness to participate in a biobank (Hassona et al., 2016). 
Similarly therapeutic benefits were reported in Australia (Critchley et al., 2012). 
However these motives were not significant independent factors in our study.  
Furthermore, in our study, concerns of biobanking for future research did not 
negatively influence the willingness to participate. However, privacy and 
confidentially concerns were significant enough in a few studies from 32 European 
countries as well as the US to negatively influence the decision to participate in a 
biobank (De Vries et al., 2016; Gaskell et al., 2013; Overby et al., 2015; Ridgeway et 
al., 2013). Similarly, concerns of misconduct or unethical use of biosamples was 
reported from China (Ma et al., 2012). 
5.5.3 Biobank operations and policies 
Accepting recontact, increased the willingness of the Emirati general public to 
participate in the population based biobank almost four-folds (Crude OR=5.69: 95% 
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CI: 3.79 to 8.55, P<0.001). However, this contrasted with the study from Jordan, 
where recontact was associated with less willingness to be a biobank donor (Ahram et 
al., 2013). 
Returning individual genomic research results increased willingness of the 
Emirati general public to participate in the population based biobank six-folds (Crude 
OR=5.84: 95% CI: 3.67 to 9.28, P<0.001). Two other studies from Jordan and the US 
reported significant positive associations with the public's decision to participate in a 
biobank (Ahram et al., 2013; Halverson & Ross, 2012a), while another study -on 
dental outpatients from Jordan found that returning results significantly reduced 
willingness to be a biobank donor (Hassona et al., 2016). 
Returning general biobank research results and recontact were found to be 
associated with Emiratis willingness to participate (Crude OR=3.66: 95% CI: 2.46 to 
5.46, P<0.001). However, the association with willingness to participate was not 
explored in other studies in the published literature.   
5.5.4 Health and medical research literacy 
Consistent with our findings, self-reported good knowledge on biomedical 
research increased the willingness of the Emirati general public to participate in the 
biobank, (Crude OR=4.42: 95% CI: 1.04 to 18.8, P=0.04). It was also reported as a 
significant independent factor in other studies from Saudi Arabia, the UK and  other 
European countries (Al-Jumah et al., 2011; Gaskell et al., 2013; Lewis, Clotworthy, 
Hilton, Magee, Robertson, Stubbins, & Corfield, 2013a; Lewis, Clotworthy, Hilton, 
Magee, Robertson, Stubbins, & Corfield, 2013b). 
Significant independent factors reported in other studies but not significant in 
our study included self-reported good knowledge in genomics as reported in Egypt 
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(Abou-Zeid et al., 2010),  and familiarity with the term biobank- in terms of having 
previously heard about it or understanding its risks and benefits as reported in the US 
(Millon Underwood et al., 2013). Likewise, previous participation in research was 
reported in Saudi Arabia and the US to be associated with increased willingness to 
participate in biobank (Al-Jumah et al., 2011; Millon Underwood et al., 2013) 
Attitudes towards biomedical research, donation for research and the value of 
the biobank to improve population health, increased the Emirati general public's 
willingness to participate in the biobank: crude OR were 1.95, 3.39 and 4.99, 
respectively. Positive attitudes to biomedical research was a significant independent 
factor that increased the public's willingness to participate in a biobank in a study 
from the US (De Vries et al., 2016).  
5.5.5 Healthcare system: Public trust and experience  
Public trust in key actors were the second commonly reported factor correlated 
with the decision to participate in a biobank. Public trust and overall experience with 
the healthcare system and research its key actors (government, medical or research 
institutions, healthcare providers and researchers) have an important role in the 
decision to participate in a biobank. This was cited in many studies (Abou-Zeid et al., 
2010; Brand et al., 2012; Critchley et al., 2012; Gaskell et al., 2013; Halverson & 
Ross, 2012a; Igbe & Adebamowo, 2012; Joly et al., 2015; Lemke et al., 2010; Lemke 
et al., 2012; Lewis, Clotworthy, Hilton, Magee, Robertson, Stubbins, & Corfield, 
2013a; Lewis, Clotworthy, Hilton, Magee, Robertson, Stubbins, & Corfield, 2013b; 
Overby et al., 2015; Ma et al., 2012; Master & Resnik, 2013; McWhirter et al., 2014; 
Millon Underwood et al., 2013; Moodley et al., 2014; Platt & Kardia, 2015; Tauali et 
al., 2014). However, most of these studies were qualitative or quantitative, and did not 
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examine the association of these factors as independent variables for‎ public’s 
willingness to participate in the biobank. 
The Emirati general public trust in government authorities, HAAD, as the 
custodian of the biobank was high (82.5%). Trust in HAAD increased the likelihood 
of willingness to participate by 82%, (Crude OR=1.82: 95% CI: 1.12 to 2.98, P=0.02). 
Trust in HAAD was associated with mostly positive experiences with the healthcare 
services in the emirate of Abu Dhabi, high trust in healthcare providers, and positive 
attitudes to medical research and donation for research to the biobank. 
Consistent with our study, the pan European study showed that trusting 
biobank key actors such as the government was associated with increased willingness 
of Europeans to participate in the biobank (Gaskell et al., 2013).  
We reported unsatisfactory experiences with healthcare services in the emirate 
of Abu Dhabi (only 61% considered it mostly positive), and very low trust in 
healthcare providers (34.6% only had high trust).  Trust in healthcare providers was 
associated with previous participation of Emiratis in medical research, positive 
attitudes to medical research and the value of the biobank, and mostly positive 
experiences with the healthcare services. Both factors were not associated with the 
willingness to participate in the biobank.  
In contrast to our finding, two studies from China and from the US showed 
that trusting medical institutions (Ma et al., 2012) and healthcare providers (Millon 
Underwood et al., 2013) were independent factors that increased public' willingness to 
participate in the biobank.  
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Furthermore, one study explored the association of willingness to participate 
with trust in biobank as independent variable, and found it to be a significant positive 
association (Critchley et al., 2012). However, trust in biobank or research institutions 
was not explored in our study but can be evaluated later in future follow up research, 
after the establishment of the biobank.    
5.5.6 Social-cultural influences 
Consistent with the theories of donations to biobank research summarized by 
(Lipworth et al., 2011), who concluded  that the decision to participate in a biobank is 
always socially situated, and it could be the result of relational activity to family, or 
the influence of pressure or respect from friends, or seeking approval from healthcare 
providers. A majority of Emirati general public believed that their participation in the 
biobank might be seen as a positive gesture, and would encourage their families to 
participate as well. This is an expected finding and was consistent with the findings 
from a preliminary study conducted in Abu Dhabi, UAE itself (El Obaid et al., 2016). 
This was also reported in a study from Nigeria, where some members liked to inform 
and discuss their participation with a family member prior to participating (Igbe & 
Adebamowo, 2012) 
Social influence in terms of family participation was only explored as an 
independent variable in our study, and was found to be strongly associated with the 
willingness to participate in the biobank, (Crude OR=5.69: 95% CI: 3.45 to 9.36, 
P<0.001); but this association was not explored  in other studies. 
5.6 Preferred Health Information and Communication Channels 
The Emirati general public's views and preferences regarding various health 
information and communication channels were assessed in our study as important 
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factors influencing the general public's engagement and participation in the 
population-based biobank research. These views would be considered while deciding 
on communication strategies for the biobank's publicity plans and improving health 
and research literacy. 
There was a noticeable overall preference for internet-based communications 
website, social media and emails as well as mobile phones test messages (SMS) as 
trusted channels for health information and communication. This was particularly 
evident among highly educated Emiratis. Those with lower education preferred 
personal communication by a doctor, other healthcare providers, family members or 
friends, public seminars and TV reports.  
These tools are considered relatively inexpensive and convenient methods of 
communication with the potential to be dependable sources for health information, 
and for receiving general research results and biobank updates, moreover allowing for 
two-way and wider engagement (Mester et al., 2015). These can be utilized as the 
culturally trusted and accepted communication strategies for publicity and social 
marketing plans, and can be considered for use as e-governance solutions, to 
overcome potential biobank governance challenges.  
In general, the preference of the Emirati general public for health information 
and communication channel varied by gender, age, level of education and 
employment status.  Similarly, when we compare our findings with other, we found 
great variation by population and subgroups of same population. Table ‎5-4 and 
Table ‎5-5, compare our study findings with those of other studies. The only common 
preferred tool for sharing the biobank general research results and updates across all 
population was the websites.  
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Table ‎5-4: Preferred source for health information. 
Country  Design  & 
participants 
Preferred health information &communication 
channels  
UAE-Our study Quantitative study, 
N=603 of  general 
Emirati 
  Website & social media 
 Personal communication by a  healthcare provider 
(doctor/others) 
 Brochures/pamphlets  
 Television (TV) 
 Public seminars 
 personal communication by family members or 
friends 
 Other traditional media: Radio/newspapers 
 
UAE 
(El Obaid et al., 2016) 
Qualitative  study,  
N=42 Emirati   
enrolled on a 
cohort study 
  Social media (Twitter/Face book/Instagram) 
 Religious leaders/ community celebrities 
 Traditional media (TV, Radio, Newspaper) 
Qatar 
(Nasrella & Clark, 2012) 
Qualitative stud, 
N=100 general 
public enrolled in 
Qatar biobank) 
  Media outlets   
 Public forms/social events 
 Community biobank  champions 
US 
(Spruill et al., 2014) 
Qualitative study,  
N= 67 from 
general US  public 
(6 counties) 
  Sending letters 
 Pamphlets 
 Personal communication by a healthcare provider t 
time of hospital discharge 
 Public seminars (community/church) 
 
US- Latino community  
(Rodriguez et al., 2013) 
Qualitative study,  
N= 28 from Latino 
community 
  Media out let: Radio/newspaper 
 pamphlets at healthcare facilities 
 Personal communication by a healthcare provider  
 community activity/seminars  
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Table ‎5-5: Preferred communication channel to share biobank updates. 
Country  Design  & 
participants 
Preferred health information &communication channels  
UAE-Our study Quantitative 
study, N=603 of  
the Emirati 
general  
  Mobile phone short message services (SMS) (86.6%) 
 Email (34.6%) 
 Mobile applications (15.6%) 
 Website (11.7%) 
 Others 6%): direct phone call from biobank staff, personal 
communication by a healthcare provider, social media, 
publication  in newspaper or magazines 
 
US 
(Mester et al., 
2015) 
Quantitative 




  Paper newsletter (65.7%) 
 Emailed newsletter (61.7%) 
 Website, blogs (29.8%) 
 Phone call from researcher (26.6%) 
 Online discussion (15.7%) 
 Direct in person updates (15.5%) 
 Face book (8.9%) 
 YouTube (6.1%) 







general Dutch and  
(N=515 patients) 
  Letters (41%) 
 Meeting (19%) 
 Website (12%) 
 Publication-articles in newspaper or magazine (4%) 
 Scientific publication 3% 
 No preference (17%) 
 
Italy 




members of patients 
attending OPD 
  Direct in person updates (51%) 
 Website (34%) 
 Publications-articles in newspaper or magazine (15%) 
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5.7 Strengths and Limitations 
5.7.1 Strengths 
We believe that the findings from our study are robust and trustworthy for the 
following reasons.  To begin with, this study was the first large-scale, emirate-wide 
study‎ to‎ explore‎ the‎ Emirati‎ general‎ public’s‎ knowledge‎ and‎ attitudes‎ regarding‎
biobanking for future genomic research, to assess their willingness to participate in a 
proposed population-based biobank, and to explore factors associated with their 
willingness to participate in the biobank. The sample size was believed to be adequate 
for the purpose of this study as was estimated prior to commencing it, based on 
several assumptions, and to reach high study power of 90%.   
Secondly, the study subjects were the target population for the proposed 
biobank, who were selected at random using Stata Statistical Data Analysis software 
version 11.2 from a list of healthy individuals from the Emirati general public who 
underwent Weqaya screening between July 1 2012- March 31 2015.  A stratified 
sampling method was used to adjust for gender to ensure that the sample represents 
the Emirati general public in terms of gender distribution (1:1) and test a prior 
hypothesis where two-thirds of the screening list had comprised females. 
Thirdly, the questionnaire was adapted from published instruments and revised 
by experts to ensure content validity.  It was then translated into Arabic and a 
backward translation to English done to ensure that they both produced identical 
versions of the questionnaire.  Cognitive interviews were conducted to ensure clarity 
of the questions, and test survey respondents' ability to provide accurate answers. 
Based on the cognitive interviews, a few changes were made to the final survey. The 
final questionnaire was then pretested and piloted to assess the average time to 
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complete the survey, and to ensure that study participants answer all of questions 
during the field calls. Interviewers were trained to increase reliability and reduce 
interviewer bias. The first few calls were attended by the research team. 
Fourthly, the telephone interview used as a tool for data collection in this 
study was extremely valuable. It helped reach a large and geographically scattered 
sample, was efficient in terms of time and resources. It also minimized interviewer 
effects including social desirability bias, and provided a high level of anonymity 
which was extremely relevant in this study, given the unfamiliarity and sensitive 
nature of the topic and questions. Moreover, it yielded a satisfactory response rate of 
71.7%, especially when compared with two studies conducted in Australia and the 
United States using similar methods. The latter two studies yielded response rates of 
22.9% and 64% respectively (Critchley et al., 2012; Simon et al., 2011). The higher 
the response rate, the better the representation of the Emirati general public views on 
the subject. One of the reasons could be the personalization in our approach and the 
use of mobile phones rather than landlines.   
Lastly, the data were collected and entered directly into the online Survey 
Monkey® tool during the telephone interviews. This has reduced errors as well as the 
time that manual entry of data would have taken. It also helped faster data processing, 
handling and storing. 
5.7.2 Limitations 
There were several limitations to our study. First, our findings was based on 
cross-sectional data, which gives an indication of knowledge and views on biobanking 
for future genomic research from a sample of the Emirati general public at a specific 
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point in time. However, the direction of relationships between willingness to 
participate and potential correlates could not be determined.  
Furthermore the random selection was performed on a list of motivated people 
who had undergone Weqaya screening. The survey respondents were 
disproportionally older, highly educated, more likely to be employed and residing in 
Al Ain, when compared with the general Emirati population. Also had high personal 
and family history of chronic diseases, suggesting some evidence of a selection bias 
and limiting external validity. Therefore study results should be carefully interpreted. 
Worth to mention that these characteristics were not significantly associated with the 
willingness to participate in the final model. In addition, this study can be described as 
deliberative engagement because it does not seek population representation. 
Furthermore, whether our results were generalizable to other Emiratis would require 
further study. 
Secondly, there was no published validated instrument that could be used to 
assess the knowledge and attitudes on biobank research in any language. Our 
questionnaire was used for the first time in this study, thus was not validated by a 
previous and independent sample.  
Thirdly, a few questions were removed from the final version of the 
questionnaire due to time constraints, as some of those questions were 
incomprehensible to most of participants during the cognitive interviews before the 
survey was fielded. These question were: exploring willingness to donate other 
biosamples (saliva, tissue, etc...), various consent policy options, trust in a range of 
research organizations, and categories of individual genomic research results to be 
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returned for participants. It will be interesting to explore these areas in future follow 
up studies. 
Finally, when comparing the survey non-respondents and respondents, non-
respondents were older than survey respondents (mean age was 41.3 years, ±SD 14.9 
versus 37.9 years, ±SD 10.9), more often females (58% versus 48.1%), and more 
likely to be residents of Abu Dhabi, the capital city (52.9% versus 43.3%). This might 
have introduced non-response bias; however, the non-response rate in our study was 
very low, 28.3%. 
5.8 Conclusions 
The Emirati general public had limited knowledge on biomedical research, the 
concept of biobanking for future research and its related risks, and reported a few 
important misconceptions about perceived benefits of biobanking. However, they 
were positive about biomedical research and optimistic about the potential value of 
the biobank. These were comparable to findings from other countries, including other 
Arabs. Remarkably, the Emirati general public were enthusiastic about participation 
in the biobank, had high trust in the government, tolerated future recontact and had 
high expectations for returning individual genomic research results. However, 
reported low trust in healthcare providers and unsatisfactory experiences with 
healthcare‎services.‎‎Overall,‎factors‎associated‎with‎the‎general‎public’s‎willingness‎
to participate in a population-based biobank were context specific and varied by 
populations’‎characteristics. 
5.9 Policy Implications  
In order to ensure informed decision-making about participation and long-term 
engagement in the biobank, this study's conclusions support the following 
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recommendation: (i) ensuring ongoing public engagement and empowerment; (ii) 
developing tailored and meaningful informational and educational resources to 
increase publicity on biobank and improve health and medical research literacy; and 
(iii) strengthening medical research regulations and establishing a governance 
framework and structure for biobanks. 
5.9.1 Public engagement and empowerment 
Our study recommends consultation and active engagement of the Emirati 
general public during all phases of this new project’s lifecycle- planning, 
implementation and monitoring.  The aim is to meet their needs and expectations, as 
well as to protect their rights. Ongoing and active engagement will empower the 
Emirati general public, build trust and ownership for this project, thereby ensuring 
successful and wider participation.   
We call for a series of deliberative discussions or surveys to be conducted, 
utilizing the popular internet-based communications strategy - website, blogs or social 
media platforms (Face book/YouTube, Twitter and others), as well as direct 
communication through public forums, focus group discussions or health centers 
meetings, particularly engaging females and less educated Emiratis. These 
communications can be conducted by trusted professionals or HAAD experts in this 
field, as well as by inviting research participants to share their experiences. The 
findings of such ongoing engagement should be continuously incorporated and taken 
into consideration while developing the biobank educational and informational 
resources, publicity plans, as well as biobank governance.  
Furthermore, we call for active engagement and adequate representation of the 
Emirati general public, who are the potential biobank participants, in all research 
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governing committees related to the biobank such as the supreme research council 
(example Abu Dhabi Health Research Council), research ethics committees (example 
Abu Dhabi Research Ethics Committee and other RECs), advisory committees and 
others, to ensure that their interests, specific concerns and culture-sensitive topics are 
prioritized and addressed.  
5.9.2 Development of information and education resources  
One of the principal mandates of the establishment of the biobank is 
developing educational and informational resources for the Emirati general public and 
other stakeholders as well as developing a publicity plan as part of the biobank 
implementation plan. 
The educational and informational resources including, most importantly, the 
consent form, should aim at improving the Emirati health and research literacy, and 
the ability to obtain, read, and understand information on biomedical research and 
biobanking processes and technologies, all necessary to facilitate informed decision-
making about participation.  
The information needs to be tailored and meaningful. It should address the 
gaps in knowledge about biobanking for biomedical research: the process, 
technologies and risks, besides clarifying misconceptions about potential benefits. In 
addition, it should provide information about important policies and procedures to 
protect privacy and confidentiality and the return of research results, especially in 
view of high acceptance for recontact and high expectation for individual research 
results. Moreover, it should provide general information on the biobank, the duration 
of storing biobank resources, as well as types and number of potential future research. 
The collaborators, source of funding and any plans for commercialization must also 
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be clearly and directly mentioned. Furthermore, the information should be balanced, 
capitalizes on potential social benefits while highlights the potential risks related to 
biobanking for future research. 
The informational and educational resources should use simple language to 
overcome health and research literacy barriers, and be culturally appropriate. For that, 
we recommend thorough pre-testing (appraisal) of the informational and educational 
resources through conducting formative focus group discussions which ensure that it 
is readable, can be comprehended by the Emirati general public, and is culturally 
appropriate.  
Lastly, they must be accessible to all. Publicity plans need to be in ongoing 
fashion and utilize appropriate communication strategies for the target audience. 
These include popular internet-based communication sources such as websites, blogs, 
social media platforms and email for wider engagement, especially for the young, 
educated generation. In addition, doctors and other healthcare providers must be 
empowered with updates and knowledge to be valuable sources for information on the 
biobank, especially for Emiratis with lower education. Moreover, we should consider 
conducting a series of public forums, seminars and discussions to spread awareness 
among community members to use the power of social-cultural networks in addition 
to traditional media such as television, radio and newspapers. Attention should be 
given to targeting females and Emiratis with less education to ensure a wider and 
more representative participation in the biobank.  
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5.9.3 Strengthen medical research regulations and establish biobank 
governance structure and framework  
Evidently, there is a need to strengthen medical research ethics regulations and 
establish biobank governance structure and framework in Abu Dhabi, UAE. 
Currently, there is no specific federal law or local decree on research on human 
participants. Furthermore, existing medical research ethic regulations- the Medical 
Liability Law and the Cabinet Resolution (33) on the implementation of Medical Law 
Liability, the Healthcare Regulator Policy Manual and HAAD guidelines- are not 
comprehensive or scattered in different other medical practices laws or standards. Last 
and most important, existing medical research ethics, are not sufficient to address 
biobanking legal and ethical aspects. This is particularly true in the following areas: 
informed consent and options for withdrawal of consent; protection of privacy and 
confidentiality, as well as the form and level of stored personal data, particularly 
genomic data; who, how and where biosamples could be stored and used long term; 
access to biobank resources and potentials for regional and international research 
collaborations; commercialization of biobank resources, ownership and benefit 
sharing; and bioinformatics regulations. Therefore, HAAD, as the regulator of health 
in Abu Dhabi, has an important role in governing such an initiative to protect the 
rights and interests of the Emirati population, meet their expectations and retain the 
high trust it enjoys. 
We strongly believe that top priority in term of legal governance instruments 
that need to be developed in the UAE should be given to passing a specific law for 
research on human participants, with explicit focus on human genome research and 
biobanking activity. Most countries that have established a national or population-
based biobank have passed either a separate law or a decree specifically on 
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biobanking or incorporated some language into other laws relating to research on 
human participants.  We believe that this is of crucial importance. This law can be 
drafted on the basis of regional experience from Saudi Arabia, Taiwan and China as 
well as other international experiences that comply with Islamic laws, and consider 
global collaboration and harmonization.  
Passing a national law is not easy in any country; however, the process in the 
UAE is clear, and time at hand may be relatively shorter compared to other countries. 
Yet, this is a crucial step as it will be the only federal legally binding governance tool. 
This step is usually lead by Ministry of health. It will require consultation with 
stakeholders, including other health authorities, research and academia institutions, 
and Islamic affairs including most importantly, the community members. According 
to researchers from the region, for laws and regulations on biobanking to be passed, it 
is very important that these laws are relevant in context, and complies with Islamic 
law, especially the Holy Quran, Sunna and other sources including International 
Islamic Fiqh Academy (Alahmad & Dierickx, 2014; Fadel, 2010).  
A second priority is to  pass a decree at the emirate level to provide the legal 
basis for establishing the biobank and cover important legal and ethical issues. For 
that HAAD needs to take the lead since this first large scale experience will be 
established in the emirate of Abu Dhabi. This decree needs to define the principle 
requirements for establishing a biobank and govern important biobank policies, 
principally the informed consent and options of withdrawal of consent; privacy and 
confidentiality protection, the form and level of stored personal data particularly 
human genome data and recontact of research participants; return of individual 
genomic research results; who, how and where biosamples could be stored, used long 
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term and disposed; access to biobank resources for research and non-research 
purposes; ownership and benefit sharing of biobank resources; and regulate 
bioinformatics. 
While working on the federal law and local decree, it is important to establish 
the UAE guideline on 'Human Subject Research Conduct', similar to the other 
regional experience such as Qatar, Saudi Arabia, Kuwait, Bahrain and Sudan. This 
guidelines should govern important ethical aspects and issues pertaining to research 
on human participants, including most importantly human genome research. It  can be 
developed on the basis of international guidance such as the CIOMS, WHO and ICH-
GCP. Additionally, establish the 'Guidelines on Human Biobanks'. This guidelines 
should provide guidance for the establishment, governance, operation, access, use and 
discontinuation of biobanks. It can be drafted based on the international guidance 
such as the OECD Guidelines on Human Biobanks and Genetic Research Databases, 
as well as others .  
Moreover, HAAD has to ensure that the biobank operator has established its 
governance structure and framework, SOP's and policies and that it is approved by 
independent REC or other oversight bodies. These SOP's and policies should comply 
with international guidance of best practices, while addressing the Emirati general 
public concerns and meeting  local expectations. This is particularly true with regard 
to informed consent, withdrawal of consent, as well as recontact and privacy and 
confidentiality protection, managing individual genomic research results and other 
important areas.  
HAAD as a regulator need to monitor closely the performance of research 
facilities, including the future biobank and the REC's. It is vital to ensure that all 
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operations comply with domestic and international research ethics principles, 
regulations and guidelines. This can be achieved through conducting regular audits, 
secondary external reviews by independent bodies, or mandate registration to 
internationally recognized accreditation programs. In addition, HAAD must 
continuously monitor and evaluate the biobank's outcomes, to ensure that it is 
achieving its ultimate goal, improving the health and wellness of the Emirati 
population and future generations.  
Finally, HAAD to reactivate and empower the role of the Abu Dhabi Health 
Research Council. This is essential to ensure that research participants' interests and 
rights are always protected, as well to advice the research agenda, development and 
revision of research ethics regulations and guidelines in Abu Dhabi emirate.   
5.10 Recommendations for Future Follow-up Research 
This is a new line of initiative, and one that will require patience, attention to 
sensitivities, and the rights of human subjects. Further follow up research is 
recommended in order to confirm our findings as well as to explore Emiratis' views 
on important areas that were not covered by our study. These areas are: willingness to 
donate other types of biosamples (saliva, tissue, etc.), other methods of acquiring 
biosamples (direct donation, residual surgical samples), accepted categories of 
individual genomic research results to be returned to participants, preference for 
various consent policy options, and trust in a range of research organizations (such as 
healthcare facilities, universities, pharmaceutical or diagnostic companies, inside and 
outside UAE). The follow-up study needs to be designed in such a way as to minimize 
our study limitations, and consider fair representation of the Emirati general public.  
Chapter 5  Discussion & Implications 
187 
 
Our study explored the willingness to participate in a proposed biobank; 
however, the findings may not necessarily correlate with actual future behavior of 
Emiratis. The study by Johnsson et al., 2010, showed that there were differences in 
the theoretical and actual participation in various European biobanks. Therefore it is 
important to carefully monitor public participation and engagement after the 
implementation of the population-based biobank, and conduct further follow up 
studies to assess actual participation, compare findings, and explore barriers (if any).   
Considering the limited biobank research literacy, unsatisfactory positive 
experience with healthcare services, and exceptionally low trust in healthcare 
providers, we recommend a study to assess health literacy of Emirati population. 
Health literacy, in addition to promoting community empowerment, improves the 
overall experience with healthcare services including the navigation and utilization of 
health services across the continuum of care, communication with healthcare 
providers, as well as understating and analyzing the risks and benefits of various 
health interventions (Berkman, Sheridan, Donahue, Halpern, & Crotty, 2011; 
Nutbeam, 2008; Sorensen et al., 2012; Sorensen et al., 2013). This study will help 
improve health literacy, enhance trust in healthcare providers and institutions, thereby 
increasing engagement and participation in the biobank. 
Additional value of the proposed study will be to develop and validate an 
Arabic language version of the European Health Literacy Survey Questionnaire 
(HLS-EU-Q), a comprehensive tool that assesses health literacy, health service use, 
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 Refined: Search was limited to 2010 onwards, English language, full text articles, 
concepts in tiab (Title /Abstract) 
 Excluded from search: patients (including) minors/ disease oriented biobank 
 The search was conducted between 15 December 2015 and 31 January 2016.   
 Terms for search are concept #1 and/or Concept #2. Found in PubMed (n= 384), Web of 
science (n=202), Scopus (n= 108).  
  Total included (n= 267 )  
Concept 2 
 
 Concept 1 
Definition 









Return of research findings/results 
Re-contact/Future contact 
Commercialization/ Ownership/Benefits sharing 
UAE/Arab/ Middle-East 
Attitudes/ /Prospective/Views/ Perception 
Knowledge/ literacy 
Benefits/Motives/Barriers/Concerns/Risks 
Community/Public/ Population- engagement /participation 





Factors /Predictors for participation/willingness to 
participate 










OR Bio bank* 
OR population biobank 
OR population-based 
OR national biobank 
OR genomic research 
OR genetic research 


















































































10 Appendix IV: Cognitive Interview Consent and Questionnaire 
 
Cognitive Interview for Testing the Biobank Survey  
 
Instructions to the respondent:  
 
[READ TO PARTCIPANTS] 
 
Thank you for agreeing to participate in this interview. The purpose of this project is to learn 
about the views of the Emiratis regarding, the storage and use of biological samples for 
medical research to improve the health of the population 
We need to find out if the questions make sense to everyone and if everyone understands the 
questions in the same way. Your interview will help us find out how the questions are 
working.  
This interview will last about one hour. Many of these questions will seem repetitive and 
even somewhat strange or personal. This is because we are testing the questions, and we need 
to understand what people are considering when they form an answer. Please do your best to 
answer the questions as you understand them.  
Everything that you tell me is confidential and will be kept private. If you do not want to 
answer a question, please tell me and I will move to the next question. Before we begin, do 
you have any questions? 
 
 دولة مواطني آراء معرفة هو  الدراسة هذة من الغرض .المقابلة هذه في المشاركة للموافقة على شكرا
 صحة لتحسين الطبية للبحوث البيولوجية العينات واستخدام بتخزين ،يتعلق فيما المتحدة العربية اإلمارات
 .السكان
 
. الطريقة بنفس األسئلة يفهم الجميع كان إذاو للجميع منطقية األسئلة كانت إذا ما معرفة إلى بحاجة نحن
 من وكثير. واحدة ساعة حوالي المقابلة هذه تستمر سوف و ذلك معرفة في معك المقابلة تساعدنا سوف
 إلى بحاجة نحنو األسئلة، تبرنخ ألننا هو هذا .شخصية أو ما نوعا غريب حتىو متكررة تبدو األسئلة هذه
 على للرد جهدكم قصارى بذل يرجى . األسئلة هذه على لإلجابة نيتوصولو كيف و الناس يفكر كيف فهم
 .  السرية غاية في سيكون تقوله  ما كل.  فهمتها ما حسب األسئلة
  .التالي السؤال إلى نتقلن وسوف لي قل فضلك من ،سؤال أي على اإلجابة تريد ال كنت إذا 














Respondent  #........ 
 
Demographic data  Remarks & suggestions  
Gender       Female 





 ______ years 
 
 








Marital Status   Single 
 Married 
 Separated/divorced  
 Widowed 
 
Parental Status   Yes 
 No  
 
Education   Did not attend school /no formal qualification 
Completed primary school 
Completed intermediate school 
Completed secondary school  
Completed college or university 














Less than 20,000  
20,000 to 39,999  
40,000 to 59,999  
60,000 to 79,999  
Greater than 80,000  
 
 
** Note if asking age in years was sensitive and respondent prefer to answer the age 
category  











 هل سبق لك التبرع بالدم؟: 1س
 نعم= 1
 ال=  2
 
 :أسئلة للتحقق
 كيف تتذكرذلك؟( أ
 ماذا يعني لك مصطلح التبرع بالدم؟ (ب










التبرع بالدم أوباألنسجة  لبحٍث طبيٍ، أو المشاركة في تجارب  :مثل) ؟ هل سبق لك المشاركة في أبحاث طبية : 2س





 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 ماذا يعني لك مصطلح أبحاث طبية؟( ب












 هل قام أحد أفراد عائلتك أو أصدقائك بالمشاركة في أبحاث طبية ؟: 3س
 نعم= 1
  ال= 2
 :أسئلة للتحقق
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ ( أ
  كيف تتذكر ذلك؟( ب












 كيف تصف مستوى معرفتك باألبحاث الطبية التي تنطوي على استخدام عينات من األنسجة البشرية ؟:  4س
 معرفة ضعيفة =1
 معرفة متوسطة = 2






 ؟عينات من األنسجة البشريةماذا يعني لك مصطلح ( أ
 لسؤال بكلمات من عندك؟ هل يمكن ان تعيد ا(ب










الخاليا ، و تحمل معلومات وراثية تنتقل من اآلباء إلى هي جزء من الحمض النووي، الموجود في نواة ( المورثات)الجينات :  5س
 كيف تصف مستوى معرفتك بالعالقة بين الجينات وصحة اإلنسان ؟. األبناء
 معرفة ضعيفة =1
 معرفة متوسطة = 2
 معرفة جيدة  = 3
 :أسئلة للتحقق
 ؟الجيناتماذا يعني لك مصطلح ( أ
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (ب










األبحاث الطبية  التي يتم فيها استخدام العينات البيولوجية، بما فيها الدم أواللعاب أو البول أو األنسجة،  تسهم في تحسين 
إن ما نشهده اليوم  من .  عالجات مطورة  لها فهمنا لألمراض و تطوير  اختبارات طبية لتشخيص هذه األمراض واكتشاف
 .تطوٍر ملحوٍظ في الفحوصات وأنواع العالج هو نتيجة تبرع أفراد في السابق لألبحاث الطبية




 تستخدم العينات البشرية ؟  ما فائدة األبحاث الطبية التي(أ
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (ب










ما مدى أهمية تبرع : ،  في رأيك ( في غاية األهمية  5غير مهم على اإلطالق و  1باعتبار )   5إلى  1على مقياس من 
 راد بالعينات لألبحاث الطبية ؟األف











 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 ذلك؟ لماذا تعتقد )ب












هل تقبل بالتبرع بما قد يتبقى من العينات بعد االنتهاء من فحوصات أو إجراءت طبية  تخصك؛ و ذلك   الستخدامه :8س




 لعاب.  ج
 سرطانية أنسجة ذلك  في بما أنسجة،.  د
 
 نعم= 1
 ال=  2
 :أسئلة للتحقق
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 ال توافق على ذلك ؟ /لماذا توافق(  ب
 هل كان من السهل أم  الصعب اإلجابة على هذا السؤال؟( ج
 
 إضافي في حالة التردد











 هل سبق لك أن سمعت بمصطلح البنك الحيوي أو المستودع الحيوي ؟:  9س
 نعم = 1
 ال = 2
 :أسئلة للتحقق
 
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 كيف توصلت لإلجابة ؟( ب












 إذا كنت تود معرفة المزيد عن البنك الحيوي، ما هي مصادر معلوماتاك التي تفضلها ؟:  11س
 [خيارات 3ممكن أختيار ]      
 كتيبات أو نشرات=1
 الجيران/ األصدقاء / أفراد العائلة=2








 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 كيف توصلت لإلجابة ؟( ب
 ؟ العامليين الصحيين ماذا يعني لك مصطلح ( ج









 مقدمة البنك الحيوي 
، في رأيك هل سيسهم  البنك الحيوي ، كمشروع، (قيم للغاية  5غيرقيم إطالقاً  و  1باعتبار ) 5-1باستخدام مقياس من :  11س
 في تحسين صحة المجتمع اإلماراتي؟
 :المقياس







 ماذا يعني لك مصطلح البنك الحيوي؟ ( أ
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ )ب












أي التبرع الطوعي بالعينات و )إذا طلب منك المشاركة في البنك الحيوي المقترح إنشاؤه في العام المقبل :  12
 ؛  فإلى أي مدى يمكن أن تكون  راغباً في المشاركة فيه ؟(المعلومات الصحية الستخدامها في األبحاث
 بالتأكيد سأشارك= 1
 ربما سأشارك= 2
 ربما لن أشارك = 3
 بالتأكيد لن أشارك= 4
 :أسئلة للتحقق
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 لحيوي؟ماذا تعني لك المشاركة بالبنك ا( ب


















 ندك؟ هل يمكن ان تعيد السؤال بكلمات من ع(أ
 أسباب رئيسية  ؟ 3إذكر ( ب
















 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 أسباب رئيسية  ؟ 3إذكر ( ب





  للسؤال  التعديل المقترح
 
 





 هل يمكن ان تعيد السؤال بكلمات من عندك؟ ( أ












 .....ة إذا  ُدعيت  للمشاركة في البنك الحيوي المقترح،  فهل ستفضل اتخاذ القرار حول المشارك:  16س
 من تلقاء نفسك مباشرة  = 1
 بمساعدة أحد أفراد العائلة أو األصدقاء= 2
 بمساعدة الطبيب أو العاملين الصحيين = 3
 بمساعدة موظف االستقبال =4
 .بمساعدة أحد العاملين في البنك الحيوي= 5
 ]يرجى التحديد[  أخرون=6
 :أسئلة للتحقق
 
 ندك؟ هل يمكن ان تعيد السؤال بكلمات من ع(أ
 كيف توصلت لإلجابة ؟( ب










  :هما ، الحيوي البنك في بالمشاركة  إذنك على للحصول طريقتان  هناك
 
 ترغب كنت إذا ما على للموافقة استمارة وقيعت و التحديد وجه على ن منكاالستئذا يتم أن تعني وهي  ، الصريحة الموافقة
 .الحيوي البنك في بك الخاصة الصحية  والمعلومات( 'وقاية' فحص بعد المتبقية) العينات إيداع في
 
 لمعلوماتوا( 'وقاية' فحص بعد المتبقية) العينات إيداع في ممانعتك  عدم افتراض يعني مما  بالموافقة التصريح عدم
 موافقتك عدم حالة في فقط استمارة وقيعت منك سيُطلب وعليه. تحديداً  ذلك يُذكرعكس لم ما  الحيوي البنك في بك الخاصة
 .الحيوي البنك العينات و المعلومات في إيداع  على
 
  األمر؟ اقتضى إذا هاتفضل الحيوي البنك في المشاركة على الموافقة ألخذ الذكر السالفتي   الطريقتين من أي:  أ 11 س
  الصريحة الموافقة= 1
  بالموافقة التصريح عدم=  2
  تفضيل ال= 3
 سبق مما شيء ال =4
 ______________________________[تحديديُرجى ال]أخرى  =5
 :أسئلة للتحقق
 هل كان من السهل أم  الصعب اإلجابة على هذا السؤال؟ ( أ
 ؟ صريحةال الموافقةماذا يعني لك مصطلح ( ب
 الموافقة؟ أستبعادماذا يعني لك مصطلح ( ج 















   النطاق  واسعة أبحاث راءإلج بعضها مع بالتعاون الغالب في أو ،فردي بشكل تعمل  الطبية باألبحاث تقوم التي المؤسسات
 المؤسسات من العديد هناك: 18 س المعتمدة؟ الحيوي البنك بأبحاث ................... التالية  لمؤسساتا تقوم أن تأيد هل: 18 س
 إلجراء البعض بعضها مع المشترك بالتعاون الغالب في أو ،فردي بشكل تعمل المؤسسات هذه .الطبية باألبحاث تقوم التي
 الحيوي؟ البنك بأبحاث .................التالية  لمؤسساتا تقوم أن تؤيد  هل. النطاق  واسعة حاثأب
 
  الحكومية المستشفيات.  أ
  الخاصة المستشفيات. ب
 الطبية لألبحاث مؤسسات(/ تعليمية) أكاديمية مؤسسات. ج
 التشخيصية المعدات أو األدوية شركات. د





 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 ماذا يعني لك مصطلح شركات المعدات التشخصية؟( ب
 واضح من دونها؟,هل شكلت الفقرة األولى أي فرق في فهمك للسؤال؟ هل السؤال ( ج










 األمر يتطلب قد  األحيان بعض في ذلك، ومع. معرفة غير بطريقة الصحية والمعلومات العينات الحيوي البنك يخزن: 19 
ً  بالمشاركين، لالتصال  الصحية والمعلومات العينات تعريف إعادة  من مراقَبة و محدودة تصالاأل معاودة تكون ما وغالبا
ً  بك االتصال معاودة ستقبل فهل الحيوي البنك في المشاركة على وافقت قد تكون أن فرض وعلى. الحيوي البنك  الحقا
 .... ألجل
 (  إضافية استبانة تعبئة خالل من)  الصحية المعلومات من المزيد طلب. أ
  إضافية فحوصات عمل.ب
 عالج أو الوقاية في منها لالستفادة قابلة المعلومات هذه كون  حال في بك، الخاصة العينة في احثونالب وجد ما نتائج إلعطائك. ج
 .مستقبالُ  بها لإلصابة عرضة تكون قد   أو منها تعاني حالة
 في منها دةلالستفا قابلة  أو هامة المعلومات هذه كون عن النظر بغض بك، الخاصة العينة في الباحثون وجد ما نتائج إلعطائك. د
 .مستقبالُ  بها تُصاب قد  أو منها تعاني حالة عالج أو الوقاية
 
  أقبل نعم،= 1
 مقبول غير ال،= 2
 :أسئلة للتحقق
 كيف تأكدت من ذلك؟  ( أ
 هل تعرف ما هو نوع من المعلومات قد يجد الباحث ؟( ب








 ]21 س أسال ،19 س في نعم لكل
 
 ؟ بك االتصال إعادة لتولي شخص أفضل سيكون من رأيك، في:  21 س
 الصحيين العاملين أحد أو الطبيب= 1
 الحيوي، البنك في عامل=2
  الباحث= 2
 ، مقبول كالهما/ تفضيل يوجد ال=3






 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 كيف توصلت لإلجابة ؟( ب










 برأيك،. الحيوي البنك في تجرى التي األبحاث واعأن على يتعرفوا أن  الناس بعض لدى  لالهتمام مثيًرا يكون قد: 21س 
 يتم قد معينة حالة عن  األبحاث ذلك في بما الطبية؛ األبحاث عن العامة المعلومات على للحصول  طريقة أفضل هي ما
  ؟ عيناتك استخدام فيها
 اإللكتروني الموقع= 1
  قصيرة نصية رسائل= 2
  دورية إخبارية نشرة= 3
 ترونياإللك  البريد= 4
 (التحديد يرجى) آخرى طريقة= 5
 المعلومات لتلقي مهتم غير= 6
 :أسئلة للتحقق
 
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ





  للسؤال  التعديل المقترح
 
 أبوظبي؟ إمارة في الصحية الرعاية نظام مع ربتكتج تصف كيف عام، بشكل  :22 س
 غالبا   إيجابية  =1
 غالبا لبيةس =2
 محدد موقف اتخاذ في أرغب ال/ يمكن ال =3
 :أسئلة للتحقق
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ
 لماذا تعتقد ذلك ؟( ب





















 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ











 الطبية المراجعة أو المستمرة الطبية الرعاية تستدعي ، إعاقة أو مزمن بمرض تشخيصك تم أن و سبق هل: 24 س
 ؟(خلقية تشوهات وراثية، أمراضالربو، السرطان ،  ، القلب أمراض سكري،ال :مثالً ) المتكررة
 نعم =1 
 ال =2
 :أسئلة للتحقق
 هل يمكن ان تعيد السؤال بكلمات من عندك؟ (أ











 ؟ إعاقة أو مزمن بمرض عائلتك أفراد أحد  تشخيص تم أن سبق هل: 25س
 نعم =1 
 ال =2
 :أسئلة للتحقق
 ن عندك؟ هل يمكن ان تعيد السؤال بكلمات م( أ
  كيف تتذكر ذلك؟( ب

























Q1: Have you ever donated blood?  
1 = Yes 
2 = No 
2. Probes 
a) how do you remember this ? 
b) what does the term donation mean to you? 











Q2: Have you ever participated in medical research? (e.g. donated blood or tissue for 
research, took part in a clinical trial such as a trial testing an experimental treatment or 
vaccine)?     
1 = Yes 
2 = No 
2. Probes 
a) Can you repeat the question in your own words? 
b) what does medical research? 











Q3: Have any of your family members or friends taken part in medical research? 
1 = Yes 
2 = No 
 
2. Probes 
a) can you repeat the question in your own words?  
b) how do you remember this? 











Q4: How would you describe your own level of knowledge about medical research that involves 
the use of human tissue samples? 
1=No knowledge 
2=Some knowledge 





a) what does the term  human tissue sample mean to you? 
b)can you repeat the question in your own words?  














Q5: Genes are part of DNA that is stored in the cells’ nucleus; and carry the hereditary 
information passed from parents to children.  How much do you know about the relationship 
between human genes and health?   





a) what does human tissue sample mean to you? 
b)can you repeat the question in your own words?  














Medical research on human samples like blood, saliva, urine and tissues, can help to improve 
our understanding of what keeps us healthy. Also it can lead to the development of new tests to 
diagnose certain diseases or to improved treatments.  Many of the tests and treatments used today 
resulted from people donating samples for research previously.  
 
Q6: Do you believe that medical research, on human samples,  leads to improvements in 
patients' outcomes?  
1 = Yes 
2 = No 
 
2. Probes 
a)  how can medical research on human sample  be useful? 
b) can you repeat the question in your own words?  














Q7: On a scale of 1 to 5 with (1 being Extremely unimportant and 5 being Extremely 





4= Important  
5=Extremely important  
2. Probes 
 
a) can you repeat the question in your own words?  
b) why you think this? 














Q 8: Would you agree to donate the following types of samples  ....... for medical research, if they 




d.  tissue ; including cancerous tissue 
 
1 = Yes 
2 = No 
2. Probes 
 
a) can you repeat the question in your own words?  
b) why would you agree/disagree? 














Q9: Have you ever heard the terms biobank or biorepository?  




2 = No  
2. Probes 
 
a) can you repeat the question in your own words?  
b) how did arrive to this? 












Q 10: If you want to learn more about the biobank, please select the sources of information 
that you prefer to use.   
           [SELECT UP TO 3] 
1=Booklets/ brochures 










a) can you repeat the question in your own words?  
b) how did arrive to this? 
c) what does the term healthcare providers means to you?d) can you think of other preferred 














Paragraph on biobank 
 
Q11:  Using a scale of 1 to 5 (1 being Extremely invaluable and 5  Extremely valuable), how 
valuable you do think, the biobank is as a resource, to improve the health of Emiratis?  
SCALE: 










b) can you repeat the question in your own words?  












Q12: If you were asked to participate in the proposed biobank, in the next year, by voluntarily 
donating samples and health information for research, how likely would you be willing to 
participate?  
1= Definitely would participate  
2= Probably would participate 
3= Probably would not participate  
4= Definitely would not participate  
2. Probes 
a) can you repeat the question in your own words?  
b)what does your participation in the biobank involve? 













Q13. What are the main reasons for you to consider participating in the proposed biobank? 
2. Probes 
a) can you repeat the question in your own words?  
b)  mention 3  most important  reasons  















Q14. What are the main reasons that you would NOT encourage you to consider participating 





a) can you repeat the question in your own words?  
b)  mention 3  most important  reasons  














Q 15: Do you think that some of your family members would agree to participate in the 
proposed biobank? 
1 = Yes 
2 = No 
2. Probes 
a) can you repeat the question in your own words?  













Q16:  If you were invited to participate in the proposed biobank, would you prefer making the 
decision to participate..... 
1=Entirely by yourself, 
2=With help from a family member or a friend 
3=With help from your doctor or health care provider 
4= With the clerk at the check in  
5=With help from someone at the biobank, or 
6=Others 
2. Probes 
a) can you repeat the question in your own words?  
b) how did arrive to this? 











There are different approaches to how we can ask for your permission to include otherwise 





Opt-in means that you will be asked specifically for your permission and sign a form, if you 
want your leftover samples and health information to be deposited in the biobank.   
Opt-out means that it is assumed that you have no objection, to deposit your leftover samples 
and health information in the biobank, unless you specifically say otherwise. In that case, you 
would be asked to sign a form only if you DO NOT want your samples and health information 
included in the biobank. 
Q17: Of these two approaches, to include samples and health information in the biobank, 




4=None of the above 
5=Other [SPECIFY 
2. Probes 
a) was is easy or hard to answer this question? 
b) what does the term opt in mean to you 
c) what does the term opt  out mean to you?  















Research organizations work individually, and often in-collaboration to carry out large scale 
research. 
 
 Q18: Would you agree to allow the following organizations............. to carry out the approved  
biobank  research? 
a) Public hospitals 
b) Private hospitals 
c) Academic Institutions or Medical Research Organizations 
d) Pharmaceutical  or Diagnostic companies 





a) can you repeat the question in your own words?  
b) what the term diagnostic companies mean to you 
c) Did the first sentence improve your understanding to Q ? or the Q is clear even without it? 














(Biobanks store samples and health information in unidentified status. However, in some 
condition, it might be necessary for identifying information to be re-linked for the purpose of 
re-contacting participants.  This is usually monitored by the biobank and are limited.   Now, 
imagine that you have agreed to participate in the biobank.) 
 
Q 19: Would it be acceptable for you to be contacted, in the future, in order to......... 
 
a. Ask you for new information ( complete additional  questionnaire)   
b. Ask you for additional assessments tests   
c. Contact you and give you information about what researchers found from your sample if the 
information could be used to prevent or treat a condition that you have or could be at risk to 
develop. 
d. Contact you and give you information about what researchers found from your sample 
regardless of whether or not the information could  be used to prevent or treat a condition that 
you have or could be at risk to develop. 
 
Response: 
1= Yes, acceptable 
 2=No, not acceptable 
2. Probes 
a)  how sure you are about this? 
b) do you understand what type of information  the researcher might find? 












[FOR EACH 'YES' TO 19a-d, ASK 20] 
Q20: Who would be the best person to establish initial re-contact with you?  
1= Your physician or healthcare provider  
2= A member of the biobank staff, 
3=The researcher  
4=You have no preference, 
5=Or someone else?  
2. Probes 
 
a) can you repeat the question in your own words?  
b) how did arrive to this? 













Q21: How would you like to get general information on medical research including 





2= SMS  
3= Newsletter  
4= Email  
5=Others (please specify) ________ 
6=Would not be interested in additional information 
2. Probes 
a) can you repeat the question in your own words?  












Q 22: Generally, how would you describe your experience with healthcare system in the 
Emirate of Abu Dhabi?  
1=Mostly positive 
2=Mostly negative 
3=Cannot/do not want to take a definite position 
2. Probes 
a) can you repeat the question in your own words?  
b) why do you think that? 











Q 23: Do you trust Health Authority Abu Dhabi’s ability to assess the risks and benefits of the biobank initiative, 
to the Emirati population?  
1 = Yes 
2 = No 
2. Probes 
a) can you repeat the question in your own words?  


















which required continuous or frequent medical attention (e.g. diabetes, heart disease, 
asthma, cancer, a genetic condition, congenital anomalies)?  
1 = Yes 
2 = No 
2. Probes 
a) can you repeat the question in your own words?  













Q25: Has a close family member ever been affected by a long-standing illness or disability?  
1 = Yes 
2 = No 
 
2. Probes 
a) can you repeat the question in your own words?  
b) how do you remember this? 






























11 Appendix V: Volunteer List and  Supporting Materials  
 
List of Volunteers 
 
 
 Name  University 
1 Noura Salem Mohammed UAE University 
2 Moyassar Al Tatari UAE University 
3 Rawand Mazen Jean UAE University 
4 AlYazia Aziz  AlAzeezi UAE University 
5 Baraa Ibrahim Mohamed UAE University 
6 Sheikha Humaid  Al Ameri UAE University 
7 Alia Sulaiman  AlAnsari UAE University 
8 Sara Ali Saeed  Alhadrami UAE University 
9 Aysha Khaled Al Marzooqi UAE University 
10 Maryam Abdulla Al Aghbari UAE University 
11 Aysha Khaled Al Marzooqi UAE University 
12 Tahani Ahmed  Al Saadi UAE University 
13 Nujood Ahmed  Al Zaabi UAE University 
14 Eman Abdulrazaq Al Bastaki UAE University 
15 Batool Abbas  Al balooshi UAE University 
16 Hind Obaid  Al Mukhattin UAE University 
17 Alaa MAl Tawil Abu Dhabi University 
18 Aya Yousef Ismail Abu Dhabi University 
19 Aya Nizar Khatab Abu Dhabi University 
20 Maram Sami Hijjah Abu Dhabi University 
21 Shereena Almehrizi New York University Abu Dhabi 
22 Dana AlHosani New York University Abu Dhabi 
27 Aisha AlHemeiri New York University Abu Dhabi 
28 Khuloo Saeed  Alshemeili Higher College of Technology-Intern 
29 Jawaher  Raed Al Haddad Petroleum Institute 
30 Razan  Raed Al Haddad Petroleum Institute 
31 Alya Al Otiba HAAD- NCD Department 
32 Hamda Al Mansori HAAD- NCD Department 
33 Kaltham Al Obidly HAAD- NCD Department 
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DR. JALA ASSAD TAHER 
P.O. BOX - 132828, ABU DHABI 
UNITED ARAB EMIRATES. 











 DR- PH HEALTHCARE LEADERSHIP & MANAGEMENT, JOHN HOPKINS, BALTIMORE- THESIS 
SUBMITTED 
 
 MPH HEALTHCARE LEADERSHIP & MANAGEMENT, JOHN HOPKINS, BALTIMORE- 2011 
 
 MSC MOTHER & CHILD HEALTH, INSTITUTE OF CHILD HEALTH, UNIVERSITY COLLEGE OF LONDON, 
UNITED KINGDOM- 2000 
 
 MBBS- COLLEGE OF MEDICINE & MEDICAL SCIENCES, KING FAISAL UNIVERSITY, SAUDI  ARABIA- 1993 
 
 






PUBLIC HEALTH AND RESEARCH DIVISION, 
HEALTH AUTHORITY ABU DHABI. 
JUNE 2013- SEPTEMBER 2013 
HEAD, CANCER CONTROL & 
PREVENTION 
 
PUBLIC HEALTH AND POLICIES 
HEALTH AUTHORITY ABU DHABI. 
NOVEMBER 2010- JUNE 2013 
 
SENIOR  PROGRAM  MANAGER GLOBAL INITIATIVE FOR BREAST CANCER AWARENESS 
IN PARTNERSHIP WITH SUSAN G KOMEN AND INSTITUTE OF 
INTERNATIONAL EDUCATION, SAN FRANCISCO  
PUBLIC HEALTH PROGRAMS, 
HEALTH AUTHORITY ABU DHABI. 
MARCH 2008- OCTOBER 2010 
 
BREAST CLINICIAN  & FIRST 
READER FOR SCREENING 
MAMMOGRAMS 
HEALTH SCREENING PROGRAM FOR WOMEN & CHILDREN- 
MINISTRY OF HEALTH NATIONAL BREAST CANCER SCREENING 
PROGRAM 
NATIONAL BREAST CANCER SCREENING PROGRAM 
JANUARY 2000 – MARCH 2008 
 
SENIOR HOUSE OFFICER- 
GENERAL SURGERY: 
 
AL JAZEIRA & CENTRAL HOSPITALS 
MINISTRY OF HEALTH 
DECEMBER 1994 – SEPTEMBER 1999 
 
INTERNSHIP  AL JAZEIRA, CENTRAL AND MAFRAQ HOSPITALS 
MINISTRY OF HEALTH 
OCTOBER 1993- DECEMBER 1994  
 
 
PRESENT POST:     MANAGER, NON-COMMUNICABLE DISEASE DEPARTMENT (NCD), 






MAJOR ACHIEVEMENTS  
 
1. PLAN, IMPLEMENT AND EVALUATE VARIOUS PUBLIC HEALTH PROGRAMS.  
2. DEVELOPED HAAD NCD  CONTROL STRATEGY AND REVIWED NUMBER OF NATIONAL STRSTEGIES 
DEVELOPED A NUMBER OF POLICIES AND STANDARDS  IN THE AREA OF CANCER CARE; SCREENING, 
DIAGNOSIS AND MANAGEMENT 
3. ON NCD CONTROL, DRUG ADDICTION & REHABILITATION  
4. ESTABLISHED THREE POPULATIONS –BASED CANCER SCREENING PROGRAMS AND THE h HPV 
VACCINATION CATCH UP PROGRAM , IN ABU DHABI 
5. DESIGNED THE CANCER SURVEILLANCE SYSTEM TO  ESTABLISH  ABU DHABI CENTRAL CANCER 
REGISTRY  
6. DESIGNED AND IMPLEMENTED VARIOUS  INFORMATIONAL RESOURCES AND HEALTH PROMOTION 
CAMPAIGNS  TO PROMOTE HEALTHY LIFESTYLE AND INCREASE  CANCER SCREENING RATES 
7. DESIGNED AND CONDUCTED SEVERAL CME CURRICULUM  FOR HEALTHCARE PROFESSIONALS 
8. LEAD HUGE ADVOCACY EFFORTS AND ESTABLISHED  INTER-SECTORIAL COLLABORATION AMONG 
VARIOUS ORGANIZATION TO SUPPORT CANCER CONTROL  




1. PROSPECTS AND CHALLENGES IN THE INTRODUCTION OF HUMAN PAPILLOMAVIRUS VACCINES IN 
THE EXTENDED MIDDLE EAST AND NORTH AFRICA REGION. AISHA O JUMAAN, SOHA GHANEM, 
JALAA TAHER, MHAMMED BRAIKAT, SALAH AL AWAIDY, GHASSAN S DBAIBO. VACCINE (IMPACT 
FACTOR: 3.49). 12/2013; 31S6:G58-G64. DOI: 10.1016/J.VACCINE.2012.06.097. SOURCE: PUBMED 
 
2. BARRIERS TO BREAST CANCER SCREENING AND TREATMENT AMONG WOMEN IN EMIRATE OF ABU 
DHABI. WALAA K SABIH, JALAA A TAHER, CAROL EL JABARI, COTHER HAJAT, SALIM M ADIB, OLIVER 
HARRISON. ETHNICITY & DISEASE (IMPACT FACTOR: 0.92). 01/2012; 22(2):148-54. SOURCE: PUBMED 
 
3. THE CHANGING FACE OF FEMALE BREAST CANCER IN ABU DHABI AND THE UNITED ARAB 
EMIRATES: IMPLICATIONS FOR BREAST CANCER CONTROL STRATEGY. MPH CAPSTONE, JOHNS 
HOPKINS, 2011. 
 







 ABU DHABI AWARD FOR EXCELLENCE IN GOVERNMENT PERFORMANCE (ADAEP), 2015. RANKED #3 
IN  SPECIALIST FIELD 




 EMIRATE MEDICAL ASSOCIATION 
 HONOROY MRMBERSHIP - MOAAZARA  CANCER PATIENTS SUPPORT GROUP  
 NUMBER OF LOCAL AND NATIONAL COMMITTEES FOR CANCER REGISTERATION, CANCER 
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